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ABSTRACT 
Garrett Robert Ainslie: A Translational Approach to Assess the Risk of Dietary 
Substance-Drug Interactions 
(Under the direction of Mary F. Paine) 
Myriad diet-derived substances, including foods, nutritional supplements, and 
exotic beverages are increasingly sought for their purported health benefits. These 
natural, seemingly safe, products can perpetrate pharmacokinetic/pharmacodynamic 
(PK/PD) interactions with conventional medications, placing the consumer at risk for 
potential adverse effects. Despite the ubiquitous nature of these products, there is a gap 
in the understanding of their drug interaction liability. This knowledge gap is due in part 
to the complex and variable chemical composition, prompting the need to characterize 
key constituents that contribute to perturbations in ‘victim’ drug PK/PD. Development of 
a framework to estimate the effect of the mixture using a single, or few, key constituents 
is principal to risk assessment.  
Grapefruit juice (GFJ) is a well-studied beverage shown to inhibit pre-systemic 
(first-pass) drug metabolism in the gut, increasing systemic drug exposure and potential 
undesirable effects. GFJ acts by irreversible inhibition of cytochrome P450 3A (CYP3A) 
activity in the intestinal wall by a class of constituents termed furanocoumarins. 6’7’-
Dihydroxybergamottin (DHB) is a well-studied and typically abundant furanocoumarin in 
GFJ, with inhibitory concentrations (1-5 μM) well below or within concentrations 
measured in GFJ (<60 μM or <5 mg / 240 mL serving ). The relative abundance and 
 iv
potent activity of DHB in GFJ makes it a promising candidate to serve as a 
marker constituent representative of the CYP3A-mediated effect of GFJ. 
Anecdotal reports touting GFJ as a PK ‘booster’ raise concern that it may be 
used to increase systemic exposure to certain drugs. Loperamide is an over-the-counter 
opioid agonist that acts locally in the gut to slow motility. Incomplete absorption, 
extensive CYP3A-mediated first-pass metabolism, and active efflux by P-glycoprotein 
(P-gp) at the blood brain barrier prevent central nervous system opiate-like effects. The 
candidate marker constituent DHB and the exemplar victim drug loperamide were used 
to test the central hypothesis that an integrative approach involving in vitro assays, 
static and dynamic modeling, and proof-of-concept clinical testing can provide robust 
risk assessment of potential dietary substance-drug interactions. Results from this 
dissertation project demonstrated that the effects of GFJ on loperamide PK and PD 
could be predicted using PBPK/PD modeling and simulation. Furthermore, this work 
provides a refined framework to assess dietary substance-drug interaction risk in a time- 
and cost- efficient manner. 
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PREFACE 
The role of environmental factors such as diet in the disposition and metabolism 
of drugs is an aspect that has been long overlooked, although it is now well known that 
certain dietary substances can interact with drugs that result in untoward effects or 
reduced efficacy. A meeting by the National Toxicology Program in 1998 highlighted the 
importance of increased research in the field of dietary substances. However, over a 
decade later there remains no guidelines to systematically evaluate dietary substance-
drug interaction risk. This project was undertaken to evaluate previously proposed 
translational frameworks to assess dietary substance-drug interaction risk. The key 
achievements of this work were (1) the identification of 6,’7-dihydroxybergamottin (DHB) 
as a promising marker constituent reflective of the CYP3A-mediated grapefruit juice 
effect; (2) the successful construction of physiologically-based 
pharmacokinetic/pharmacodynamic models capable of predicting a clinically relevant 
pharmacodynamic endpoint and; (3) the development of a human model to assess the 
opioid effect attenuation by naloxone. I conducted the majority of in vitro experiments 
described in this dissertation, and Maciej Zamek-Gliszczynski provided drug-tissue 
binding data for loperamide and DHB. My background in bioanalytical chemistry allowed 
me to conduct all LC-MS/MS analysis with the exception of that described in two clinical 
studies (loperamide and naloxone). In total, the work described within this dissertation 
included three clinical studies. The first study was a grapefruit juice-loperamide 
interaction study, which was conducted prior to my involvement in this project. This 
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study was conducted primarily by Elizabeth Connolly, Yolanda Scarlett, Yingxin Li, and 
Mary Paine. The quantification of loperamide and its metabolite was conducted by 
Kristina Wolf, and power calculations were conducted by J. Heyward Hull.  A second 
clinical study described in this dissertation involved the determination of naloxone 
bioavailability for three extravascular formulations in six subjects. This pharmacokinetic 
study was led by John White and Mathew Layton and pharmacokinetic analysis was 
conducted by myself and Jeannie Padowski. I was involved in the study design along 
with Mary Paine and was the coordinator of the third clinical study described in Chapter 
3. During this study I received extensive support from Brandon Gufford, Mathew Layton 
and John White, who were qualitied to administer medications and evaluate the health 
of and safety to study subjects. Furthermore, I received oversight and guidance from my 
research advisor, Dr. Mary Paine. Much of the work described in Chapter 2 involved 
advanced pharmacokinetic and pharmacodynamic modeling techniques. In the 
development of these, models I received constructive feedback from several key 
individuals, including Gary Pollack, Maciej Zamek-Gliszczynski, and Jeannie Padowski. 
J. Heyward Hull and Brandon Gufford advised on statistical analysis throughout this 
research. The achievements resulting from this work are those to be shared by all the 
great minds who contributed to the progress of this doctoral dissertation.
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CHAPTER 1 : INTRODUCTION 
Dietary substance-drug interactions are a public health concern 
The U.S. Environmental Protection Agency (EPA) implemented their ToxCast 
high throughput screening (HTS) initiative in 2007 (Dix et al., 2007). This project was 
designed to screen a bevy of failed pharmaceuticals, alternative plasticizers, pesticides, 
and food additives across 331 cell-free enzymatic and ligand-binding HTS assays 
(Haynes, 2010). These assays evaluated direct mechanisms of toxicity, such as those 
associated with carcinogenicity and neurotoxicity, and alterations in the activity of some 
cytochrome P450 (CYP) enzymes and transporters (Sipes et al., 2013). The ToxCast 
assays are demonstrating a potential to prioritize chemicals for more targeted risk 
assessment testing. The ToxCast approach parallels pharmaceutical discovery in 
certain ways; however, relative to drugs, little is understood about the quantitative 
influence of environmental exposures on the metabolism and transport of concurrent 
medications. Studies to determine the induction of certain CYPs by environmental 
agents have been reported. For example, heterocyclic aromatic amines, pro-
carcinogens found in overcooked red meats, enhance their own metabolism via CYP1A 
and CYP3A gene induction (Kleman and Gustafsson, 1996; Fontana et al., 1999). St. 
John’s wort (Hypericum perforatum), an herbal remedy for anxiety and depression, 
induces CYP3A and CYP2C9 (Di et al., 2008). While these observations are important, 
many drug metabolizing enzymes and transporters are overlooked, particularly with 
respect to dietary substances. There are documented interactions 
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between ‘victim’ drugs and ‘perpetrator’ herbs or foods when consumed concurrently 
(Won et al., 2012). Beverages, such as grapefruit juice (GFJ), are known to interact with 
>100 drugs through inhibition of intestinal CYP3A, P-glycoprotein (P-gp), or organic 
anion transporting polypeptide (OATP). Therefore, the result of consuming otherwise 
seemingly safe products with certain drugs may be detrimental and is concerning to 
public health. 
The impact of certain dietary substances, including foods, nutritional 
supplements, and exotic juices on public health is increasing due to an increase in 
consumer popularity resulting from the purported health benefits and the misperception 
that “natural” equates with “safe”. The ever-growing market appearance of these 
substances raises concern when co-exposed with drugs, both prescription and non-
prescription, potentially leading to untoward or toxic effects (Won et al., 2012). Both 
qualitative and quantitative assessment of dietary substance-enzyme/transporter 
interactions will provide more robust risk assessment of their combined intake.   
Since dietary substances and many drugs are taken orally, mechanisms 
involving the inhibition of first-pass (i.e., pre-systemic) elimination are most likely to be 
involved. Inhibition of the ‘first pass effect’ can result in substantial increases in victim 
drug systemic exposure, which may lead to untoward effects. The gut and the liver are 
the primary organs that mediate the first pass effect.  CYP3A is a prominent enzyme 
subfamily in both the gut and liver and contributes to the metabolism of numerous 
marketed drugs and some dietary substances (Shimada et al., 1994; Paine et al., 2006). 
The human CYP3A family includes four genes: CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. CYP3A4/5 are the primary isoforms responsible for drug metabolism in 
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adults, whereas CYP3A7 is expressed in fetal and neonatal stages of life, and 
CYP3A43 has a role in steroid and cholesterol metabolism (Fanni et al., 2014). Given 
that CYP3A4/5 are responsible for the metabolism of >30% of marketed drugs (Zanger 
and Schwab, 2013), the liver and intestine are major sites of an interaction. 
 While the liver remains a major contributor to first-pass metabolism, the gut is 
also sensitive to enzyme or transporter inhibition. The gut, primarily the small intestine, 
is a critical portal for the absorption of ingested xenobiotics. Xenobiotic oxidative 
metabolism in the intestine is mediated primarily by CYP3A4/5 (Paine et al., 2006). The 
absorptive intestinal epithelial cells, enterocytes, provide active transport processes for 
the uptake and efflux of xenobiotics, including dietary substances and drugs. Organic 
anion transporting polypeptide (OATP) is one a family of uptake transporters expressed 
in the intestine, among other tissues, is and involved in the absorption of several drugs. 
A major apically located efflux transporter is P-glycoprotein (P-gp) and is expressed in a 
variety of other cell types, including endothelial cells in the liver and kidney and capillary 
cells constituting the blood-testis barrier and blood-brain barrier (BBB) (Ho and Kim, 
2005). Perpetrator dietary substance constituents likely attain high concentrations in the 
enterocytes despite not achieving inhibitory concentrations in the liver.  
The U.S. Food and Drug Administration (FDA) requires a comprehensive 
understanding of the drug interaction liability for new drug candidates prior to market 
approval. However, the FDA has limited jurisdiction regarding such characterization of 
dietary substances (US Food and Drug Administration, 2012a). Agencies in other 
countries, including the European Medicines Agency, Health Canada, and Therapeutic 
Goods Administration (Australia), have implemented more strict manufacturing 
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requirements for botanicals than in the US, although safety assessment of these 
products frequently lags behind that of drugs (Health Canada, 2011; European 
Medicines Agency: Committee for Human Medical Products, 2012). The FDA 
acknowledges the need for improved safety testing, and recent funding mechanisms 
offered by the National Center for Complementary and Alternative Medicines (division of 
the U.S. National Institute of Health) highlight this unmet need (de Lima Toccafondo 
Vieira and Huang, 2012). 
Despite a change in the regulatory climate addressing the necessity for some 
standardization of products [European Medicines Agency (European Medicines Agency: 
Committee for Human Medical Products, 2012), Health Canada (Health Canada, 2011)] 
marketed as herbal products and dietary supplements, formal guidelines to assess the 
risk of dietary substance-drug interactions remain nonexistent. The study of dietary 
substances has certain challenges unique to those for drug development due to the 
highly variable biochemical makeup of dietary substances. A standard framework to 
assess these interactions without expensive clinical trials remains elusive. Since it 
would be extremely costly and time consuming to fully characterize all constituents of a 
given dietary substance, investigators have postulated that one or few constituents of 
the mixture, termed ‘marker constituents’, may be predictive of the effect of the whole 
mixture (Won et al., 2012; National Center for Complementary and Alternative Medicine, 
2013; Ainslie et al., 2014). These marker constituents can be identified and used for 
testing. However, further work is needed using well-studied exemplar dietary 
substances and drugs to develop and substantiate a testing paradigm for dietary 
substance-drug interaction risk assessment. 
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Common mechanisms of enzyme inhibition  
Reversible inhibition involves the rapid association and disassociation of an 
enzyme-inhibitor complex. Reversible inhibition frequently occurs by one of three 
specific mechanisms, including competitive, noncompetitive and uncompetitive (Shou et 
al., 2001; Walsh et al., 2011). Competitive inhibition is the result of a perpetrator 
substance binding to the active site of the enzyme preventing access by the victim 
substrate. The result in victim drug enzyme kinetics is an increase in the concentration 
needed for half-maximal rate of metabolism (Km) with no change in maximal rate of 
metabolism (Vmax) (Lin and Lu, 1998; Venkatakrishnan et al., 2003). Noncompetitive 
inhibition occurs when a perpetrator substance associates to a site of the enzyme other 
than the active site to attenuate enzyme activity.  Noncompetitive inhibition is revealed 
by a decrease in Vmax and no change in Km. Uncompetitive inhibition occurs with the 
perpetrator substance binding to the enzyme-substrate complex, resulting in a decrease 
in both Km and Vmax. In the case of reversible inhibition enzyme activity is restored with 
removal of the perpetrator substance (Lin and Lu, 1998; Venkatakrishnan et al., 2003).  
Reversible inhibition can initially be assed in the relevant enzyme system at a 
constant substrate concentration and a range of inhibitor concentrations. The inhibitor 
concentration required to inhibit enzyme activity by 50% (IC50) can be recovered. The 
IC50 is dependent on substrate concentration and can be correlated to the reversible 
inhibitory potency constant (Ki) by the (Cheng and Prusoff, 1973). An inhibitor’s Ki is a 
more definitive measure of reversible inhibitory potency and can be achieved by varying 
both substrate and inhibitor concentrations as covered in more detail below (Fowler and 
Zhang, 2008).    
 6
In general irreversible inhibition results from covalent or tight binding (quasi-
irreversible) of a chemically reactive intermediate resulting in a loss of enzyme function 
(Grimm et al., 2009). This specific mode involving enzyme inactivation is known as 
mechanism-based inhibition (MBI). The MBI associated constant (KI) and the rate of 
maximal enzyme inactivation (kinact) are the parameters associated with MBI (Kalgutkar 
et al., 2007; Venkatakrishnan et al., 2010). The effects of irreversible inhibition can be 
prolonged after the inhibitor is removed, since transcription of new enzyme or cell 
regeneration is required to recover enzyme activity. 
Grapefruit juice as an exemplar dietary substance and 6’,7’-dihydroxybergamottin 
as a candidate marker constituent 
Grapefruit juice (GFJ) is one of the most extensively studied dietary substances 
shown to perpetrate CYP3A-mediated inhibition of drug metabolism (Paine and 
Oberlies, 2007; Bailey et al., 2013). Many of these drugs undergo extensive first-pass 
metabolism by CYP3A. An extensive list of these medications has been reported 
elsewhere (Bailey et al. 2013). When consumed in usual volumes, GFJ elevates 
systemic concentrations of the victim drug by inhibiting enteric, but not hepatic, CYP3A.  
Despite that the juice inhibits only enteric CYP3A, the magnitude of the effect can be 
large enough to elicit untoward effects, such as severe muscle pain with some HMG-
CoA reductase inhibitors (statins)(Dreier and Endres, 2004; Karch, 2004) and 
hypotension/dizziness with some calcium channel antagonists (Bailey and Dresser, 
2004). 
Myriad components in GFJ capable of inhibiting CYP3A in vitro have been 
identified, including furanocoumarins, several of which are potent reversible and 
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irreversible inhibitors of CYP3A (Paine and Oberlies, 2007). Using a “furanocoumarin-
free” GFJ suitable for human consumption and the CYP3A probe substrate felodipine, 
furanocoumarins, in aggregate, were demonstrated unequivocally as major CYP3A 
inhibitors in vivo.  In addition to their ability to inhibit enteric CYP3A, furanocoumarins 
have been shown to inhibit the P-gp in vitro (Eagling et al., 1999; Paine and Oberlies, 
2007). Moreover, using the aforementioned furanocoumarin-free juice, 
GFJ/furanocoumarins were shown to inhibit the enteric P-gp-mediated translocation of 
the dual CYP3A/P-gp substrate cyclosporine in healthy volunteers, as well as in the 
human intestine-derived cell line Caco-2 (Paine et al., 2008). Parallel in vitro studies 
identified the furanocoumarins bergamottin (BG) and 6’,7’-dihydroxybergamottin (DHB) 
(Figure 1.1.) as mechanism based inhibitors of CYP3A (KI, 1.6 and 0.7 µM, 
respectively) and P-gp activity (IC50, 0.74 and 0.33 µM, respectively) (Eagling et al., 
1999; Paine et al., 2004).  
Despite the potent inhibitory activity of BG towards CYP3A in vitro, BG has high 
tissue binding properties and is less readily absorbed than DHB, indicating it may 
contribute less to the GFJ effect in vivo (Paine et al., 2004; Paine et al., 2005). The 
clinical role of BG is evidenced largely by two studies designed to evaluate the 
contribution of BG to CYP3A-mediated GFJ-drug interactions. Bailey et al. conducted 
the first in 2003, which compared lime juice, which is typically high in BG but not DHB 
(Wagner et al., 2002; Gorgus et al., 2010; Guth et al., 2011; Costa et al., 2014), with 
GFJ as a reference perpetrator of a felodipine interaction (Bailey et al., 2003). In this 
randomized crossover study, subjects were administered 250 ml of water, lime juice 
(100 µM BG and undetectable DHB) diluted 4-fold or GFJ (containing 25 µM BG; DHB 
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was not reported) prior to felodipine (10 mg). The lime juice was diluted such that the 
concentration of BG was the same as that in GFJ. Relative to water, GFJ increased 
felodipine area under the plasma concentration-time curve from time zero to infinite time 
(AUC0-inf) and maximum observed plasma concentration (Cmax) by 2- and 1.9-fold, 
respectively. In contrast, lime juice had no effect on the pharmacokinetics of felodipine 
despite an extract having both reversible and irreversible inhibitory activity in a 
microsomal CYP3A activity assay. In vitro activity assays were conducted using 
recombinant CYP3A4, increasing amounts of juice extracts, and testosterone 6β-
hydroxylation as the index reaction. The observed in vitro-to-in vivo disconnect may be 
due to the slower absorption of BG compared to DHB in Caco-2 cells (Paine et al., 
2005) and perhaps a delay in felodipine treatment following lime juice would have 
resulted in an interaction. Alternatively, there may have been components in the lime 
juice extract which did not attain high enough enteric concentrations.  
Goosen and colleagues at North-West University in South Africa conducted the 
second benchmark clinical study evaluating BG as a causative constituent in GFJ in 
2004 (Goosen et al., 2004). BG was obtained from a commercial source (Sigma Aldrich, 
≥ 98% purity) and was administered to 11 healthy volunteers in a five-phase clinical 
study. Felodipine (5 mg) was tested as the victim drug and was given on each study 
day. On study days 1-2, subjects were randomized to receive either water or GFJ 
(containing 1.7 mg BG, DHB was not measured). On study days 3-5, subjects were 
randomized to receive capsules containing 2, 6 or 12 mg BG with water. Blood was 
drawn for 12 h following the felodipine dose, and plasma was quantified for felodipine, 
BG and DHB using HPLC-MS/MS. Relative to pre-treatment with water, BG doses of 6 
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and 12 mg increased felodipine AUC0-12h by 1.3-fold. The GFJ product containing 1.7 
mg of BG resulted in a 1.5-fold increase, whereas 2 mg of BG had no significant effect. 
This study suggested that BG contributes to the GFJ effect but alone does not account 
for the effect of the mixture in vivo. Additionally, at the higher BG doses, DHB was 
detected in plasma, indicating that BG is biotransformed to DHB in vivo or the study 
product was contaminated with DHB.  
In vitro assessment of other furanocoumarins, including dimers and trimers, have 
indicated that some of these constituents are highly potent as well (IC50, 0.003-1 µM) 
(Guo et al., 2000b; Guo et al., 2000a; Tassaneeyakul et al., 2000; Row et al., 2006; Oda 
et al., 2007). Despite these data, such constituents have unknown/poor stability (light, 
pH, and metabolic), and their clinical relevance is unknown (Morliere et al., 1990; Kent 
et al., 2006). Improved methods to quantify these constituents in both the juice and 
biologic matrices are required to further understand their role in the CYP3A-mediated 
GFJ effect.  
There are limitations to using furanocoumarin dimers or BG as marker 
constituents that include the known unfavorable physicochemical properties (high 
nonspecific binding affinities) (Paine et al., 2004) of BG and unknown physiochemical 
properties of dimers make these chemicals less desirable candidates as a marker 
constituent. In contrast, DHB has multiple desirable characteristics: (1) physicochemical 
properties in alignment with straightforward quantification in both GFJ and biologic 
matrices; (2) typically ample quantities in GFJ that exceed the reported MBI associated 
constant (KI, 1-5 µM); (3) the onset of maximum loss of enteric CYP3A4 protein in 
human intestine-derived cell monolayers (Caco-2) (Paine et al., 2005) corresponds to 
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that in healthy volunteers administered GFJ (Lown et al., 1997); and (4) the existence of 
commercially available authentic standards that are not cost prohibitive. 
Grapefruit juice as a ‘pharmacokinetic boosting’ agent 
 The discovery of GFJ as an irreversible inhibitor of intestinal CYP3A4 has 
spurred the marketing of dietary supplements labeled to contain BG, DHB and/or GFJ 
extracts. These products have been marketed as ‘pharmacokinetic boosting’ agents 
aimed towards body builders to increase the bioavailability of oral hormones and 
supplements. Many hormones (e.g., androgens) are metabolized by CYP3A (Hara and 
Nishiyama, 2014), and GFJ has been shown to increase systemic exposure to the sex 
hormone, 17 β-estradiol (Schubert et al., 1994), providing loose justification for the 
products marketed use. Even in conventional pharmacotherapy, GFJ has been 
proposed as a means to increase the exposure to expensive and poorly bioavailable 
drugs as a cost-savings strategy, including some immunosuppressive and anticancer 
agents (Reif et al., 2002; Liu et al., 2009; Kimura et al., 2011; Cohen et al., 2012). 
Similarly, the role of GFJ as a pharmacokinetic booster has been implicated in 
anecdotal reports as a means to increase the systemic exposure to certain opioids (e.g., 
methadone, morphine, oxycodone, hydrocodone and loperamide) (Bluelight, 2014b; 
Bluelight, 2014a).  
Loperamide as a candidate GFJ victim drug with abuse potential 
 Loperamide is a peripherally acting µ-opioid receptor agonist, which, despite 
having a high affinity towards its target receptor, is not associated with central nervous 
system effects due to an extremely low oral bioavailability (0.3%) (Yu et al., 2004) and 
active P-gp-mediated efflux at the blood brain barrier (Skarke et al., 2003; Zamek-
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Gliszczynski et al., 2012). The low bioavailability is in part due to the high first pass 
effect mediated primarily by CYP2C8 and CYP3A4 (Figure 1.2) (Kim et al., 2004). 
Anecdotal reports and case studies have implicated the potential for loperamide abuse 
when taken concomitantly with CYP3A4 or dual CYP3A/P-gp inhibitors (Daniulaityte et 
al., 2013). A limited number of case studies have also signified that high doses of 
loperamide can result in abuse or death (Langlitz et al., 2001; Sklerov et al., 2005). In 
contrast, clinical evaluations in healthy volunteers have shown that increases in 
loperamide plasma exposure do not translate to a central opiate-like effect (Tayrouz et 
al., 2001; Skarke et al., 2003; Niemi et al., 2006). Although supratherapeutic doses of 
loperamide have been examined (up to 24 mg) in non-addict populations, these doses 
are much lower than those from anecdotal reports of abuse (70-200 mg) (Daniulaityte et 
al., 2013). Due to ethical and safety concerns, an alternative approach must be taken to 
evaluate the validity of these claims and to assess the abuse potential of loperamide.  
The in vivo impact of grapefruit juice on various clinically used opioids 
Naturally-occurring opiates and synthetic opioids are metabolized predominately 
by CYP3A, CYP2B6, CYP2D6, and the UDP-glucuronosyltransferases (UGTs), 
particularly UGT2B7 (Iribarne et al., 1997; Iribarne et al., 1998; Benetton et al., 2004; 
Hutchinson et al., 2004; Yasar et al., 2005; Kharasch et al., 2007; Klimas and Mikus, 
2014). Some of these opioids are presented in table 1.1; however, of the many opioids 
metabolized by CYP3A, only five (i.e., alfentanil, methadone, morphine, oxycodone, and 
tilidine) have been evaluated in vivo as victims of the GFJ effect. As certain opioids 
have a narrow therapeutic window, when given acutely, an examination of these GFJ-
 12 
opioid interaction studies is warranted. A common limitation of the following studies is 
lack of measured constituents in the study juice (Overholser and Foster, 2011). 
ALFENTANIL  
Alfentanil is a short-acting (t1/2 = 1.5 h) (Egan et al., 1996) synthetic opioid used 
in anesthesia for surgical procedures (Scholz et al., 1996). Clinically, alfentanil is 
administered intravenously, although it has been administered both orally and 
intravenously as a ‘probe’ of intestinal and hepatic CYP3A (Kharasch et al., 2004a; 
Klees et al., 2005a; Klees et al., 2005b; Kharasch et al., 2007; Kharasch et al., 2011). A 
decade ago, GFJ was shown to increase oral alfentanil (23 µg/kg) plasma exposure 
(AUC) by 1.7-fold relative to water in healthy volunteers (Kharasch et al., 2004a). In this 
study, a pharmacodynamic endpoint (pupil diameter) was measured, resulting in a 1.4-
fold increase in the area under the effect curve (AUEC).  
METHADONE 
 Methadone is a long-acting opioid (t1/2 = 40 h) administered orally to treat opioid 
withdrawal symptoms in opioid-addicted patients and abusers (Nilsson et al., 1982). 
Since methadone is given both orally and chronically, a GFJ-methadone interaction 
would be concerning, as unforeseen accumulation of the drug would result in overdose. 
However, a clinical study conducted in 12 healthy volunteers with no history of drug 
abuse revealed a low risk of a GFJ-methadone interaction (1.2-fold increase in AUC) 
(Kharasch et al., 2004b). Pupil diameter also was measured in this study and was 
reflective of the minimal increase in total methadone plasma exposure (1.1-fold increase 
in AUEC). However, plasma exposure to the primary metabolite, 2-ethyl-1,5-dimethyl-
3,3-diphenylpyrrolinium, decreased by 43% with no change in Cmax. Results from this 
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study suggested that the role of intestinal CYP3A, in methadone metabolism, is minimal 
compared to that in the liver and of CYP2B6 (Kharasch et al., 2004b).  
In a second GFJ-methadone interaction study, the racemic components were 
examined (Benmebarek et al., 2004). Subjects (n=8) undergoing methadone 
maintenance therapy consumed water or GFJ (200 mL) 30 minutes prior to and in 
conjunction with their methadone dose for 5 days. Blood was collected for 24 hours 
following the methadone dose and quantified for total methadone and the individual 
enantiomers (R and S). A mean increase in AUC of 17% was observed for both 
enantiomers, with a similar increase in Cmax. However, the maximal increase in plasma 
AUC of R-methadone, the most potent enantiomer, was 29%. This study in methadone 
patients confirmed that reported in healthy volunteers, which indicated a low magnitude 
of effect by GFJ.     
MORPHINE 
Morphine is perhaps the most historically significant opioid agonist. It was first 
used in opium-derived elixirs hundreds of years ago and later isolated and identified in 
1804. The discovery of morphine spurred synthetic development of many of the opioids 
currently used in pain management. Morphine is primarily metabolized by hepatic 
UGT2B7, forming a 6-glucuronide conjugate that is a more potent µ-opioid receptor 
agonist than morphine, and the 3-glucuronide conjugate that is inactive and possibly 
antagonistic (Osborne et al., 1992; Handal et al., 2007; Klimas and Mikus, 2014).  
The affinity for CYP3A4 and the low oral bioavailability (Table 1.1) makes 
morphine a possible candidate for a GFJ interaction. A CYP3A-mediated interaction 
with morphine, in theory, could reduce enteric elimination of parent, resulting in further 
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UGT2B7-mediated glucuronide formation by hepatic UGT2B7 (Groer et al., 2014). 
Okura and colleagues studied the GFJ-morphine interaction in rats, by, demonstrating 
that a GFJ preparation could increase antinociception by 50% (Okura et al., 2008). This 
interaction has not been confirmed in humans.     
OXYCODONE 
Oxycodone is one of the most frequently prescribed oral opioids to treat pain. A 
clinical evaluation of the GFJ-oxycodone interaction detected a 70% increase in 
oxycodone (10 mg dose) plasma AUC in the presence of GFJ (200 ml t.i.d. x 5 days). 
Effect was measured using the cold compression test, visual analog scale and the self-
reported performance test of which only the self-reported performance test detected a 
significant albeit modest increase in response (20%) in the presence of GFJ (Nieminen 
et al., 2010). These findings may raise the concern of an alternative means of 
oxycodone abuse.   
TILIDINE 
 Tilidine is an orally administered prodrug, given as a racemic mixture, which is 
believed to be primarily bioactivated by CYP3A via N-desmethlyation in the gut to form 
the active metabolite nortidine (Grun et al., 2012; Wustrow et al., 2012; Eichbaum et al., 
2014). Nortidine is further desmethylated and inactivated by the liver, forming 
bisnortilidine. Inhibition of intestinal CYP3A could reduce pharmacologic response, 
prompting clinical evaluation with GFJ (Wustrow et al., 2012). This was conducted in a 
randomized, open-label, placebo-controlled, cross-over study in 12 healthy volunteers 
administered tilidine (100 mg p.o.) with and without GFJ (250 mL q 12 hr x 3). GFJ did 
not augment the AUC or Cmax of tilidine or its metabolites (nortilidine and bisnortilidine), 
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suggesting that intestinal CYP3A does not contribute to the first-pass metabolism of 
tilidine. The authors concluded that enzymes other than CYP3A might be involved in 
tilidine metabolism; however, the study juice was not quantified for furanocoumarin 
content, precluding definitive interpretation. The lack of measured marker constituents 
in study products is a common limitation of GFJ-drug interaction studies (Won et al., 
2012).  
IN VIVO OPIOID INTERACTION SUMMARY 
 Despite the limited number of GFJ-opioid interaction studies conducted to date, 
those existing provide important evidence to clinicians regarding the safety and efficacy 
of these dietary substance-drug combinations. While the interaction reported with 
alfentanil occurs, the clinical impact is likely minimal, whereas that with oxycodone may 
be concerning. The GFJ-oxycodone interaction may elicit accidental overdose or 
promote intentional opioid abuse and deserves further investigation. Assessing the 
abuse and interaction potential of opioids clinically is accompanied by certain ethical 
concerns. (1) Opioids are often associated with abuse, dependence and overdose; 
therefore, studies investigating dietary substance-opioid interaction potential in opioid 
naïve subjects require more careful consideration than with relatively safer medications. 
(2) Despite the addictive properties of opioids, they remain important in pain 
management. Recruiting patients undergoing pain management regimens would be a 
natural alternative to healthy subjects, yet there is a responsibility by the investigator to 
minimize potential harm to these patients who may experience excruciating pain with 
decreasing opioid exposures or develop dependence with elevated opioid exposures. 
(3) To avoid the risk of developing dependence in a non-addict population, or to study 
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treatments for addicts, human studies have utilized opioid addict populations. Studies in 
these populations raise even more issues, which have been extensively reviewed, and 
include considerations of coercion and exploitation in subject recruit concerns (Smith, 
2008; Timmermans and McKay, 2009). Finally, the Declaration of Helsinki provides a 
statement that, “In advance of a clinical trial, sponsors, researchers and host country 
governments should make provisions for post-trial access for all participants who still 
need an intervention identified as beneficial in the trial” (World Medical, 2013; Fletcher, 
2014). As the ethical apprehensions are daunting, such clinical evaluation of a dietary 
substance-opioid interaction should be preceded with careful preclinical evaluation and 
considerations of risk. Preparation for such studies would be well-informed from 
preclinical modeling and simulation approaches.  
Preclinical models for assessing dietary substance-drug interaction potential 
 In vitro-to-in vivo extrapolation (IVIVE) of dietary substance-drug interaction 
liability has been conducted using several techniques, which span a spectrum of cost, 
complexity and accuracy. Methods may be as straightforward as direct extrapolation of 
in vitro inhibition assay data to predict clinical interactions, to the application of simple or 
complex algebraic equations from in vitro data, to the use of more complex models 
comprised of differential equations.  
 Historically, due to the high cost and lack of regulatory requirements to conduct 
clinical studies, dietary substance-drug interactions have been predominantly examined 
in both in vitro systems and preclinical animal models. Several groups have investigated 
the use of rodents as a useful screening tool to evaluate these interactions early in early 
drug discovery (Okura et al., 2008; Song et al., 2014; Zhao et al., 2014). The advantage 
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of using live animals is that they can be administered a test beverage or extract in the 
presence of a victim drug with relative ease, by generally accepted oral administration 
routes (e.g. oral gavage, dietary supplementation), resulting in a moderate throughput 
assay. However, these models are limited by differences in metabolism and enzyme 
expression that is differentially distributed in humans. Despite limited reports of a 
reasonable assessment of CYP3A-mediated interactions in rats (Kosugi et al., 2012; 
Vuppugalla et al., 2012; Rioux et al., 2013), this approach has been generally 
unsuccessful but remains in practice and may gain in popularity with the refinement of 
humanized rodent models (Jaiswal et al., 2014).  
 A second ‘direct extrapolation’ technique has been the use of human cell 
fractions (microsomes, S9 or recombinantly expressed enzyme) as an enzyme source 
to determine inhibitory potency of dietary substances. This is a high throughput 
technique involving the incubation of human microsomes (e.g. liver, intestine and 
kidney) (Al Saabi et al., 2013; Gufford et al., 2014) with cofactor (e.g. NADPH, UDGPA), 
and a probe substrate (e.g. midazolam, 4-methylumbelliferone) in the absence and 
presence of inhibitor. The test inhibitor may be added to the mixture as a crude extract, 
semi-purified extract or isolated constituent. To assess reversible inhibition, experiments 
may be conducted in this manner over a range of inhibitor concentrations at a constant 
substrate concentration and incubation time. The reaction velocity in the absence of 
inhibitor in conjunction with that in the presence of inhibitor may be used to extrapolate 
the IC50, using eq. 1, for a test perpetrator substance (Grime et al., 2009). The values 
recovered from this assay are dependent on substrate concentration and may not 
translate from assay to assay (Cheng and Prusoff, 1973). To obtain more robust 
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parameters of inhibitory potency, the Ki can be determined with a matrix of substrate 
and inhibitor concentration spanning, ideally, 5-fold below and above the estimated 
inhibitor Ki (e.g., based on IC50) and substrate Km (eq. 2). To assess MBI of an enzyme, 
a common approach analogous to the IC50 recovery is to determine the “IC50 shift”. The 
IC50 shift assay includes a pre-incubation of varying inhibitor concentrations in the 
presence of enzyme source (with and without) the appropriate cofactor, followed by 
enzyme activity measurements with the probe substrate of interest (Grimm et al., 2009). 
The fold change in the apparent IC50 is a widely used measure of time-dependent 
inhibition (TDI). MBI, a specific mechanism of TDI, can be further characterized by 
recovering the kinact and KI (Riley et al., 2007). Incubations containing crude extracts, a 
conventional approach, at times result in challenging data interpretation due to the 
unknown composition and often existence of fatty acids and lipids. These constituents 
have unknown clinical relevance due to poor cell membrane permeability of high 
molecular weight lipids and extensive metabolism of fatty acids by gut microflora (Clarke 
et al., 2014; Trier et al., 2014). Single constituents have been postulated to be ideal if in 
vitro kinetic parameters are to be incorporated into static models or dynamic models 
(National Center for Complementary and Alternative Medicine, 2013). 
      eq. 1 
where v denotes the measured reaction velocity; v0, initial reaction velocity; I, 
inhibitor concentration. 
     eq. 2 
v =
v0
1+
I
IC50
v =
Vmax •S
Km • 1+
I
Ki





+ S
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where Vmax denotes maximum reaction velocity; S, substrate concentration.  
     eq. 3 
where kinact,app denotes the apparent inactivation rate constant at each inhibitor 
concentration, determined by the slope of the monoexponential decline in activity. 
 Mathematical methods to extrapolate in vitro data to humans vary in complexity 
and can be categorized into two classes: those to predict parameters for victim drugs 
and inhibitors (e.g., inhibitor/drug plasma concentration; fraction of dose escaping 
intestinal extraction, Fg; or intrinsic clearance) (Table 1.2) and those to evaluate the 
interaction potential. The latter can be further divided into to three types of models: 
simple static, mechanistic static, and physiologically-based pharmacokinetic (PBPK). 
Simple static models (Table 1.3) allow for a quantifiable estimate of the interaction 
liability using as little as a single experimentally recovered parameter (e.g. Ki). Kinetic 
parameters for reversible (Ki) or irreversible (KI and kinact) inhibition can be used along 
with estimated inhibitor concentrations in humans to determine the likelihood of an 
interaction. These models are often used to justify further investigation or to declare the 
likelihood of an interaction to be low (US Food and Drug Administration, 2012a). Simple 
static models exist to predict both reversible and time-dependent inhibition; however, 
some lack the ability to predict the magnitude of interaction and do not account for the 
location of the interaction (i.e., intestine, liver, kidney). Lastly, these models are not 
typically robust enough to accurately predict the magnitude of a clinical interaction 
directly.  
 Mechanistic static models have been applied to account for interactions limited to 
specific tissues (e.g., gut or liver) and predict clinically important outcomes (e.g., 
kinact,app =
kinact • I
KI + I
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changes in AUC, intrinsic clearance or Fg). Success by the pharmaceutical industry has 
been seen in many cases, justifying the continued use of mechanistic static models 
(Obach et al., 2006; Obach et al., 2007; Gertz et al., 2010). Popularity of mechanistic 
static models should grow in early assessment of dietary substance-drug interactions 
because the requisite data can be readily obtained from reversible inhibition or time 
dependent assay data (IC50 shift, KI/kinact ). One differentiating characteristic of simple 
versus mechanistic static models is that the latter requires more information (i.e., more 
experimentally derived parameters) about the victim drug, such as the Fg, which may 
not be known in early drug discovery, precluding dietary substance interaction risk at 
this early stage. Mechanistic static models (Table 1.3) may also be combined or refined 
to include additional modes of action or routes/modes of elimination/inhibition. The 
application of mechanistic static models to dietary substances as perpetrators is limited, 
due to the gap in human pharmacokinetic knowledge of perpetrator substances and/or 
the lack of isolated constituents for in vitro parameter recovery.  
 The use of either a simple or mechanistic static model remains limited with their 
inability to account for varying dose and dose frequency of test perpetrator substances. 
These limitations can be accounted for with PBPK models, which utilize physiological 
parameters to account for anatomy, enzyme expression and transporter activity among 
others.  
The first report of a PK model with a physiologically relevant structure was by 
Torsten Teorell in 1937 (Teorell, 1937b; Teorell, 1937a). It was not until the 1970s and 
1980s that PBPK modeling began to mature and find purpose in drug discovery and in 
environmental risk assessment (Dedrick et al., 1973; Huffman et al., 1973; Andersen et 
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al., 1977; Andersen et al., 1979; Clewell and Andersen, 1985). Ever since, these types 
of models have been used by pharmaceutical, cosmetic and chemical industries 
(Charnick et al., 1995; Sinha et al., 2012; Rowland, 2013; Bachler et al., 2014; Chen et 
al., 2014; Cristofoletti and Dressman, 2014; Schuhmacher et al., 2014; Suemizu et al., 
2014). 
This growth has been catalyzed in part by the increased computing power of the 
modern era and available software packages. Programs available to construct and use 
PBPK models can be categorized as either ‘free form coding’ or ‘preassembled’. Free 
form coding programs such as Matlab®, Berkeley MadonnaTM, acslX, and ModelMaker® 
allow the user complete control of model structure and parameterization, limited only by 
the user’s ability and data availability. Preassembled programs include BioDMET, 
GastroplusTM, Simbiology® (Matlab), PK Sim and Simcyp® (Table 1.4) (Schmitt and 
Willmann, 2005; Graf et al., 2012). These packages comprise built-in model structures 
and physiological parameters. Some allow for modification and customization but are 
typically limited to the manufacturer’s specifications, which are ever evolving to meet the 
customer’s expectations and needs.   
A second reason for the interest in PBPK modeling is the availability of certain 
physiological data previously not known (e.g. transporter tissue expression, polymorphic 
enzymes, disease specific changes to physiology) (Prasad et al., 2014). With these 
tools, modelers are armed with the ability to estimate drug-tissue concentrations and to 
predict nonlinear pharmacokinetics, xenobiotic-drug interactions and efficacy/toxicity, 
particularly in special populations and disease states (Jiang et al., 2013; Lin et al., 2013; 
Abduljalil et al., 2014; Li et al., 2014; Lu et al., 2014).  
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Physiologically based pharmacokinetic/pharmacodynamic models 
 Publications including simulated PK of drugs using PBPK models have exploded 
during the past several years. Clinical investigation of dietary substance-drug 
interactions with both pharmacokinetic and effect endpoints has increased (Sugimoto et 
al., 2006; Misaka et al., 2013; Chakraborty et al., 2014; Ide et al., 2014). Following this 
trend, the next innovative step would be to incorporate pharmacodynamic endpoints into 
interaction simulations using PBPK/ PD models. As with the initial resurgence of PBPK 
models in the 1970s, contemporary environmental toxicologists have taken the lead on 
examining PBPK/PD models for exposure risk assessment. Models have been applied 
to assess the risk of arsenic, carbonyl, chlorpyrifos, methyl-parathion and methyl-
diazion exposure (Ling and Liao, 2009; Foxenberg et al., 2011; Hinderliter et al., 2011; 
Tan et al., 2011; Knaak et al., 2012; Wason et al., 2012; Poet et al., 2014; Smith et al., 
2014; Yoon et al., 2014). PBPK/PD modeling is entering pharmaceutical assessment as 
embodied in recent work aimed at predicting the bioequivalence of generic ibuprofen 
formulations (Cristofoletti and Dressman, 2014). In this study, the authors used the 
PBPK/PD modeling and simulation software, Simcyp®, and two reference studies where 
ibuprofen was given at 400 mg and 10 mg/kg. These outcomes were compared to test 
formulations at 280 mg and 7 mg/kg, where bioequivalence was archived based on 
effect but not on pharmacokinetic outcomes.  
 A requisite of PBPK/PD modeling as an approach will be the availability of a 
meaningful and understood pharmacodynamic endpoint for which to model. The effect 
of pain medications, for example, can be measured in humans with subjective surveys, 
or in some cases objective measurements. The available measures of centrally-acting 
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opioid effect lend toward the ability to construct such PBPK/PD models with this class of 
drugs. Namely, pupil diameter (miosis) offers a sensitive and relatively precise measure 
of effect of centrally-acting opioid agonists.  
Clinical assessment of dietary substance-opioid interactions and reversal of 
opioid effect  
 Despite maturation of the abovementioned predictive models, clinical evaluation 
remains the only absolute measure of dietary substance-opioid interaction risk. Clinical 
studies can be used to validate predictive models or to gain mechanistic insight 
following an in silico-to-in vivo disconnect. Either outcome may be informative. Once 
model simulations conducted in virtual healthy subjects are successfully validated with a 
healthy volunteer (i.e., ‘proof-of-concept’) clinical study, the PBPK or PBPK/PD model 
may be applied to special populations (pediatrics, geriatrics, patients). In a recent 
publication, Li et al. applied this PBPK modeling and simulation strategy to seven drugs 
(antipyrine, nisoldipine, repaglinide, glibenclamide, glimepiride, chlorzoxazone, and 
metformin) (Li et al., 2014). PBPK models of all seven drugs were individually 
constructed, and model simulations were compared to outcomes observed in healthy 
volunteer studies. After confirming model robustness, the plasma concentration-time 
profiles for each drug were simulated in diabetic patients.  The resulting model-
predicted AUCs all lay within 50% of those observed in diabetic patients. Sensitivity 
analysis of key disease specific parameters was conducted, identifying gut transit time, 
altered hepatic enzyme activity and impaired renal function as disease specific 
alterations most responsible to changes in drug exposure in diabetic patients. This 
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synergy between PBPK modeling and clinical evaluation may also be applied to dietary 
substance-opioid interactions.  
 In many cases, the primary obstacles to conducting clinical studies are time, 
cost, personnel and materials (The National Academies Collection: Reports funded by 
National Institutes of Health, 2010). Each of these barriers is interconnected with one 
another. While the time to obtain Institutional Review Board approval can vary greatly 
depending on the sponsoring institution and host country, the study duration is 
dependent on the availability of personnel/facilities and speed of sample analysis 
(frequently quantification of drug in blood or plasma). Increased study complexity may 
benefit the scientific merit, yet detriments the cost-efficiency, as additional study phases 
or long collection time-periods accelerate expenditures. 
 While these challenges apply to all clinical studies, those designed to evaluate 
dietary substance-opioid interaction risk could readily address each of these hurdles. In 
a market where contract research organizations charge $40-65 per sample for plasma 
LC/MS/MS analysis, testing measures of opioid effect would eliminate the associated 
blood collection and bioanalytical costs and time. Specific measures of central opioid 
effect, such as respiratory rate, blood oxygen saturation, and pupil diameter are readily 
obtained by less skilled personnel and data analysis is in real time. This approach 
liberates the more highly trained medical professionals and allows insertion of trainees 
in the clinical environment. While the FDA has preferred CYP3A probe substrates for 
drug-drug interaction risk assessment, there are no guidelines specific to dietary 
substance-drug interaction risk assessment in vivo. To facilitate or prioritize this risk 
assessment, additional probes, where opioid effect can be measured, should be 
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considered. A short-acting and well-studied opioid would reduce the duration of a study 
day, and associated monetary burden of staff and subject compensation. A sensitive, 
noninvasive measurement of opioid effect would decrease analytical time and cost and 
at minimum help prioritize more thorough and complex studies.  
 The short-acting µ-opioid receptor agonist, alfentanil (t1/2, ~1.5 h), is a CYP3A 
specific substrate and candidate to assess dietary substance-opioid interactions 
mediated by CYP3A. Kharasch et al. have proposed alfentanil as a probe to assess 
CYP3A phenotypes in humans and has utility in assessing dietary substance-drug 
interactions mediated by CYP3A (Kharasch et al., 2004a; Kharasch et al., 2007; 
Kharasch et al., 2011). The promise of using this probe is that it can be administered 
both orally and intravenously in the absence and presence of a test dietary substance, 
and pupil diameter can be measured in lieu of plasma drug concentrations. This less 
invasive approach would require less medically trained staff, would decrease time and 
costs associated with plasma analysis and decrease the risk infectious disease 
transmission. 
 As described earlier, the clinical application of opioids is challenged with the 
potential of adverse events, mainly respiratory depression. The definitive treatment for 
opioid overdose is the opioid antagonist, naloxone, approved for intravenous (IV) and 
intramuscular (IM) administration (Dowling et al., 2008). Oral delivery of naloxone 
results in poor absolute bioavailability (≤2%) due to extensive pre-systemic 
glucuronidation in both the gut and liver (Gill et al., 2012; Smith et al., 2012). The high 
first-pass extraction of naloxone has been exploited in new tamper resistant 
formulations of oxycodone (Remoxy® and Targiniq™ ER), buprenorphine (Suboxone®) 
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and morphine (Embeda® ; withdrawn from the market due to production issues) 
(Johnson et al., 2010; Stanos et al., 2012). When naloxone-containing combinatorial 
medications are used as intended, systemic naloxone concentrations to reverse the 
effects of the active opioid are not achieved. Conversely, if the formulation is altered 
(i.e., crushed) for intravenous use, naloxone is expected to attenuate opioid effects. A 
liability of these orally administered drugs is the potential for a complex dietary 
substance-drug interaction. Naloxone is metabolized by primarily by UGT2B7 and 
therefore inhibition of these enzymes by perpetrator dietary substances could increase 
naloxone exposure sufficiently for it to act systemically and potentially elicit withdrawal 
symptoms (Gill et al., 2012; Gufford et al., 2014).  
 While the low oral bioavailability of naloxone is beneficial in tamper resistant 
medications, it is problematic for its use in emergency medicine. Until the recent FDA 
approval of a single-dose naloxone, product, EvizioTM, intravenous and intramuscular 
(IM) naloxone were the only available naloxone formulations and required medically 
trained personal to administer this lifesaving drug. EvzioTM, which allows for the lay 
bystander to administer naloxone IM naloxone. Production of this device is a step in the 
right direction but is cost-prohibitive (>$200/dose) and invasive, risking the transmission 
of infectious diseases (The Medical Letter, 2014). Intranasal (IN) naloxone would be an 
alternative formulation that could be readily administered. Several programs across the 
U.S. support IN naloxone for in-field treatment of opioid overdose by lay persons, who 
typically are the first responders (Barton et al., 2002; Glaser et al., 2005; Heard et al., 
2009). These programs use the parenteral formulations and an atomization device. 
Although rescue rates are relatively high, the absolute bioavailability of this formulation 
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(4%) does not support widespread use or FDA approval (Barton et al., 2002; Dowling et 
al., 2008). Development of novel IN naloxone products will continue following a call by 
the FDA (US Food and Drug Administration, 2012b) and support by the Australian 
government (Lenton et al., 2014). 
 The recent development and market appearance of these new naloxone-
containing products is challenged with a lack of a human model to measure the efficacy 
(i.e., reversal of opioid effects) of naloxone formulations. Ideally, early stage clinical 
evaluation with such a model would facilitate the production of noninvasive naloxone 
products or help evaluate the dietary substance-drug interaction potential of naloxone-
containing products.  Taken together, there is an urgency for a noninvasive cost- and 
time- effective human model to (1) assess dietary substance-opioid interactions, (2) 
determine dietary substance-drug interaction potential of combinatorial naloxone 
products, and (3) develop novel antidotes to treat opioid overdose. 
Summary and project aims 
 Certain dietary substances can perpetrate alterations in the absorption, 
distribution, and elimination of victim drugs, resulting in altered systemic exposure and, 
potentially, untoward effects. Regulatory agencies are acknowledging this public health 
concern, yet there are no guidelines to assess dietary-substance-drug interaction risk. It 
has been postulated that, despite the complex mixtures of most dietary substances, one 
or a few marker constituents can be identified to serve as ‘marker constituent(s)’ 
reflective of the whole mixture. The ideal marker constituent would be readily 
measurable in the test product and in biological matrices and would not be cost-
prohibitive. An exemplar dietary substance (GFJ) and test marker constituent (DHB) can 
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be evaluated using approaches taken from the pharmaceutical industry. Some of these 
methodologies include rodent models, in vitro testing and in silico predictions. While 
clinical evaluation is the definitive assessment of a dietary substance-drug interaction, 
certain measures should be taken to reduce the burden on sponsoring agencies to 
increase the throughput of dietary substance testing clinically. Despite the well-studied 
nature of GFJ in both the clinical and preclinical setting, there remain some gaps in 
current interaction risk knowledge and in methods to predict GFJ-drug interaction a 
priori. Recent restrictions on opioid prescribing may promote an alternate means of 
abuse, including pharmacokinetic boosting with GFJ. Methods to assess GFJ-opioid 
interaction potential are critical, since clinical studies with these drugs may be 
particularly challenging due to ethical concerns. As such, in vitro studies and IVIVE 
techniques must be well developed to accurately inform clinical studies. Furthermore, 
the trends of opioid abuse have prompted the need for tamper resistant opioids and 
novel naloxone formulations for which a human model to assess the reversal of opioids 
is lacking. Since dietary substances may promote the abuse of opioids or interact with 
the antidote (i.e., naloxone), this dissertation will address these gaps in knowledge with 
the following specific aims: 
Specific Aim 1: Develop robust in vitro methods to recover key kinetic parameters 
associated with DHB-mediated inhibition of loperamide metabolism. 
Hypothesis: Human-derived in vitro systems will provide requisite kinetic parameters 
associated with the metabolism of loperamide in the absence and presence of DHB. 
1a. Develop a rapid and sensitive LC/MS/MS method for the quantification of 
loperamide, the major CYP3A-mediated metabolite, N-desmethylloperamide, and 
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DHB in biological matrices. 
1b. Determine enzyme kinetic parameters (Km, Vmax) of loperamide N-demethylation 
using established human enzyme systems (human intestinal microsomes, 
recombinant CYP3A enzymes). 
1c. Determine the reversible (Ki) and mechanism-based (KI, kinact) inhibition kinetics of 
DHB toward N-desmethylloperamide formation using human intestinal microsomes. 
Specific Aim 2: Predict the interaction risk of a GFJ with loperamide using a 
single marker constituent. 
Hypothesis: A robust PBPK/PD model can be used to predict the likelihood and 
magnitude of an interaction between a GFJ and loperamide. 
2a. Develop a PBPK/PD interaction model using kinetic parameters derived from Aim 1 
and from the literature. 
2b. Evaluate the PBPK model using existing in-house clinical data from a GFJ-
loperamide study in which DHB was measured in the GFJ product. 
2c. Simulate the PK and PD outcomes of a DHB supplement/GFJ-loperamide 
interaction under various DHB doses to emulate the rage found in dietary 
supplements, as well as with the therapeutic and maximum tolerated doses of 
loperamide. 
Specific Aim 3: Evaluate the performance of a human model to assess the 
reversal of opioid effect. 
Hypothesis: A human model using the model opioid, alfentanil, and the exemplar 
antagonist, naloxone can be used to test novel naloxone formulations.  
3a. Design a proof-of-concept clinical study to assess the reversal of opioid effect in the 
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absence and presence of grapefruit juice. 
3b. Implement a clinical study to assess the reversal of opioid effect by a novel 
naloxone formulation. 
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Table 1.1. Phase I and II pathways and bioavailability (F) of common opioids. 
Opioid Phase I  Phase II  F (%)a 
Alfentanilb CYP3A    30c 
Codeined CYP2D6  UGT2B7 50±7 
  CYP3A    
Fentanyle CYP3A   ~50b 
  CYP3A    
Hydrocodoned CYP2D6 UGT1A3  
  CYP3A UGT2B7  
Hydromorphoned   UGT1A3 42±23 
    UGT2B7  
Loperamidef CYP2B6  0.3g 
 CYP2C8   
 CYP2D6   
 CYP3A4   
Methadoned CYP2B6   92±21 
 CYP2D6    
  CYP3A    
Morphined CYP3A UGT2B7 24±12 
Oxycodoned CYP2D6   ER: 60-87 
  CYP3A   IR:42±7 
Oxymorphoned   UGT2B7 10h 
Sufentanile CYP3A    
Tramadold CYP2D6   70-75i 
Tropendtanoli CYP2C9  UGT2B7 32i 
 CYP2C19   
 CYP2D6   
  CYP3A    
IR, immediate release formulation; 
ER, extended release formulation; 
a Bioavailability reported in Goodman and Gilman’s unless otherwise denoted (Brunton 
et al., 2010). 
b Transdermal administration 
c  Bioavailability reported by Klees et al. (2005a) 
d Metabolic pathway reported by Overholser and Foster (2011) 
e Metabolic pathway reported by Guitton et al. (1997) 
f  Metabolic pathway reported by Kim et al. (2004) 
g Bioavailability reported by Yu et al. (2004) 
h Bioavailability reported by Davis (2005) 
I Bioavailability reported by Brayfield (2011) 
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Table 1.2. Models to predict perpetrator or victim substance specific parameters. 
Parameter Site  Equation Ref. 
[I]     
 
Intestinal 
 
(Obach et al., 2006) 
 
Liver 
 
(Obach et al., 2006) 
Clint,g Intestine   
Fg Intestine 
 
(Yang et al., 2007) 
    
Ig, inhibitor concentration in the enterocyte; Ih, inhibitor concentration in the hepatocyte 
the hepatocyte; D, the oral dose of inhibitor; ka, the first-order oral absorption rate 
constant of inhibitor; fa, the fraction of dose of inhibitor absorbed into enterocytes; Qent, 
the enteric blood flow (may be interchanged with villous blood flow); fu, fraction unbound 
in plasma or tissue; Qh, hepatic blood flow; Fg, fraction of dose of drug/inhibitor escaping 
intestinal extraction; Qvilli, villous blood flow; Clintg, intrinsic metabolic clearance in the 
gut; Fug, fraction of drug unbound in the enterocyte; CLug, the net intrinsic metabolic 
clearance in the gut based on unbound drug concentration; CLperm, permeability 
clearance. 
 
Ig =
D× k a× fa
Qent
Ih = fu Imax ×
D× ka × fa
Qh






Cl intg =CLuint ×ContentEnzyme
Fg =
Qvilli
Qvilli + fug ×CLug 1−
Qvilli
CLperm






  
Table 1.3. Static models to assess drug interaction potential.  
Model 
type 
Mechanis
m of 
inhibition 
Site of 
inhibition 
Equation Notes Ref. 
Simple static     
Reversible Liver 
 
R>1.1, possible a 
 
Reversible Liver 
 OR  
Ri > 1, likely 
1>Ri>0.1, possible 
Ri<0.1, unlikely 
b 
 
Irreversible Liver 
 
R2>1, likely 
1>R2>0.1, possible 
R3<0.1, unlikely 
c 
 
Irreversible Liver 
 
Assumes Fm = 1  
     
Mechanistic static   
 
Reversible Intestine 
;  
 f 
Reversible Liver 
;  
 f 
 
Irreversible Intestine 
;  
   f 
R =
I
Ki
+1
Ri =
I
Ki
Ri =
Cmax
Ki
R2 =
λ
kdeg
R3 =
kinact
KI
AUCi
AUC
=
1
Ag × (1−Fg )+Fg
Ag =
1
1+
Ig
Ki
AUCi
AUC
=
1
Ah × (1−Fm )×Fm
Ah =
1
1+
Ih
Ki
AUCi
AUC
=
1
Bg × (1−Fg )+Fg
Bg =
Kdeg,g
Kdeg,g +
Ig × kinact
Ig +KI
3
3
  
  
 
 
Irreversible Liver From IC50 shift data                 d 
Irreversible Liver 
;  
  
 
Irreversible Intestine 
 
From IC50 shift data E 
AUCi
AUC
=
1+ 1+
1+
IC50
−
IC50
+






kdeg × t












× Ln
2
1+
IC5050
+
IC50
−


















×
I
IC50
−
1+
1
IC50
−
AUCi
AUC
=
1
Bh × (1−Fm )×Fm
Bh =
Kdeg,h
Kdeg,h +
Ih × kinact
Ih +K I
AUCi
AUC
=
1
(1−Fm )
1+
Ig
tinc × IC50












+Fg
3
4
 
  
 
Irreversible Liver 
 
From IC50 shift data e 
 
Combined Combined From IC50 shift data e 
Combined Intestine 
 
         f    
 
Combined Liver 
 
 F 
 
Combined Combined 
 
 F 
R, value associated with drug interaction probability; I, inhibitor concentration; Cmax, maximal observed or predicted 
inhibitor concentration; λ, first-order inactivation rate at a given MBI concentration; kdeg, degradation rate of enzyme; kinact, 
maximal enzyme inactivation rate; KI, concentration to elicit half-the maximal rate of enzyme inactivation; AUCi/AUC, the 
area under the victim drug plasma concentration-time curve in the presence of inhibitor over that in the absence of 
inhibitor; Fg, fraction of drug escaping intestinal extraction; fm, fraction of victim drug metabolized; Ki, the reversible 
inhibition constant;IC50, inhibitor concentration to elicit 50% of the maximal inhibition; the subscript ‘h’ denotes the term 
corresponds to the liver (hepatocyte); the subscript ‘g’ denotes the term refers to the gut (intestine); a US Food and Drug 
Administration (2012a); b Bjornsson et al. (2003); c Fujioka et al. (2012); d Sekiguchi et al. (2009); e (Obach et al., 2005; 
Obach et al., 2006; Obach et al., 2007); f Fahmi et al. (2009) 
AUCi
AUC
=
1
Fm
1+
Ih
tinc × IC50












+ (1−Fm )
AUCi
AUC
=
1
Fm
1+
Ih
tinc × IC50












+ (1−Fm )
×
1
Fg ×
(1−Fg)
1+
Ig
tinc × IC50









AUCi
AUC
=Cg =
1
[Ag ×Bg ]× (1−Fg )+Fg
AUCi
AUC
=Ch =
1
[Ah ×Bh ]× (1−Fm )×Fm
AUCi
AUC
=Cg ×Ch
3
5
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Table 1.4. Software packages for PBPK modeling. 
Program Provider Link Cost ($) 
Free form 
acslX AEgis Technologies 
Group 
http://www.acslx.com 500-7,500 
Berkeley Madonna www.berkeleymadonna.com 69-299  
Matlab (Simulink) MathWorks® www.mathworks.com 3,250 
ModelMaker ModelKinetix© www.modelkinetix.com 233-770 
Powersim Studio PowerSim Software http://www.powersim.com 99+ 
Preassembled 
BioDMET General Electric http://pdsl.research.ge.com Beta is free 
GastroplusTM SimulationPlus, Inc www.simulations-plus.com/Products a 
PK Sim® Bayer Technology 
Services 
www.systems-
biology.com/products/pk-sim.html 
a 
Simbiology® MathWorks® 
http://www.mathworks.com/products
/simbiology 3,250 
Simcyp® Certara http://www.simcyp.com a 
a Quote available upon request; Cost varies on academic/industry and the number of 
licenses purchased.  
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Figure 1.1. Furanocoumarin structures. Bergamottin (A) and 6’,7’-dihydroxybergamottin 
(B). 
 
 
  
A B 
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Figure 1.2. Loperamide metabolites in rat and human liver microsomes. Modified from 
Kalgutkar and Nguyen (2004) with additional evidence from Yoshida et al. (1979), Yu et 
al. (2004) and Kim et al. (2004). 
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CHAPTER 2 : ASSESSMENT OF A CANDIDATE MARKER CONSTITUENT 
PREDICTIVE OF A DIETARY SUBSTANCE-DRUG INTERACTION: CASE STUDY 
WITH GRAPEFRUIT JUICE AND CYP3A4 DRUG SUBSTRATES1 
Introduction 
Drug-drug interactions (DDIs) due to inhibition of drug metabolizing enzymes can 
lead to severe adverse effects, resulting in cautionary statements on drug labels or 
withdrawal of the drug from the market (Fujioka et al., 2012). Consequently, regulatory 
agencies recommend or require thorough characterization of new drug candidates as 
both DDI ‘victims’ and ‘perpetrators’ prior to marketing. Such characterization, spanning 
from discovery to clinical development, is well-defined and generally harmonized 
amongst the various agencies. In contrast, relevant guidelines are nonexistent for diet-
derived products, including dietary supplements and certain beverages, which represent 
an ever-increasing share of the Western healthcare market. This deficiency reflects the 
relative lack of robust human-derived in vitro and in vivo data, precluding development 
of a systematic approach that would help identify dietary substances as potential 
perpetrators of interactions with drugs, as well as prioritize for clinical evaluation. As an 
initial step towards developing an aforementioned approach, methods used to predict 
and characterize metabolism-based DDIs can be extended to dietary substance-drug 
                                            
1 This chapter previously appeared as an article in the Journal of Pharmacology and 
Experimental Therapeutics. The original citation is as follows: Ainslie, GR, Wolf KK, 
Connolly EA, Scarlett YV, Hull JH, Paine MF. Assessment of a Candidate Marker 
Constituent Predictive of a Dietary Substance-Drug Interaction: Case Study with 
Grapefruit Juice and CYP3A4 Drug Substrates. J Pharmacol Exp Ther. 2014 Dec; 
351(3):576-84. 
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interactions. DDI predictions using in vitro enzyme kinetic parameters have become 
increasingly more advanced in drug discovery (Vieira et al., 2014). Mechanistic static 
models have shown success for DDIs localized in the liver, the primary site of these 
interactions. However, because diet-derived constituents generally have a low systemic 
exposure (due to extensive pre-systemic metabolism) but high intestinal exposure, and 
most drugs are taken orally, the gut likely represents the primary interaction site for 
dietary substance-drug interactions. Accordingly, models that are tailored to processes 
exclusive to the gut may be more appropriate for predicting dietary substance-drug 
interactions. 
Assessing dietary substance-drug interaction risk poses additional challenges 
compared to DDIs. Unlike drug products, dietary substances typically are complex 
mixtures that vary substantially in phytochemical composition, both between brands and 
batches of the same brand (Cancalon et al., 2011; Won et al., 2012). Accordingly, it has 
been postulated that ‘marker’ constituents can be identified and used to predict the 
effect of the mixture in vivo (Won et al., 2012; National Center for Complementary and 
Alternative Medicine, 2013). Such a constituent predictive of a mixture also would 
enable a simplified and cost-effective means to assess dietary substance-drug 
interaction liability. 
Grapefruit juice is an extensively studied diet-derived perpetrator of dietary 
substance-drug interactions. When consumed in usual volumes, the ‘grapefruit juice 
effect’ is limited to the intestine, as evidenced by the general lack of an effect on the 
pharmacokinetics of intravenously administered drugs and on the terminal half-life of 
orally administered drugs. Most victim drugs share three requisite traits: orally 
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administered, a low to intermediate absolute bioavailability, and undergo cytochrome 
P450 3A4 (CYP3A4)-mediated first-pass metabolism in the intestine by (Bailey et al., 
2013). Grapefruit juice contains a chemical class of constituents, furanocoumarins, 
which are potent mechanism-based inhibitors of CYP3A4 (Paine et al., 2006a), a 
prominent drug metabolizing enzyme expressed in both the intestine and liver (Paine et 
al., 2006b). One typically abundant furanocoumarin, 6’,7’-dihydroxybergamottin (DHB), 
may represent a marker constituent predictive of the CYP3A4-mediated effect of 
grapefruit juice based on the following key properties/observations: the polarity relative 
to other furanocoumarins enables straightforward quantification in both grapefruit juice 
and biologic matrices; the mechanism-based inhibition (MBI) associated constant (KI, 1-
5 µM) is well below/within concentrations measured in the juice; the onset of peak 
effect, defined as the maximum loss of enteric CYP3A4 protein in human intestine-
derived cell monolayers (Caco-2) (Paine et al., 2005), is predictive of that in healthy 
volunteers administered grapefruit juice (Lown et al., 1997); and authentic standard is 
commercially available that is not cost prohibitive.  
In the present work, an in vitro to in vivo extrapolation (IVIVE) approach using 
DHB as a marker constituent of grapefruit juice was applied to a purported victim drug 
that had not been reported previously in the literature. Loperamide, a μ-opioid receptor 
agonist, was selected as the test victim drug based on the aforementioned criteria. In 
addition, anecdotal reports suggest an abuse potential when taken at supratherapeutic 
doses with grapefruit juice (Daniulaityte et al., 2013), substantiating investigation of the 
interaction liability. The aims of this study were to (1) confirm the grapefruit juice-
loperamide interaction in healthy volunteers, (2) obtain MBI kinetic parameters for DHB 
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using loperamide N-desmethylation by human intestinal microsomes as the index 
reaction, (3) determine the accuracy of a mechanistic static model using DHB as a 
marker constituent predictive of the grapefruit juice-loperamide interaction, and (4) apply 
the model to previously reported grapefruit juice-drug interaction studies to evaluate the 
robustness of this IVIVE method. Results will aid in assessing the grapefruit juice 
interaction liability with candidate and marketed drugs and help prioritize for clinical 
evaluation.  
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Materials and Methods 
Materials and Chemicals 
Human intestinal microsomes (HIMs), pooled from 13 donors of mixed gender (7 
male, 6 female), were purchased from Xenotech, LLC (Lenexa, KS). Plasma pooled 
from multiple donors (mixed gender, distribution unknown) was purchased from 
Biological Specialty Corporation (Colmar, PA). Loperamide hydrochloride, D6-
loperamide, N-desmethylloperamide, and D3-N-desmethylloperamide were purchased 
from Toronto Research Chemicals, Inc. (North York, Ontario, Canada). DHB was 
purchased from Cayman Chemical (Ann Arbor, MI). Psoralen, NADPH, and 
dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). 
LC/MS/MS-grade acetonitrile, water, methanol, and formic acid were purchased from 
Thermo Fisher Scientific (Waltham, MA).  
Human Subject Study 
Preparation of Grapefruit Juice. Multiple cans of a single brand (Minute Maid®) 
and lot of frozen grapefruit juice concentrate were purchased from a local grocery store. 
The frozen juice concentrates were thawed and pooled, and an aliquot was saved for 
measurement of DHB by HPLC (Paine et al., 2006a). The pooled concentrate was 
reconstituted with water to achieve a ‘double-strength’ juice (DHB final concentration 
~60 μM). The reconstituted juice was divided into 240 ml aliquots and stored at -20°C 
and protected from light until needed. 
Clinical Protocol and Participants. The University of North Carolina Office of 
Human Research Ethics/Biomedical Institutional Review Board and Clinical and 
Translational Research Center (CTRC) Oversight Committee reviewed and approved 
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the protocol. Potential subjects provided written informed consent and Health Insurance 
Portability and Accountability Act authorization before screening at the CTRC, which 
consisted of a medical history, physical examination, liver function tests, and complete 
blood count. All women underwent a serum pregnancy test.  
Study Design and Procedures. A prospective, randomized two-phase, open-
label crossover study was conducted at the CTRC (Figure 2.1). Prior to the first study 
phase, the participants were asked to abstain from all fruit juices for one week before 
and during the study and from alcohol and caffeinated beverages the evening before 
each study day. Participants were admitted to the CTRC the evening before each study 
phase. Vital signs (blood pressure, temperature, pulse, respirations) and oxygen 
saturation were obtained upon admission and monitored periodically throughout the 
inpatient portion of each phase. All of the women underwent a repeat serum pregnancy 
test. After an overnight fast, each participant was administered 16 mg loperamide 
(Mylan Inc., Canonsburg, PA) with 240 ml of water or grapefruit juice. Blood (7 ml) was 
collected from an indwelling intravenous catheter before loperamide administration and 
at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h after loperamide administration. Blood was 
centrifuged within 1 h of collection; plasma was removed and stored at -80°C pending 
analysis for loperamide and the primary CYP3A4-mediated metabolite, N-
desmethylloperamide, by LC/MS/MS (see below). Subjects continued to fast until after 
the 4-h blood collection, after which meals and snacks, devoid of fruit juices and 
caffeinated beverages, were provided. After the 12-h blood collection, subjects were 
discharged. Subjects returned to the CTRC as outpatients for blood draws at 24, 36, 48, 
and 72 h after loperamide administration. 
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Concurrent with the blood collections, dark-adapted pupil diameter, the most 
sensitive index of opioid effect (Grunberger et al., 1990), was measured using a 
NeurOptics VIP-200® pupillometer with a resolution of 0.1 mm (San Clemente, CA). 
Pupil diameter was obtained at least in triplicate, with coefficients of variation ≤2.8%. 
The light intensity of the room, measured by a Sper Scientific 840021 light meter 
(Scottsdale, AZ), was always <1 lux. As a positive control for the miotic effect, 9 
subjects (5 men, 4 women) were administered a ‘morphine challenge’ on the evening of 
the first phase. Morphine sulfate (0.07 mg/kg; Hospira Inc., Lake Forest, IL) was 
administered as a 5-min intravenous infusion via a syringe pump. Pupil diameter was 
measured before and at 5, 10, 20, 30, 60, 90, and 120 min after infusion. Subjects were 
in the supine position and were monitored with an automated blood pressure cuff and 
pulse oximeter during the infusion and for 2 hours thereafter. Vital signs were monitored 
concurrent with pupil diameter measurement. Supplemental oxygen was available if 
oxygen saturation decreased to <94%. The opioid antagonist, naloxone (International 
Medication Systems Ltd, South El Monte, CA), and anti-emetic agent, promethazine 
(Goldline Laboratories, Inc., North Wales, PA), were available if needed. 
Determination of Mechanism-Based Inhibition Kinetic Parameters for DHB 
Time- and concentration-dependent inhibition of CYP3A4 activity by DHB in 
HIMs was assessed as described previously (Paine et al., 2004), only N-
desmethylloperamide formation was used as the index reaction. Briefly, loperamide and 
DHB were dissolved in DMSO to yield working solutions of 5 and 2 mM, respectively. 
Primary incubation mixtures consisted of HIMs (5 mg/ml), DHB (0, 2.5, 5, 10, 30 µM), 
and potassium phosphate buffer (0.1 M, pH 7.4). The mixtures were equilibrated at 
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37°C for 5 min before initiating reactions with NADPH (1 mM final concentration), 
yielding a final volume of 80 µl; the final concentration of DMSO was ~1% (v/v). At 
designated times from 0-5 min, an aliquot (10 µl) was removed and diluted 20-fold into 
secondary incubation mixtures containing loperamide and NADPH (1 mM), yielding a 
final loperamide concentration of 60 μM. Secondary reactions were terminated after 20 
min by transferring 100 µl to a 96-well plate containing 300 µl of acetonitrile/0.1% (v/v) 
formic acid and internal standard (0.5 μM D3-N-desmethylloperamide). Plates were 
centrifuged at 2000 x g for 10 min, and 200 µl of supernatant were transferred to clean 
plates. The contents were dried under heated nitrogen (50°C), reconstituted in 200 µl of 
95% water:5% acetonitrile:0.1% formic acid (v/v/v) (initial chromatographic conditions), 
and analyzed for N-desmethylloperamide by LC/MS/MS (see below). 
Quantification of Loperamide and N-Desmethylloperamide 
 Human Plasma. Plasma (50 µl) was added to methanol (70 µl) containing 
internal standard (4.3 nM D6-loperamide and D3-N-desmethylloperamide) then 
precipitated with 360 µl of methanol. The mixtures were vortexed for 5 min and 
centrifuged (3000 g x 10 min at 4°C). Calibration (0.1-25 nM) and quality control (0.75, 
4, 12 nM) solutions were prepared using authentic standards and blank human plasma. 
Sample (5 µl) was injected onto an Aquasil C18 (2.1 x 50 mm, 5 µm particle size) 
analytical column (Thermo Fisher Scientific). Analytes were eluted with a binary 
gradient consisting of water/0.1% (v/v) formic acid (mobile phase A) and 
acetonitrile/0.1% (v/v) formic acid (mobile phase B) at a total flow rate of 0.75 ml/min. 
Initially, mobile phase B was held at 20% for 0.4 min then increased linearly to 95% for 
3.6 min. Mobile phase B was held at 95% for 0.5 min then returned to initial conditions 
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over 6 seconds and equilibrated. The total run time was 5 min. All eluted solvent was 
directed to an API4000 QTRAP® triple quadrupole mass spectrometer (AB Sciex, 
Framingham, MA). Loperamide (477.3→266.2 m/z), N-desmethylloperamide 
(463.2→252.2 m/z), D6-loperamide (483.3→272.2 m/z), and D3-N-desmethylloperamide 
(466.3→255.2 m/z) were quantified in multiple reaction monitoring mode; collision 
energy was set to 20 mV for all analytes. Analyte concentrations were quantified using 
Analyst software (v1.4.1) by interpolation from matrix matched calibration curves and 
quality controls with a linear range of 0.1-25 nM. The calibration standards and quality 
controls were judged for batch quality based on the 2013 FDA guidance for industry 
regarding bioanalytical method validation (US Food and Drug Administration, 2013). 
 Microsomal Incubations. Calibration (1-1000 nM) and quality control (2.5, 500, 
800 nM) solutions were prepared using authentic N-desmethylloperamide standard and 
HIMs. Sample (5 µl) was injected onto an Aquasil C18 (2.1 x 50 mm, 5 µm particle size) 
analytical column. Chromatographic separation was achieved using the same HPLC 
system and mobile phases as for plasma. Due to the high buffer and salt content of the 
microsomal samples relative to plasma, the binary gradient method was modified. Initial 
conditions consisted of 10% mobile phase B, held for 1 minute, then increased linearly 
to 95% B over 1.5 min and held for 0.5 min. The gradient was returned to initial 
conditions over 0.1 min to equilibrate the column. The total run time was 4 min. The 
eluted solvent was directed to a Sciex API5600 triple quadrupole-time of flight mass 
spectrometer. Ionization was achieved with a turbo electrospray source operated in 
positive ion mode. The declustering potential and collision energy were set to 25 V and 
30 mV, respectively. N-Desmethylloperamide was quantified using MultiquantTM 
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software (v2.1.1), selecting the fragment ion range of 252.1-252.8 and 255.1-255.8 m/z 
for N-desmethylloperamide and D3-N-desmethylloperamide, respectively. As with 
plasma analysis, all calibration standards and quality control samples were judged for 
batch quality based on the 2013 FDA guidance (US Food and Drug Administration, 
2013). 
Data Analysis 
Pharmacokinetic and Pharmacodynamic Analysis. Pharmacokinetic and 
pharmacodynamic outcomes were recovered via noncompartmental methods using 
Phoenix® WinNonlin® (v6.3; Certara, St Louis, MO). Pharmacokinetics. The maximum 
concentration (Cmax), time to reach Cmax (tmax), and last measured concentration (C72h) 
were obtained directly from the plasma concentration-time profiles. The terminal 
elimination rate constant (λz) was determined by linear regression of the terminal portion 
of the log-transformed concentration-time profile using at least three data points. The 
terminal half-life (t1/2) was calculated as ln(2)/λz. Area under the plasma concentration-
time curve (AUC) from time zero to 72 h (AUC0-72h) was determined using the 
trapezoidal method with linear up/log down interpolation. The AUC from time zero to 
infinity (AUC0-inf) was calculated as the sum of AUC0-72h and C72h/λz. The oral clearance 
of loperamide (Cl/F) was calculated as the ratio of dose to AUC0-inf. The metabolite-to-
parent AUC ratio [(AUCm/AUCp)0-72h] was calculated as the ratio of the AUC0-72h of N-
desmethylloperamide to that of loperamide. The primary pharmacokinetic outcome was 
the ratio of loperamide AUC0-inf in the presence to that in the absence of grapefruit juice 
(AUCGFJ/AUC). Pharmacodynamics. Baseline pupil diameter was obtained at time zero, 
and miosis was determined as the decrease in pupil diameter from baseline. The area 
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under the effect (miosis)-time curve from 0-72 h (AUEC0-72h) was calculated by the 
linear trapezoidal method with an adjustment from the baseline pupil diameter 
measurement. The maximum decrease in pupil diameter (Rmax) was obtained directly 
from the miosis-time profile.  
MBI Kinetic Parameters for DHB. KI and kinact were recovered using previously 
published methods (Paine et al., 2004; Obach et al., 2007; Brantley et al., 2013). Final 
parameter estimates were obtained by nonlinear least-squares regression using 
Phoenix® WinNonlin® and eq. 1: 
       (1)  
where kinact,app denotes the apparent inactivation rate constant at each inhibitor 
(DHB) concentration,  determined by the slope of the mono-exponential decline in 
activity. Model fit was evaluated from visual inspection of the observed versus predicted 
data, randomness of the residuals, and standard errors of the parameter estimates. The 
efficiency of inactivation was calculated as the ratio of kinact to KI.  
Grapefruit Juice-Loperamide Interaction Prediction Using DHB as a Marker 
Constituent. The grapefruit juice-mediated increase in AUC (AUCGFJ/AUC) for 
loperamide was predicted using DHB as a marker constituent and a mechanistic static 
model (eq. 2) for intestinal MBI (Obach et al., 2006; Brantley et al., 2013): 
     (2) 
where Fg denotes the fraction of the dose of victim drug (loperamide) escaping 
first-pass extraction in the intestine (0.62), Ig denotes the concentration of inhibitor 
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(DHB) in the enterocyte (5 µM), and kdeg denotes the degradation rate constant 
associated with intestinal CYP3A4 (0.000481 min-1) (Obach et al., 2006). The Qgut and 
Advanced Dissolution and Metabolism models in Simcyp® (v13; Certara, St. Louis, MO) 
were used to estimate loperamide Fg and DHB Ig using MDCK cell permeability (Tran et 
al., 2004) and recombinant CYP3A4 metabolism (Kim et al., 2004) data for loperamide 
and Caco-2 cell permeability data for DHB (Paine et al., 2005). The fraction of the dose 
of loperamide absorbed into enterocytes (Fabs) was assumed to remain unchanged in 
the presence of grapefruit juice. 
Grapefruit Juice-Drug Interaction Predictions with Marketed Drugs Using 
DHB as a Marker Constituent. The utility of DHB as a marker constituent predictive of 
grapefruit juice-drug interactions was examined further with marketed drugs that have 
been evaluated in the clinic. Test victim drugs (Table 2.1) were selected based on the 
following criteria: intestinal CYP3A4 substrate, availability of human pharmacokinetic 
data, and availability of Fg. Fg was obtained from liver transplant recipients during the 
anhepatic phase of the operation, by the combined intravenous/oral administration 
method, or from in vitro-in vivo scaling techniques (Galetin et al., 2010). Drugs whose Fg 
were estimated by a third method, which involves grapefruit juice administration (Gertz 
et al., 2008), were excluded to avoid bias. Predictions were made using eq. 2. Predicted 
AUCGFJ/AUCs were evaluated against observations from the literature. As the grapefruit 
juice-loperamide interaction study was powered to detect a 25% change in loperamide 
AUC0-inf, predicted AUCGFJ/AUCs were evaluated against observed ratios with a 
predefined cutoff of 25% to define a successful prediction (Vieira et al., 2014).  
 66 
Sensitivity Analysis to Assess the Relationship between DHB Ig, Victim 
Drug Fg, and the Predicted AUCGFJ/AUC. Due to the uncertainty in DHB Ig, the 
variability in grapefruit juice administration frequency in clinical studies, and the 
uncertainty in victim drug Fg predictions, AUCGFJ/AUC ratios were simulated by 
increasing Fg and Ig. Simulations were conducted in Phoenix® WinNonlin® using eq. 2, 
with Fgs ranging from 0.1-0.9 and DHB concentrations from 0-5 µM in increments of 
0.05 and 0.1 µM, respectively.   
Statistical Analysis 
Statistical analyses were conducted using SAS (v9.1.3; SAS Institute, Cary, NC). 
Clinical study. The sample size was based on 80% power to detect a 25% difference in 
the primary outcome of loperamide, AUCGFJ/AUC, with an alpha of 0.05. Data are 
presented as the geometric mean [90% confidence interval] with the exception of tmax, 
which is reported as the median (range). The primary outcome was evaluated against 
the predefined no effect range of 0.75-1.33. The Wilcoxon signed-rank test was used to 
test for a difference in tmax. Differences in AUC0-72h, AUC0-inf, Cmax,, t1/2, Cl/F, and AUEC 
between treatment groups were analyzed by standard repeated-measures ANOVA (α = 
0.05) using log-transformed data. In vitro study. Data are presented as the mean of 
duplicate incubations. MBI kinetic parameters are presented as estimates ± S.E.’s. 
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Results 
All enrolled subjects completed the clinical study with negligible side 
effects. The mean (± S.D.) concentration of DHB in the test juice was 73.7 ± 4.0 µM, 
measured in triplicate. Of the 18 potential subjects screened, 8 men and 8 non-pregnant 
women were enrolled. The median [range] age was 29 [22-59] and 40 [29-53] years, 
respectively. Participants were self-identified as white (5 men, 4 women), African 
American (1 man, 4 women), Hispanic (1 man), or Asian (1 man). None of the subjects 
reported taking concomitant medications or dietary substances known to modulate the 
metabolism and transport of both loperamide and morphine. Concomitant medications 
included acetaminophen (two women) and promethazine (one woman). All subjects 
completed both phases of the study. Grapefruit juice and both test drugs were well-
tolerated; one subject reported mild constipation with loperamide during the grapefruit 
juice phase that resolved within 24 h.  
 Grapefruit juice increased the systemic exposure of loperamide with no 
effect on pupil diameter. Pharmacokinetics. Loperamide and N-desmethylloperamide 
were detected readily in plasma in all subjects throughout the 72-h collection period. 
Relative to water, grapefruit juice elevated the plasma concentrations of loperamide but 
had no effect on those of N-desmethylloperamide (Fig. 2.1A). The percentage of 
loperamide AUC0-inf extrapolated from 72 h to infinite time was <25% in both the water 
and grapefruit juice phases. The primary outcome, AUCGFJ/AUC, was outside the range 
associated with bioequivalence (0.75-1.33) (Table 1). Relative to water, grapefruit juice 
increased geometric mean loperamide Cmax, AUC0-72h, and AUC0-inf significantly, by ~60-
70%; geometric mean Cl/F decreased significantly, by 43% (Table 2.1). Grapefruit juice 
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had no effect on geometric mean loperamide terminal t1/2. Median loperamide tmax did 
not differ significantly between treatments. The percentage of N-desmethylloperamide 
AUC0-inf extrapolated from 72 h to infinite time was >40% in the water and grapefruit 
juice phases in 10 of the subjects, precluding accurate recovery of AUC0-inf, as well as 
t1/2, in these subjects. As such, geometric means for these outcomes are not reported. 
Grapefruit juice had no effect on N-desmethylloperamide geometric mean Cmax and 
AUC0-72h and median tmax; (AUCm/AUCp)0-72h decreased by 40% (Table 2.1). 
Pharmacodynamics. Relative to baseline, morphine, but not loperamide, decreased 
pupil diameter (Fig. 1B). The geometric mean [90% confidence interval] AUEC0-2h and 
Rmax for morphine was 150 [115-195] mm*h and 1.9 [1.5-2.5] mm, respectively. The 
median (range) time to Rmax was 1.0 (0.5-1.5) h. The geometric mean AUEC0-72h for 
loperamide in the absence and presence of grapefruit juice was 11.3 [9.2-13.9] and 11.8 
[8.5-16.4] mm*h, respectively; geometric mean Rmax was 0.38 [0.30-0.47] and 0.40 
[0.33-0.51] mm, respectively.  
 DHB is a mechanism-based inhibitor of loperamide N-desmethylation in 
HIMs. DHB inhibited N-desmethylloperamide formation in a time- and concentration-
dependent manner in HIMs (Fig. 2.2). The KI and kinact were 5.0 ± 0.9 µM and 0.38 ± 
0.02 min-1, respectively. The efficiency of inactivation (kinact/KI) was 76 µl/min/pmol.  
 DHB is predictive of interactions between grapefruit juice and loperamide 
and several marketed drugs. Using DHB as a marker constituent of grapefruit juice 
and a mechanistic static model, the predicted AUCGFJ/AUC for loperamide was 1.6. The 
AUCGFJ/AUC and Fg for other marketed drugs were obtained from the literature 
according to predefined criteria. The reported absolute bioavailability and Fg of these 
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drugs ranged from 0.12-0.94 and 0.14-0.94, respectively (Table 2.2). Application of the 
mechanistic static model to these marketed drugs predicted the AUCGFJ/AUC of 12 of 
15 interactions to within the pre-defined 25% criterion (Fig. 2.3). 
Victim drug Fg is more sensitive than DHB (Ig) in the prediction of 
AUCGFJ/AUC. At an Fg for loperamide of 0.62 (predicted using the Qgut model in 
Simcyp®), incremental (0.1 µM) increases in Ig reached a maximum AUCGFJ/AUC (1.6) 
at 1.2 µM (Fig. 2.4). The Ig required to achieve the maximum AUCGFJ/AUC increased 
with decreasing Fg. An incremental decrease (0.05) in Fg from 0.90 to 0.45 at a constant 
Ig (1.2 µM) resulted in a nearly proportional increase in AUCGFJ/AUC. Simulated Fgs less 
than 0.45 resulted in a greater than proportional increase in AUCGFJ/AUC. 
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Discussion 
  Dietary substance-drug interaction risk assessment is fraught with challenges, 
adding to those encountered with DDIs. Dietary substances of plant-based origin have a 
more complex biochemical makeup compared to oral drug formulations. Identification of 
major constituents (chemical classes or single chemical entities) that contribute to 
inhibition of drug metabolizing enzymes, as well as transporters, in vivo would help 
overcome some of these challenges (Won et al., 2012; National Center for 
Complementary and Alternative Medicine, 2013). Ideally, a single phytochemical marker 
would be identified and evaluated using methods similar to those used in the 
pharmaceutical industry, including in vitro bioactivity assays, IVIVE, and clinical 
assessment. An approach involving a combination of these methods was evaluated 
using the exemplar perpetrator dietary substance grapefruit juice and the marker 
constituent DHB. 
 Loperamide was selected as the test victim drug because it meets the criteria for 
an interaction with grapefruit juice (Bailey et al., 2013), and a grapefruit juice-loperamide 
interaction study has not been reported. This purported interaction was confirmed with 
16 healthy volunteers, in which the primary pharmacokinetic outcome, geometric mean 
loperamide AUCGFJ/AUC, was 1.7. The lack of effect on loperamide terminal elimination 
half-life was consistent with an interaction limited to the gut, which is typical of grapefruit 
juice-drug interactions (Won et al., 2012; Bailey et al., 2013). In contrast to loperamide, 
the pharmacokinetics of the primary CYP3A4-mediated metabolite, N-
desmethylloperamide, were unchanged in the presence of grapefruit juice, which may 
reflect elimination rate-limited kinetics and/or more rapid distribution into peripheral 
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tissues relative to loperamide (Sklerov et al., 2005). The pharmacokinetics of both 
loperamide and N-desmethylloperamide in the absence of grapefruit juice were 
consistent with those reported at an equivalent loperamide dose (16 mg) (Mukwaya, 
2005) or lower (2-4 mg) after dose-normalization (Streel et al., 2005; Niemi et al., 2006).  
 Based on anecdotal reports describing abuse of loperamide when taken with 
grapefruit juice (Daniulaityte et al., 2013) and the ease of measuring pupil diameter as 
an index of central nervous system opiate-like effect, the opportunity was taken to 
assess a pharmacodynamic interaction. Compared to baseline, a relatively high dose of 
loperamide (16 mg), in both the absence and presence of grapefruit juice, did not 
decrease pupil diameter (i.e., produce miosis). The lack of miosis was consistent with 
previous healthy volunteer studies in which loperamide was administered at higher 
doses (≥24 mg) (Skarke et al., 2003) or with potent CYP3A4 or dual CYP3A4/P-
glycoprotein (P-gp) inhibitors (Mukwaya et al., 2005; Niemi et al., 2006).   
 Confirmation of the grapefruit juice-loperamide interaction permitted evaluation of 
DHB as a marker constituent of whole juice. MBI kinetic parameters for DHB were 
recovered using HIMs and N-desmethylloperamide formation as the index reaction to 
inform a mechanistic static interaction model specific to the gut. The parameters, KI and 
kinact (5.0 μM and 0.38 min-1, respectively), were comparable to those recovered using 
other CYP3A4-mediated reactions and HIMs, specifically testosterone 6β-hydroxylation 
(2.5 µM and 0.40 min-1, respectively) and midazolam 1’-hydroxylation (3.5 µM and 0.31 
min-1, respectively) (Paine et al., 2004). The other parameters needed to inform the 
mechanistic static model, Fg and Ig, were estimated using literature data. The Fg for 
loperamide and the Ig for DHB were predicted using the Qgut and Advanced Dissolution 
 72 
and Metabolism models within Simcyp® (Yang et al., 2007), which were informed by 
permeability data (loperamide and DHB) (Tran et al., 2004; Paine et al., 2005), 
metabolic kinetic data (loperamide) (current work), and intestinal villous blood flow. The 
predicted AUCGFJ/AUC agreed with the observed AUCGFJ/AUC (1.6 versus 1.7) to within 
the 25% pre-defined criterion, supporting DHB as a marker constituent predictive of the 
effect of whole juice.    
The successful IVIVE with the grapefruit juice-loperamide interaction prompted 
further evaluation with other previously tested drugs. Based on the availability of human 
pharmacokinetic data and Fgs, as well as the test drug being a CYP3A4 substrate, 15 
grapefruit juice-drug interaction studies were identified. Although the absolute 
bioavailability of three of the drugs was relatively high (>70%), and thus not victim drugs 
per se, these drugs were included to provide a wide range of AUCGFJ/AUCs. The Fgs of 
the test drugs, determined from liver transplant patients during the anhepatic phase of 
the operation, by combined intravenous and oral administration, or in vitro-in vivo 
scaling techniques, ranged from 0.14 to 0.94. Drugs whose Fg was determined using 
grapefruit juice as an inhibitor of intestinal metabolism were excluded to avoid bias. The 
same DHB Ig used for the loperamide interaction prediction was used for the other 
victim drugs. As with loperamide, DHB was predictive to within 25% of the observed 
AUCGFJ/AUC for 10 of the interactions. The three outlier victim drugs were atorvastatin, 
simvastatin, and triazolam. The interaction with atorvastatin was over predicted by 3.3-
fold (4.0 versus 1.2), which may reflect atorvastatin being a substrate for organic anion 
transporting polypeptide (OATP) 2B1 (Km, 0.2 µM) (Kalliokoski and Niemi, 2009), an 
uptake transporter expressed on the apical membrane of enterocytes and other cell 
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types (Ito et al., 2005). Grapefruit juice has been shown to decrease systemic exposure 
to the OATP substrate fexofenadine via inhibition of intestinal OATP(s) (Dresser et al., 
2002). As inhibition of intestinal OATP(s) and CYP3A4 decrease and increase systemic 
drug exposure, respectively, these two processes acting in concert would be expected 
to reduce the AUCGFJ/AUC compared to CYP3A4 inhibition alone. Conversely, 
substrates of both CYP3A4 and the apically-located efflux transporter, P-gp, would be 
expected to increase AUCGFJ/AUC compared to CYP3A4 inhibition alone. The 
AUCGFJ/AUC of such dual CYP3A4/P-gp substrates (cyclosporine, methadone, 
quinidine, tacrolimus) were well-predicted despite implications that DHB inhibits P-gp 
(Eagling et al., 1999; de Castro et al., 2007) in addition to CYP3A4. This observation 
suggests that the contribution of intestinal CYP3A4 inhibition supersedes that of 
intestinal P-gp inhibition when grapefruit juice is co-administered with dual CYP3A4/P-
gp substrates.  
Unlike with atorvastatin, the interaction with simvastatin was underpredicted, by a 
factor of 2.4 (1.5 versus 3.6). Simvastatin was one of three drugs whose Fg was 
determined using an in vitro extrapolation technique, which may have overestimated Fg, 
resulting in the underprediction. The method used to derive the Fg for simvastatin (0.66) 
involved oral clinical pharmacokinetic data and in vitro microsomal clearance data. This 
estimate was used in lieu of that obtained with the Qgut model (0.06) (Gertz et al., 2010), 
as the former was derived using at least some clinical data versus in vitro data alone. 
The Fg from the Qgut model would have over predicted simvastatin AUCGFJ/AUC  by 9-
fold. The disconnect between the two methods and between the observed and 
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predicted AUCGFJ/AUC suggest that other unknown mechanisms/factors contribute to 
the grapefruit juice-simvastatin interaction.  
As with simvastatin, the interaction with triazolam was under predicted, albeit 
modestly (1.5 versus 2.0). This underprediction may be due to ethnic and/or sex 
differences between subjects. The reference clinical study involved nine healthy 
Japanese men (Sugimoto et al., 2006), and the estimated Fg was derived from healthy 
Caucasians (10 men, 11 women) (Masica et al., 2004). In addition, the dose-normalized 
AUC in the absence of grapefruit juice was lower in the Japanese study compared to 
that reported for American men (11 Caucasians, 2 African Americans) (Greenblatt et al., 
2005). Taken together, the extent of intestinal extraction of triazolam may be greater 
(i.e., Fg may be lower) in Japanese than American men, which would explain the greater 
AUCGFJ/AUC in the Japanese cohort. 
 The aforementioned discrepancies highlight limitations of the IVIVE method used 
in the current work. First, the accuracy of this estimate is dependent on an accurate 
victim drug Fg, as the model is sensitive to this parameter, particularly when less than 
0.45 (Fig. 4). Second, significant involvement of transporters in the disposition of the 
test drug would preclude the use of this model. Despite these limitations, this IVIVE 
approach, which is used routinely by the pharmaceutical industry, can be implemented 
readily into work streams in the drug discovery process upon the identification of 
candidate marker constituents. 
In summary, the importance of dietary substance-drug interaction risk 
assessment has been recognized by regulatory agencies, yet relevant guidelines have 
not been established. A framework to identify causative constituents in dietary 
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substances has been proposed (National Center for Complementary and Alternative 
Medicine, 2013), which was applied in the current work using grapefruit juice as an 
exemplar perpetrator, DHB as a marker constituent, and loperamide as a test victim 
drug. A clinical study confirmed a pharmacokinetic interaction between grapefruit juice 
and loperamide. A mechanistic static model of intestinal CYP3A4 MBI incorporating 
DHB kinetic parameters was sufficient to predict the grapefruit juice-loperamide 
interaction, as well as 12 of 15 previously reported grapefruit juice-drug interaction 
studies, to within 25%. This approach has limitations when applied to victim drugs 
whose estimated Fg is inaccurate/uncertain and/or that are substrates for intestinal 
OATPs or other uptake transporters. This IVIVE method is a relatively simple and cost-
effective means to assess grapefruit juice-drug interaction liability or to prioritize 
compounds for more advanced and resource heavy assessment, such as dynamic 
modeling approaches and/or clinical evaluation. In conclusion, this IVIVE method 
expands upon proposed frameworks to assess clinically relevant dietary substance-drug 
interactions, results of which will help guide dietary substance-drug interaction risk 
assessment. 
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Table 2.1. Pharmacokinetic outcomes of loperamide and N-desmethylloperamide in 16 
healthy volunteers administered loperamide with 240 ml of water or grapefruit juice. 
Outcome Water GFJ 
GFJ/Water  
Ratio 
Loperamide 
   
Cmax (nM) 6.5 [5.3-8.1] 10 [8.2-13]  1.58 [1.33-1.88] 
b 
AUC0-72h (nM · h) 105 [87-126] 180 [149-220]  1.72 [1.58-1.87] 
b 
AUC0-inf (nM · h) 118 [96-145] 203 [165-250]  1.73 [1.58-1.89] 
b 
Cl/F (L/h) 285 [232-351] 165 [134-203]  0.57 [0.53-0.62] b 
Terminal t½ (h) 23.3 [20.7-26.3] 23.2 [20.8-26.0] 1.04 [0.94-1.16] 
    tmax (h) [median (range)] 3.0 (0.5-12) 5.0 (2.0-6.0) 
a  
N-Desmethylloperamide 
   
Cmax (nM) 7.9 [6.7-9.2] 7.7 [6.6-9.0] 0.98 [0.83-1.15] 
AUC0-72h (nM · h) 271 [253-290] 290 [270-310] 1.04 [0.99-1.10] 
    tmax (h) [median (range)] 5.5 (2.0-12) 7.0 (4.0-26) 
a  
Metabolite/parent AUC ratio    
(AUCm/AUCp)0-72h  2.6 [2.2-3.1] 1.6 [1.3-1.9]  
AUC0-72h, area under the plasma concentration-time curve from 0 to 72 h; AUC0-inf, AUC 
from 0 to infinite time; AUCm, AUC of N-desmethylloperamide; AUCp, AUC of 
loperamide; CL/F, oral clearance; Cmax, maximum plasma concentration; t1/2, terminal 
elimination half-life; tmax, time to Cmax. Values denote the geometric mean [90% 
confidence intervals] unless indicated otherwise. aNot significant (p<0.05, Wilcoxon 
signed-rank test). bOutside the predefined no effect range (0.75-1.33). 
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Table 2.2. Victim drug, Fg, F, and clinical study information for the IVIVE. 
Victim drug Fg F 
a AUCGFJ/AUC 
b 
 Estimate Reference  Observed Reference 
Alfentanil 0.60 c (Kharasch et al., 2008) 0.42 d 1.6 (Kharasch et al., 2004a) 
Alprazolam 0.94 e (Hirota et al., 2001) 0.88 ± 0.16 1.1 (Yasui et al., 2000) 
Atorvastatin 0.24 c (Lennernas, 2003) 0.12 1.2 (Reddy et al., 2011) 
Buspirone 0.21 e (Obach et al., 2005) 0.40 ± 0.04 4.3 (Lilja et al., 1998) 
Cyclosporine 
0.28-0.68 
c 
(Ducharme et al., 1995) 0.28 ± 0.18 1.4-1.9 
(Schwarz et al., 2006; 
Paine et al., 2008) 
Felodipine 0.45 c (Lundahl et al., 1997) 0.15 ± 0.8 2.0 (Paine et al., 2006) 
Methadone 0.78 c (Kharasch et al., 2004b) 0.92 ± 0.21 1.1 (Kharasch et al., 2008) 
Midazolam 0.57 f (Paine et al., 1996) 0.44 ±0.17 1.7 (Kharasch et al., 2004a) 
Nifedipine 0.78 c (Holtbecker et al., 1996) 0.50 ± 0.13 1.1 (Odou et al., 2005) 
Nisoldipine 0.11 c (Gertz et al., 2010) 0.05 8.2 (Takanaga et al., 2000) 
Sildenafil 0.78 c (Gertz et al., 2010) 0.38 1.2 (Jetter et al., 2002) 
Simvastatin 0.66 e (Obach et al., 2006) ≤0.5 3.6 (Lilja et al., 2004) 
Quinidine 0.90 c (Darbar et al., 1997) 0.71 ± 0.17 1.05 g (Damkier et al., 1999) 
Tacrolimus 0.14 c (Floren et al., 1997) 0.25 ± 0.10 6.6 i (Liu et al., 2009) 
Triazolam 0.75 c (Masica et al., 2004) 0.55-0.60 h 2.0 (Sugimoto et al., 2006) 
Fg, fraction of dose of victim drug that escapes intestinal first-pass extraction; F, oral 
bioavailability; aobtained from Brunton et al. (Brunton et al., 2010) unless indicated 
otherwise; bratio of the area under the plasma concentration-time curve in the presence 
to absence of grapefruit juice, unless indicated otherwise; cestimated using intravenous 
administration, systemic clearance, and oral bioavailability data; dobtained from 
Kharasch et al., 2004b; edetermined by in vitro to in vivo extrapolation using in vitro 
intrinsic clearance data; fdetermined from anhepatic patients; gratio of maximum 
concentration in the presence to absence of grapefruit juice; hobtained from Masica et 
al., 2004; iratio of trough concentrations in liver transplant recipients following one week 
of treatment and chronic grapefruit juice consumption.
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Figure 2.1. Clinical study design and procedures 
Figure 2.1. Clinical study design and procedures. As a positive control for miosis, 9 
subjects were administered morphine sulfate (0.07 mg/kg; 5-min intravenous infusion); 
pupil diameter was measured before and at 5, 10, 20, 30, 60, 90 and 120 min after 
infusion. After an overnight fast, subjects (n = 16) were administered 16 mg loperamide 
with either 240 ml of water (control) or grapefruit juice (treatment). Blood and dark-
adapted pupil diameter measurements were obtained before and 0.5, 1, 2, 3, 4, 5, 6, 8, 
10, and 12 h after loperamide administration on the first day of each study phase. 
Subjects returned as outpatients for blood draws and pupil diameter measurements at 
24, 36, 48, and 72 h after loperamide administration. The two phases were separated 
by at least two weeks. 
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Figure 2.2. Loperamide (solid symbols) and N-desmethylloperamide (open symbols) 
plasma concentrations (A) and pupil diameter measurements (B) in 16 healthy 
volunteers administered loperamide (16 mg) with 240 ml of water (circles, solid lines) or 
grapefruit juice (triangles, dashed lines). The inset depicts the 0-2 h pupil diameter-time 
profile after loperamide (in the absence and presence of grapefruit juice) and morphine 
(diamonds) administration for the 9 volunteers administered the morphine challenge 
(0.07 mg/kg intravenously). Symbols and error bars denote the geometric mean and 
upper 90% confidence intervals, respectively.  
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Figure 2.2. Time- and concentration-dependent inhibition of loperamide N-
desmethylation by DHB in human intestinal microsomes 
 
 
Figure 2.3. Time- and concentration-dependent inhibition of loperamide N-
desmethylation by DHB in human intestinal microsomes. Symbols denote the mean of 
duplicate incubations, all of which deviated by <20%. Lines denote linear regression of 
the initial mono-exponential decline; solid lines denote nonlinear least-squares 
regression of observed values using Phoenix® WinNonlin® (v6.3). The inset depicts the 
apparent enzyme inactivation rate as a function of DHB concentration.  
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Figure 2.3. Relationship between the predicted and observed AUCGFJ/AUC for 15 test 
drug substrates of the ‘grapefruit juice effect’ due to inhibition of intestinal CYP3A4. 
 
Figure 2.4. Relationship between the predicted and observed AUCGFJ/AUC for 15 test 
drug substrates of the ‘grapefruit juice effect’ due to inhibition of intestinal CYP3A4. 
Predictions were made using a mechanistic static model. The solid line denotes unity. 
Dashed lines denote 25% variability around the line of unity. Error bars denote predicted 
values at an Ig of 0.05 µM (lower) and 50 µM (upper, which are smaller than the circles);  
circles denote the predicted values at an Ig of 5 µM. Closed circles denote predictions 
that were accurate to within 25% of observed values. Open circles denote predictions 
that were >25% of observed values.  
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Figure 2.4. Relationship between the magnitude of a grapefruit juice-drug interaction for 
varying enterocyte concentrations of DHB and victim drug Fg. 
 
Figure 2.5. Relationship between the magnitude of a grapefruit juice-drug interaction 
(defined by AUCGFJ/AUC) for varying enterocyte concentrations of DHB (Ig) and the 
fraction of victim drug escaping intestinal extraction (Fg). Simulations were conducted 
using Phoenix® WinNonlin® and eq. 2. 
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CHAPTER 3 : CHARACTERIZING THE ABUSE POTENTIAL OF OPIOIDS USING 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC / PHARMACODYNAMIC 
MODELING: CASE STUDY WITH THE GRAPEFRUIT JUICE-LOPERAMIDE 
INTERACTION.2 
 
Introduction  
Opioid abuse in the US is second to alcohol abuse with respect to the proportion 
of individuals admitted to publically-funded treatment programs (National Institute of 
Drug Abuse, 2011; National Institute of Drug Abuse, 2014). Opioids are associated with 
chemical dependence- and overdose-related hospitalization (Meyer et al., 2014; 
National Institute of Drug Abuse, 2014). Prescription opioids are implicated in 
approximately 6% of total reported hospital admissions, exceeding all other prescription 
medications (National Institute of Drug Abuse, 2014). These observations have led to 
increased restrictions on opioid prescribing (Bohnert et al., 2011), which, combined with 
ready access to pharmacokinetic ‘boosting’ agents (e.g., grapefruit juice), may promote 
alternate means of abuse.    
Anecdotal reports (Daniulaityte et al., 2013) and case studies (Johansen and 
Jensen, 2004; Sklerov et al., 2005) describe abuse of the over-the-counter anti-
diarrheal agent loperamide, which acts on μ-opioid receptors in the gastrointestinal tract 
to slow motility. Despite having high potency toward the µ-opioid receptor (KD, 0.5-1.5
                                            
2 This chapter will be submitted to Clinical Pharmacokinetics as an original research 
paper and is presented in the style of the journal. Ainslie GR, Zamek-Gliszczynski MJ, 
Pollak GP, Kharasch ED and Paine MF. Characterizing the abuse potential of opioids 
using a physiologically-based pharmacokinetic/pharmacodynamic modeling approach: a 
case study with the grapefruit juice-loperamide interactions. Clin Pharmacokinet. 
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nM) (Terenius, 1975; Kalvass et al., 2007), central nervous system (CNS) effects are 
not apparent at usual (≤16 mg) or even supratherapeutic (24-32 mg) doses in healthy 
volunteers (Baker, 2007). This lack of effect is due to both a very low oral bioavailability 
(~0.3%) (Yu et al., 2004) and efficient efflux at the blood-brain barrier (BBB) by P-
glycoprotein (P-gp), an apically-located transporter expressed in brain endothelial cells 
and other cell types, including enterocytes and hepatocytes (Paine et al., 2005a). The 
low oral bioavailability reflects both incomplete absorption in the intestine, due in part to 
P-gp, and extensive pre-systemic (‘first-pass’) metabolism in the intestine and liver, 
primarily by cytochrome P450 (CYP) 3A4 and CYP2C8. Opioid abusers describe using 
higher doses (70-200 mg) of loperamide to overcome these barriers, sometimes in 
combination with CYP3A4 and dual CYP3A4/P-gp inhibitors (Daniulaityte et al., 2013).  
Grapefruit juice (GFJ) is a readily accessible dual CYP3A4/P-gp inhibitor that has been 
implicated with loperamide abuse (Daniulaityte et al., 2013). This juice is an extensively 
studied dietary substance that can increase the systemic exposure of orally 
administered ‘victim’ drugs, including the opioids loperamide (Ainslie et al., 2014), 
oxycodone (Nieminen et al., 2010), and alfentanil (when administered orally) (Kharasch 
et al., 2004a), by inhibiting intestinal CYP3A4 in an irreversible manner (Bailey et al., 
2013).  
Clinical assessment of loperamide abuse claims presents challenges. For 
example, administering loperamide to healthy volunteers at doses reported to elicit 
euphoric effects (≥70 mg) would pose both safety and ethical concerns. In addition, 
recruiting opioid abusers may produce a highly variable cohort, requiring a large sample 
size. Physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling 
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would help allay these challenges. However, interaction predictions involving 
‘perpetrators’ that are complex mixtures, such as GFJ, pose additional challenges. 
Dietary substances in general are mixtures that vary markedly in phytochemical 
composition, both between brands and batches of the same brand. Identification of a 
single marker constituent predictive of the mixture would mitigate this complexity. One 
such constituent in GFJ, 6’,7’-dihydroxybergamottin (DHB), was demonstrated recently 
to predict the effect of whole juice on the systemic exposure of 13 of 16 victim CYP3A4 
and CYP3A4/P-gp substrates, including loperamide, using a mechanistic static model 
(Ainslie et al., 2014).  
The lack of a definitive loperamide concentration-CNS effect relationship in 
humans precludes development of a PD component of a predictive PBPK/PD model. 
The PD of seven μ-opioid agonists (alfentanil, fentanyl, loperamide, meperidine, 
methadone, morphine, sufentanil) were determined using a murine model of 
antinociception (Kalvass et al., 2007). Excluding loperamide (due to the lack of data for 
humans), unbound brain concentration required to elicit half the maximum effect 
(EC50,brain,unbound) correlated with human equipotent intravenous dose (r2 = 0.98), 
supporting mouse as a suitable model for opioid brain disposition and pharmacology in 
humans. Although mouse EC50,brain,unbound was correlated to human intravenous dose, a 
maximum attainable effect (Emax) measured using a hot-plate latency test flick assay, 
does not translate to clinical measures of opioid effect. This discordance could be 
addressed by recovering an Emax using a readily obtainable and sensitive endpoint 
(change in pupil diameter) in humans and an exemplar opioid.   
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Alfentanil is a short-acting opioid indicated for analgesia during surgical 
procedures. Unlike other opioids (e.g., morphine, methadone, and oxycodone), the 
plasma concentration-effect relationship is not associated with a time delay, i.e., 
counterclockwise hysteresis. These characteristics, combined with the availability of 
extensive preclinical and clinical data, render alfentanil an ideal exemplar opioid to 
recover key parameters needed to develop the PD component of a PBPK/PD model for 
loperamide.  
The goal of the present work was to determine an alfentanil-equivalent dose of 
loperamide, in the absence and presence of GFJ, to assess the abuse potential of 
loperamide. First, a PBPK/PD model for alfentanil was developed using PD parameters 
recovered from clinical and in vivo mouse studies. Second, PBPK/PD model robustness 
was assessed further using a second, well-studied opioid, methadone. Third, a PBPK 
model describing the GFJ-loperamide interaction was developed using DHB as a 
surrogate of whole juice. Fourth, a PBPK/PD model for loperamide was developed 
using alfentanil PD parameters to predict a PD endpoint (change in pupil diameter). 
Finally, using the DHB-loperamide interaction model and the PBPK/PD model for 
loperamide, an alfentanil equivalent dose of loperamide was determined with and 
without GFJ. This work provides an initial assessment of loperamide abuse potential in 
healthy volunteers by comparing the simulated pupillary response with that of alfentanil. 
This PBPK/PD modeling approach may be more broadly applied to other populations, 
opioids, or perpetrator xenobiotics.  
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1. Methods 
1.1. Materials and Chemicals  
Loperamide hydrochloride and D6-loperamide were purchased from Toronto 
Research Chemicals Inc. (North York, Ontario Canada). DHB was purchased from 
Sigma Aldrich (St. Louis, MO) (for binding experiments) or from Caymen Chemical (Ann 
Arbor, MI) (as analytical standard for quantification in human plasma). Psoralen was 
purchased from Caymen Chemical. LC-MS/MS grade acetonitrile, methanol, 
dimethylsulfoxide, ethyl acetate, and formic acid were purchased from Thermo Fisher 
(Waltham, MA). 
1.2. Recovery of Binding and Partitioning Properties 
1.2.1. Plasma Protein and Brain Tissue Binding 
The unbound fraction for loperamide and DHB in human plasma and rat brain 
tissue was determined experimentally by equilibrium dialysis (Zamek-Gliszczynski et al., 
2012).    
1.2.2. Blood to Plasma Partition Ratio 
Loperamide and DHB were added to fresh human whole blood to yield final 
concentrations of 0.1, 1, and 10 µM. After 2 h at 37°C, blood cells and plasma were 
separated by centrifugation (3000 rpm, 4°C, 10 min). Aliquots of whole blood and 
plasma were precipitated with methanol:acetonitrile (1:1, v:v) containing internal 
standard. The supernatants were quantified for loperamide or DHB by LC-MS/MS Blood 
to plasma (B/P) ratios were calculated as the ratio of analyte in blood to that in plasma 
(Zamek-Gliszczynski et al., 2013). 
1.3. Determination of DHB Pharmacokinetics 
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1.3.1. Quantification of DHB in Human Plasma 
Plasma samples from a GFJ-loperamide interaction study (Ainslie et al., 2014) 
were quantified for DHB concentrations. Plasma had been stored at -80°C and was 
thawed at room temperature under low light conditions. Calibration standards and 
quality controls were prepared using blank human plasma (Bioreclamation, Baltimore, 
MD) at concentrations ranging from 0.25-1000 and 0.8-800 nM, respectively. Ethyl 
acetate (500 μL) containing 400 nM internal standard (psoralen) was added to thawed 
plasma (100 μL) to precipitate proteins. Samples were vortexed for 3 min at room 
temperature then centrifuged (2000 x g, 10 min, 4°C). Supernatant (400 µl) was 
transferred to 0.6 mL cluster tubes and dried under heated (50°C) nitrogen gas. 
Residues were reconstituted in 95% water:5% acetonitrile:0.1% formic acid (v:v:v). 
Samples (10 µl) were injected onto a Thermo Aquasil C18 column (3 µm, 2.1 x 
50 mm). Analytes were eluted using a gradient initially held at 95% mobile phase A 
(water with 0.1% formic acid) and 5% mobile phase B (acetonitrile with 0.1% formic 
acid) for 0.4 min. Mobile phase B was increased linearly for 1.1 min to 95%, maintained 
for 0.2 min, then returned to initial conditions over 6 sec. The column was equilibrated 
for 2 min. Eluent was directed to waste for the first 0.4 min then to a Sciex API 6500 
hybrid triple quadrupole mass spectrometer (Framingham, MA). The mass spectrometer 
was operated in multiple reaction monitoring (MRM) mode, with a source temperature of 
250°C and ion spray voltage of 2500 V. MRM transitions for DHB and psoralen were 
273.2→203.1 (collision energy, 25 mV) and 187.1→131.2 (collision energy, 32 mV), 
respectively. DHB was quantified using peak area ratios, calibration standards, and 
MultiquantTM software (v3.0, AB Sciex, Framingham, MA). The lower limit of 
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quantification was 250 pM based on FDA guidelines (US Food and Drug Administration, 
2013).  
1.3.2. Pharmacokinetic Analysis 
Pharmacokinetic outcomes were obtained via standard non-compartmental 
methods using Phoenix® WinNonlin® (v6.3, Certara, St. Louis, MO). The maximum 
concentration (Cmax) and time to reach Cmax (tmax) were obtained directly from the 
plasma concentration-time profiles. Area under the plasma concentration-time curve 
(AUC) from time zero to 4 h (AUC0-4h) was determined using the trapezoidal method 
with linear up/log down interpolation. 
1.4. Physiologically-Based Pharmacokinetic Model Development 
PBPK models for loperamide, DHB, alfentanil, and methadone were developed 
using the ‘Full PBPK model’ (Fig. 1) within Simcyp® (version 13, Certara), a population-
based simulator.  
1.4.1.  Model Parameterization: Absorption 
  Loperamide and DHB absorption were described using the Advanced 
Dissolution, Absorption, and Metabolism (ADAM) model, which considers intestinal 
metabolism and transport and is required to assess interactions at the level of the gut 
(Jamei et al., 2009). Human enteric permeability coefficients (Peff,man) were predicted 
using data obtained from MDCK (loperamide) (Tran et al., 2004) or Caco-2 (DHB) 
(Paine et al., 2005b) cells (Table 3.1). First-order absorption rate constants (ka) for 
alfentanil, R-methadone, and S-methadone were obtained from the literature (Yang et 
al., 2006).  
1.4.2. Model Parameterization: Distribution 
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Molecular weight, logP, and pKa were obtained from the literature (Table 1). 
Plasma protein binding, brain tissue binding, and B/P ratios were obtained 
experimentally (section 2.2.2) or from the literature (Table 3.1). Partitioning into tissue 
compartments was predicted within Simcyp® using ‘method 2’ (Berezhkovskiy, 2011). 
Model-predicted volumes of distribution at steady state (Vss) were compared to literature 
values to confirm the appropriateness of the tissue distribution model. 
1.4.3. Model Parameterization: Metabolism 
Loperamide is metabolized primarily to N-desmethylloperamide by CYP2B6, -
2C8, -2D6, and -3A4 (Kim et al., 2004). Alfentanil is metabolized primarily to 
noralfentanil and N-phenylpropionamide by CYP3A4/5 (Klees et al., 2005). Methadone 
is metabolized to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP) by CYP2B6 and 
CYP3A4 in a stereospecific manner  (Chang et al., 2011). Vmax and Km obtained from 
recombinant CYPs were available for the three opioids (Table 3.1). The Km (1 µM) and 
Vmax (19 pmol/min/pmol CYP3A4) for DHB were predicted using Ki (1 μM) (Ohnishi et 
al., 2000; Paine et al., 2004) and ADMETTM predictor (Simulations Plus, Lancaster, CA) 
estimates, respectively, and compared to reported DHB plasma concentrations, of 
which the detection limit was 2.7 nM (Goosen et al., 2004).   
1.4.4. Model Parameterization: Excretion 
Biliary clearance of each compound was either low (<5%) or not reported (Brown 
et al., 2004) and was not considered. Because ~1% of a loperamide dose is recovered 
in the urine (Baker, 2007), renal clearance for loperamide was not considered. Renal 
clearance for alfentanil (1.0 L/h) and methadone (1.8 L/h) (Yang et al., 2006) were 
available and were included in the respective models.  
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1.4.5. Brain Compartment Concentrations 
The permeability-limited four-compartment brain model (Figure 3.1B) within 
Simcyp® was used to simulate intracranial brain blood, brain mass, cranial 
cerebrospinal fluid (CSF), and spinal CSF drug concentrations. The passive 
permeability of each compound was estimated in Simcyp® (Table 3.2), and whole organ 
P-gp-mediated efflux was determined by scaling in vitro P-gp mediated transport 
clearance parameters based on BBB surface area within Simcyp®. The intrinsic P-gp-
mediated transport clearance for loperamide (CLT,int, 1.67 µL/min) was obtained from 
MDCK cells (Tran et al., 2004). Methadone CLT,int (2 μL/min) was obtained from Caco-2 
cells (Hassan et al., 2009) and was assumed to be the same for the two enantiomers. 
Alfentanil is not a P-gp substrate (Wandel et al., 2002). 
1.5. Pharmacodynamic Model Parameterization 
1.5.1.  Pharmacodynamic Parameter Recovery for Alfentanil 
Alfentanil plasma concentration-time and effect (miosis)-time data from a 
previous healthy volunteer study (Kharasch et al., 2004a) were used to recover plasma 
Emax for pupillary miosis after intravenous or oral administration. Emax and plasma EC50 
(EC50,plasma,total) were recovered using equation 1 and a fixed Hill coefficient (γ) obtained 
from mouse (1.8) (Kalvass et al., 2007):  
    Equation 1 
where Eobs denotes the observed effect (miosis, mm), EC50,plasma,total, total plasma 
concentration required to elicit half Emax; and Cobs denotes observed plasma 
concentration.   
1.5.2. Pharmacodynamic Model Development 
Eobs =
Emax •Cobs
γ
EC50,plasma,total
γ +Cobs
γ
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Because human CNS PD data for loperamide do not exist, parameters 
(EC50,brain,unbound, γ) obtained from mouse (Kalvass et al., 2007) were used (Table 3.2). 
This approach was applied to alfentanil data as a ‘training set’ and to methadone data 
as a ‘validation set’. Unbound brain concentration (Cbrain,unbound) was assumed to drive 
effects. PD model simulations for alfentanil and loperamide were conducted using 
Simcyp® (Figure 1) and equation 2: 
   Equation 2 
where Esim denotes the simulated pupillary response (mm).  
 Due to limitations of Simcyp®, PD simulations for R- and S-methadone were conducted 
using Phoenix® WinNonlin® and equation 3 to allow for unbound concentrations of both 
enantiomers to drive effect: 
  Equation 3 
Alfentanil and loperamide miosis-time profiles were simulated in Phoenix WinNonlin® to 
ensure equivalent outcomes across software platforms.  
1.6. PBPK and PBPK/PD Model Evaluation  
Model-predicted loperamide AUC from time 0 to 72 h (AUC0-72h), Cmax, and tmax 
were compared to observed outcomes (Ainslie et al., 2014). DHB model-simulated 
plasma-concentration-time profiles were compared to observed profiles (section 2.3.1). 
The primary endpoints, maximum observed response (Rmax) and area under the effect-
time curve (AUEC), for loperamide, alfentanil, and methadone were compared to 
observed values (Skarke et al., 2003; Kharasch et al., 2004b; Mukwaya et al., 2005; 
Niemi et al., 2006). Predictions were considered successful if model-predicted 
Esim =
Emax •Cbrain,unbound
γ
EC50,brain,unbound
γ +Cbrain,unbound
γ
Esim =
Emax •Cunbound,brain,R−Meth
λ
EC50,unbound,brain
λ +Cunbound,brain,R−Meth
λ +
Emax •Cunbound,brain,S−Meth
γ
EC50,unbound,brain
γ +Cunbound,brain,S−Meth
γ
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pharmacokinetic (AUC, Cmax) and pharmacodynamic (AUEC and Rmax) endpoints were 
within 30% of observe endpoints (Brantley et al., 2013).  
1.7. Loperamide Dose Escalation Simulations  
Loperamide PK and PD were simulated in virtual populations of healthy 
volunteers, with doses ranging from 2-200 mg in the absence and presence of DHB (5 
mg). Simulations were conducted in a cohort (n = 100) of equal numbers of men and 
women and in separate cohorts of men (n = 100) and women (n = 100) to assess 
potential sex differences. The primary endpoint was Rmax. Model-predicted loperamide 
Rmax was compared to oral alfentanil observed and model-predicted Rmax to determine 
the alfentanil-equivalent dose of loperamide.   
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2. RESULTS 
2.1. Performance of the PBPK DHB-loperamide interaction model  
The PBPK model for loperamide modestly over-predicted geometric mean AUC0-
72 h (by 1.3-fold). Cmax, tmax, and terminal half-life were predicted to within 20% of 
observed outcomes (Table 3.3, Figure 3.2). DHB was detected in the plasma of 14 of 16 
subjects, and PK outcomes were recoverable in 11 subjects (Figure 3.2C). The PBPK 
model for DHB predicted median DHB AUC0-4h, and Cmax to within 10% of observed 
values (Figure 3.2C, Table 3.3). The model-predicted ratio of loperamide AUC in the 
presence to absence of DHB was underpredicted by 20%.  
2.2. Performance of the alfentanil PBPK/PD model 
Plasma concentration- and pupil miosis-time data and a sigmoidal direct effect 
model were used to recover a population mean (%CV) Emax and EC50,plasma,total of 6.5 
(40%) mm and 54.2 nM (12%), respectively. The recovered Emax was used for 
subsequent PD modeling.  
The alfentanil PBPK model was developed using human in vitro and clinical data. 
The PD model used an Emax recovered from human pupil miosis-time data and an 
EC50,brain,unbound from mouse (Kalvass et al., 2007). Plasma concentration- and miosis-
time profiles were simulated for both intravenous and oral administration of alfentanil 
and compared to observed data (Figure 3.3). With intravenous alfentanil, model-
predicted geometric mean [90% CI] Vss (0.54 [0.53-0.55] L/kg) lay within the observed 
range (0.30-0.65 L/kg). With oral administration, model-predicted geometric mean AUC 
and Cmax were within 22% of observed outcomes. PD simulations of oral alfentanil 
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underpredicted Rmax, by 30%. The overpredicted AUC, combined with the 
underpredicted Rmax, resulted in an accurate prediction of AUEC.  
2.3. Simulated methadone profiles to substantiate the modeling framework 
The plasma concentration-time profile of both enantiomers following an oral dose 
(9.9 mg) of racemic methadone (4.95 mg assumed for each enantiomer) agreed with 
the plasma concentration-time data from two independent clinical studies (Figure 3.4A) 
(Kharasch et al., 2004b; Ke et al., 2014). The model-predicted methadone geometric 
mean Rmax, which accounted for both enantiomers, was within 10% of the observed 
Rmax (Kharasch et al., 2004b). 
2.4. Simulated loperamide dose escalation studies 
Escalating doses (2-200 mg) of loperamide were simulated in 100 virtual healthy 
subjects (50 men, 50 women) in the absence and presence of the marker GFJ 
constituent DHB (5 mg). In the absence of DHB, a 72 mg dose of loperamide was 
predicted to achieve the model-predicted oral alfentanil Rmax (1.4 mm), whereas a 96 
mg dose was predicted to achieve the observed alfentanil Rmax (2.0 mm) (Fig. 5). The 
presence of DHB was predicted to lower the alfentanil-equivalent dose of loperamide 
dose by ~30% (Fig.3.5). Virtual trials with 100 men or women indicated a slight leftward 
shift in the dose-response profile for women compared to men (Fig. 3.5B). 
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3. Discussion 
Increased restrictions on opioid prescribing may promote alternate means of 
abuse. Anecdotal and case reports describe abuse of the over-the-counter opioid, 
loperamide, in combination with the readily accessible PK boosting agent, GFJ 
(Daniulaityte et al., 2013). Given the ethical and safety concerns associated with clinical 
determination of the loperamide dose needed to elicit CNS opiate-like effects in both the 
absence and presence of GFJ, a PBPK/PD modeling and simulation approach was 
used to address these limitations.  
 Alfentanil was used as an exemplar opioid due to a straightforward plasma 
concentration-effect relationship and the availability of rich clinical plasma 
concentration-effect data. Alfentanil was used to recover Emax, as measured by a 
clinically relevant, sensitive, and noninvasive endpoint, change in pupil diameter. The 
recovered Emax (6.5 mm) lay within the constraints of human physiology (minimal pupil 
diameter, 0.5-1.5 mm; average dark-adapted pupil diameter, 7.3-8.7 mm) (Campbell 
and Gubisch, 1966; Bradley et al., 2010; Bradley et al., 2011). Alfentanil model-
predicted AUC, Cmax, AUC, AUEC and Rmax were within the predefined criterion (≤30%). 
Rmax was used as a primary outcome for dose escalation analysis.  
Because evaluation of an alfentanil PBPK/PD model using an Emax recovered 
from alfentanil data is circular, the model was tested with a second opioid. Additionally, 
given that loperamide is a P-gp substrate, unlike alfentanil, the ideal test opioid would 
be a P-gp substrate. Methadone was selected because it is both a P-gp substrate 
(Hassan et al., 2009) and rich clinical plasma concentration- and pupil diameter-time 
data are available (Skarke et al., 2003; Kharasch et al., 2004b; Mukwaya et al., 2005; 
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Niemi et al., 2006). As such, methadone could be used to evaluate the scaling of in vitro 
(P-gp transport clearance) to that at the BBB using in human using a relative activity 
factor. Finally, a PBPK model was available (Yang et al., 2006) that could be adapted to 
Simcyp® and expanded to include brain distribution and PD parameters. Using the 
approach applied to alfentanil, the PBPK model-simulated AUC and Cmax for R- and S-
methadone were within 30% of observed values. 
Although methadone has several positive attributes as a test opioid, the fact that 
the drug exists as a racemic mixture adds to the PD modeling complexity. The R-
enantiomer is 10-fold more potent than the S-enantiomer at the μ-opioid receptor (Pert 
and Snyder, 1973). Murine effect data for methadone were recovered following 
administration of the racemic mixture (Kalvass et al., 2007), and clinical studies involve 
the racemic mixture. Accordingly, the Emax equation (equation 2) was modified to 
account for the additive effect of R- and S-methadone (equation 3). The predicted Rmax 
was within 30% of observed Rmax; however, the predicted time to reach Rmax was 
delayed compared to observed data. This observation may imply a limitation in the 
distributional model within Simcyp® or by the tissue partitioning method (described in 
section 2.4.2). Despite these caveats, the accurate prediction of the primary outcome, 
Rmax, substantiated the loperamide PBPK/PD model.  
A loperamide PBPK model developed using a ‘bottom-up’ approach successfully 
predicted plasma Cmax and AUC, permitting development of an interaction model with 
GFJ. Because GFJ is a complex mixture of phytochemical constituents, the candidate 
marker constituent, DHB, was selected as a surrogate of whole juice. As demonstrated 
recently, a mechanistic static model involving DHB predicted the magnitude of a 
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CYP3A-mediated GFJ interaction (AUC ratio of the victim drug in the presence to 
absence of GFJ) for 13 of 16 victim drugs, including the three opioids examined in the 
current work, to within 25% of observed ratios (Ainslie et al., 2014). 
The DHB PBPK model was developed and evaluated using in-house plasma 
concentration-time data obtained from a GFJ-loperamide interaction study (Ainslie et al., 
2014). DHB was quantified in the plasma and in the test juice, permitting evaluation of 
the DHB PBPK model. Prior to the current work, no human PK DHB information was 
available, and only one report described DHB being detected in human plasma (Goosen 
et al., 2004). However, the recovered DHB outcomes may be biased as subjects were 
excluded if DHB was unquantifiable. The DHB-loperamide interaction slightly 
underpredicted the fold increase in loperamide AUC in the presence of GFJ (1.5 versus 
1.7). This outcome was not surprising given the presence of other CYP3A4/P-gp 
inhibitors in the juice, including bergamottin (Bailey et al., 2003; Paine et al., 2006) and 
structural analogs (Oda et al., 2007). 
Loperamide PBPK/PD model simulations at clinically studied doses (16-24 mg) 
predicted the absence of a significant effect in healthy volunteer studies (Tayrouz et al., 
2001; Skarke et al., 2003; Ainslie et al., 2014). Simulated loperamide dose escalation 
studies, in the absence of DHB, indicated that a loperamide dose of 72 mg was 
equivalent to an oral alfentanil dose of 1.7 mg. These results are consistent with 
anecdotal reports of loperamide abuse (70-200 mg) (Daniulaityte et al., 2013). 
Conversely, in a clinical study in which 60 mg of loperamide was administered to former 
opioid abusers, no significant effect was observed relative to codeine (96 mg of base) or 
placebo. However, this population may not be generalizable to healthy volunteers, 
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representing a limitation of the model. Nevertheless, this PBPK/PD modeling and 
simulation paradigm provides a novel approach to assess loperamide abuse potential in 
healthy subjects and opioid naïve patients.  
The dose escalation studies stratifying by sex suggested that women are slightly 
more susceptible than men to a centrally acting opiate-like effect with loperamide. The 
predicted sex difference is likely the result of men weighing more on average than 
women, coupled with the lack of weight-normalized doses with model simulations. 
However, since loperamide is a substrate of P-gp and multiple CYPs, sex-related 
differences in these factors could contribute. This preliminary evaluation of sex 
differences exemplifies the broader applications of this PBPK/PD model that can build 
on the understanding of PK boosting agents, including GFJ, on the abuse potential of 
opioids.  
In summary, an oral alfentanil-equivalent dose of loperamide was determined, 
with and without the readily accessible PK boosting agent, GFJ, using a PBPK/PD 
modeling and simulation approach. An Emax for alfentanil induced pupillary response 
was recovered to inform an alfentanil PBPK/PD model. The alfentanil PBPK/PD model 
successfully predicted clinical PK and PD outcomes, prompting further evaluation of the 
modeling approach by a second opioid. Methadone was selected as a second 
‘validation’ opioid due to it being a P-gp substrate with available rich clinical plasma 
concentration-time and pupil miosis-time data. To begin to assess the abuse potential of 
loperamide, a loperamide-DHB PBPK interaction model was developed and predicted 
the magnitude of a loperamide-GFJ interaction to within 20%. Subsequently, a 
loperamide PBPK/PD was developed and a virtual dose-escalation study was simulated 
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in healthy subjects both in the absence and presence of DHB. These results indicated 
loperamide doses in excess of 70 mg (in the absence of GFJ) would be required to elicit 
a pupillary response equivalent to an oral alfentanil dose of 1.7 mg (0.23 µg/kg). This 
translational approach to predict opioid pharmacodynamics could be applied to patient 
populations and to assess the abuse and/or interaction potential of novel opioid 
agonists.
  
Table 3.1. PBPK model input parameters. 
Parameter   Alfentanil DHB   Loperamide R-Methadone S-Methadone 
Physicochemical 
   
   Molecular weight (g/mol) 416.5 372 477 309 309 
   LogP  2.16 2.79 5.13 3.95  3.95 
   Compound type Monoprotic Acid Diprotic Acid Monoprotic Base Monoprotic Base  Monoprotic Base 
   pKa 1 7.5a 13.58a 8.6a  9.2a 9.2a 
   pKa 2   12.8       
   B/P 1.14a 0.6b 0.71b  1c 0.75a  
   fu,plasma  0.1 0.06b 0.03b 0.16a   0.12a 
Absorption           
   Model type First-order ADAM ADAM First-order First-order 
   ka (h-1) 2.6b     0.58  0.58 
   Peff,man (10-4 cm/s)   6.202 0.586     
Distribution           
   Vss (L/kg) 0.55c 2.4c 14c 6.3c  4.7c  
Elimination           
   Vmax,CYP3A4 (pmol/min/pmol)  6.05; 1.03a 19d 1.7a 6.7a 0.028f 
   Km,CYP3A4 (µM)  14.1; 18.9a 1.2e  6.3a 13a   
   Vmax,CYP3A5 (pmol/min/pmol)  5.12; 0.36a         
   Km,CYP3A5 (µM)  10.7; 14.8a         
   Vmax,CYP2B6 (pmol/min/pmol)      81a 50.9a 0.427f 
   Km,CYP2B6 (µM)      65.6a 691a   
   Vmax,CYP2C8 (pmol/min/pmol)      53a 0.2a 0.078f 
   Km,CYP2C8 (µM)      11.3a 60a   
   Vmax,CYP2C19 
(pmol/min/pmol)  
      0.2a 
 
   Km,CYP2C19 (µM)        60a   
   Vmax,CYP2D6 (pmol/min/pmol)      16a 0.2a   
   Km,CYP2D6 (µM)      2.8a 60a   
a Recovered from the literature; b determined experimentally within the present work; c determined using in silico predictive 
tools within Simcyp®; d determined using ADMET predictor; e Km for DHB was estimated as the reversible inhibitory kinetic 
parameter, Ki; f values denotes an experimentally reported intrinsic clearance (µl/min/pmol P450) in place of a Km and 
Vmax for S-methadone.  
1
0
4
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Table 3.2. Pharmacodynamic model parameter input. 
Parameter   Alfentanil Loperamide Methadone 
   PSB (L/h) 28.9 155.7 185.5 
   fu, brain 0.33 0.007 0.123 
   CLT (µL/min)   1.67 2.0 
   RAF   3.5 2.2 
   EC50 (nM)7 7.3 1.47 14 
   Hill coefficient7 1.8 2.7 3.7 
PSB, passive permeability clearance at the blood-brain-barrier calculated within 
Simcyp®; fu, brain, fraction of drug unbound in brain tissue; CLT, transport mediated efflux 
intrinsic clearance at the blood-brain-barrier; RAF, relative activity factor used to scale 
transporter mediated clearance; EC50, the concentration required to elicit half of the 
maximal effect. 
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Table 3.3.Observed and model-predicted pharmacokinetic and pharmacodynamic 
outcomes following oral opioid administration. 
Outcome Observed  Model-Predicted 
Loperamide 
AUC0-last (nM-h) 105 [87-126] 134 [126-142] 
Cmax (nM) 6.5 [5.3-8.1] 7.2 [6.8-7-7] 
Tmax (h) 3.0 (0.5-12) 4.5 (0.95-7.3) 
t1/2 (h) 23.3 [20.7-26.3] 32.7 [25.2-42.4] 
DHB 
AUC 0-6 (nM-h) 44.0 [26.0-74.5] 47.4 [38.9-57.9) 
Cmax (nM) 21.5 [15.1-30.7] 22.8 [19.0-27-2] 
Tmax (h), median [range] 1 (0.5-4) 0.7 (0.5-1.5) 
Alfentanil 
Cmax (ng/mL) 21.0 [17.3-25.4] 22.0 [17.0-28.5] 
AUC0-last (ng-h/mL 36.0 [29.4-44.0] 43.8 [27.5-70.0] 
Rmax (mm) 2.0 [1.6-2.5] 1.4 [1.2-1.5] 
AUEC0-last (mm-h) 2.3 [1.7-3.1] 2.4 [2.0-2.8] 
t1/2 (h) 1.1 [0.98-1.25] 1.5 [1.2-2.1] 
Methadone 
Cmax, R-Meth (ng/mL) 13 ± 3 11.9 ± 3.2 
AUC0-last, R-Meth (ng-h/mL 461 ± 72 407 ± 146 
Cmax, S-Meth  (ng/mL) 23 ± 6 25.8 ± 8.4 
AUC0-last, S-Meth (ng-h/mL 639 ± 165 667 ± 233 
Rmax (mm) 3.5 ±1.5 3.2 ± 2.7 
AUEC0-last (mm-h) 78 ± 39 77 ± 51 
AUC0-last, area under the plasma concentration-time curve from time zero to the last 
measured time point; Cmax, maximal plasma concentration; Tmax, time to reach Cmax; t1/2, 
terminal half-life; Rmax, maximal pupillary response; AUEC0-last, area under the effect-
time curve from time zero to the last measured time point. Values are expressed as the 
geometric mean [90% Confidence intervals] except for Tmax, which is reported the 
median (range).   
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Figure 3.1. The general model structure of a physiologically-based 
pharmacokinetic/ ph
armacodynamic model 
Figure 3.1. The general model structure of a physiologically-based pharmacokinetic/ 
pharmacodynamic model (a) the central nervous system sub compartment (b) and the 
pharmacodynamic effect model used for model simulations. PSB, denotes the 
bidirectional passive permeability clearance at the blood brain barrier; PSC, denotes the 
bidirectional passive permeability clearance at the cranial cerebral spinal fluid (CSF) 
blood barrier; PSE, denotes the bidirectional passive permeability clearance at the brain 
cranial CSF barrier; CLp-gp denotes the efflux clearance mediated by p-glycoprotein.    
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Figure 3.2. Observed geometric mean and model-predicted mean plasma 
concentration-time profiles of loperamide taken with water or GFJ and of DHB. 
Figure 3.2. Observed geometric mean (circles) and model-predicted mean (colored 
lines) plasma concentration-time profiles of loperamide and the 90% confidence 
intervals (grey lines) when taken with water (A) or GFJ/DHB (B) and of DHB plasma 
concentrations (C). Model-predicted simulations were conducted using 100 virtual 
healthy subjects. 
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Figure 3.3. Observed and model predicted alfentanil plasma concentration- and effect- 
tim e 
profiles after an intravenous dose or an oral dose. 
Figure 3.3. Observed geometric mean (circles, or diamonds) and model predicted 
(crimson lines) and the 90% confidence intervals (grey lines) of the alfentanil plasma 
concentration- (A,C) and effect- (B,D) time profiles after an intravenous dose (15 µg/Kg, 
A and B) or an oral dose (23 µg/Kg, C,D). Model-predicted simulations were conducted 
using 100 healthy virtual subjects.  
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Figure 3.4. Observed and model predicted methadone plasma concentration- and e
ffect- 
time profiles.  
Figure 3.4. Observed geometric mean (circles) and model predicted R-methadone (red 
lines), S-methadone (blue lines) and the 90% confidence intervals (dashed lines) of the 
methadone plasma concentration- (A) and model predicted geometric mean (green line) 
90% confidence intervals (solid line) and observed (circles) effect- time profiles (B) after 
an oral R, S-methadone (4.95 mg each). Model-predicted simulations were conducted 
in 100 healthy virtual subjects. 
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Figure 3.5. Model-predicted maximum decrease in pupil diameter with increasing 
loperamide dose in the absence and presence of DHB. 
 
Figure 3.5. Model-predicted geometric mean maximum decrease in pupil diameter 
(Rmax) with increasing loperamide dose in the absence (blue) and presence (gold) of 
DHB (5 mg) (A and B). Simulations represent 100 virtual healthy subjects (50 women) 
(A) or 200 virtual healthy subjects (100 women) (B). Grey dashed line and grey solid 
line (A) denote observed and predicted alfentanil (1.7 mg) maximum change in pupil 
diameter (Rmax), respectively. Error bars indicate 90% confidence intervals.
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CHAPTER 4 : EVALUATION OF A NOVEL HUMAN MODEL TO ASSESS REVERSAL 
OF OPIOID EFFECTS BY NALOXONE.3 
INTRODUCTION  
Opioids are among the most frequently prescribed analgesic medications due to 
superior efficacy and limited alternatives to treat severe pain (Bohnert et al., 2011). In 
parallel, this chemical class is notorious for addiction and accidental or intentional 
overdose (National Institute of Drug Abuse, 2011; Meyer et al., 2014). The definitive 
treatment for opioid overdose is the potent μ-opioid receptor antagonist naloxone, 
approved for parenteral administration. Although effective, parenteral naloxone is 
suboptimal due to the need for medically trained personnel (at least for intravenous 
administration) and potentially, multiple doses, particularly for the long-acting opioids 
(e.g., methadone, morphine, oxycodone, heroin). One product was approved recently 
for intramuscular (IM) or subcutaneous administration by non-medically trained 
personnel (Evzio™) but is invasive and costly ($200-300/dose). Other, noninvasive, 
naloxone products are under development, particularly intranasal (IN) formulations 
(Kelly and Koutsogiannis, 2002; Merlin et al., 2010). 
Development of IN naloxone formulations is not without hurdles. One is the lack 
of predictive pre-clinical models. Although rodent models have been shown to predict 
                                            
3 This chapter will be submitted to Clinical Pharmacology and Therapeutics as an 
original research paper and is presented in the style of the journal. Ainslie GR, White 
JR, Gufford BT, Layton ME, Padowski JM, Pollack GM and Paine  MF. A novel human 
model to assess reversal of opioid effects by naloxone. CPT.  
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the human pharmacodynamics of opioid agonists (Kalvass et al., 2007), an analogous 
relationship for opioid antagonists has not been reported. Another hurdle is that, unlike 
for opioid agonists, the plasma concentration-effect relationship for opioid antagonists in 
humans cannot be readily well-characterized. In addition, the endpoints used to assess 
central opioid effect (e.g., respiratory rate, blood oxygen saturation) are associated with 
low sensitivity and large inter-individual variability, necessitating large sample size to 
adequately power efficacy studies. Based on these observations, a cost-effective 
human model to characterize the reversal of opioid effects by naloxone would address 
an unmet need in the development of new naloxone products.  
The objective of this work was to develop a noninvasive, cost-effective, and time-
efficient human model to assess the opioid reversing effects by naloxone. The aims 
were to (1) compare the absolute bioavailability of two IN naloxone formulations with 
that of intramuscular (IM) naloxone, (2) evaluate the clinical effect of IN compared to IM 
naloxone in reversing central opioid effects, and (3) interrogate the model with a 
pharmacokinetic ‘boosting’ agent. The opioid agonist and cytochrome CYP3A probe 
substrate alfentanil was selected due to a straightforward plasma concentration-effect 
relationship and short duration of effect. Pupil miosis, the most sensitive measure of 
central alfentanil effect (Grunberger et al., 1990), was selected as a noninvasive, 
inexpensive endpoint. The CYP3A inhibitor grapefruit juice was selected as an 
inexpensive and readily accessible boosting agent that has been shown to augment 
alfentanil-induced miosis (Kharasch et al., 2004). Results provide a foundation for 
further testing of a novel human model to aid in optimizing dose and frequency of 
administration of new naloxone products in reversing opioid overdose. 
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RESULTS 
Pharmacokinetics of naloxone. The pharmacokinetics of two IN naloxone 
formulations were compared to those of IM and IV naloxone. All six subjects completed 
all four phases. All administration routes were generally well-tolerated; five subjects 
reported a bitter taste and pharyngeal discomfort (tingling or burning sensation) after IN 
administration of at least one of the formulations, which resolved within 20-30 min. 
The percent of the area under the curve (AUC) extrapolated to infinite time 
(AUCinf) was <20% for all subjects and all administration routes (Table 4.1). The 
geometric mean terminal elimination half-life (t1/2) of IM and IN naloxone was consistent 
with that of IV naloxone (Figure 4.2, Table 4.1). Relative to IM naloxone, geometric 
mean Cmax for IN200 naloxone (5 mg/ml, 200 μl/nostril) was comparable, whereas that of 
IN100 naloxone (10 mg/ml, 100 μl/nostril) was doubled. Median tmax following IM 
naloxone was roughly twice that of IN100 naloxone, which was roughly twice that of IN200 
naloxone. The average mean absorption time (MAT) of IN100 and IN200 naloxone was 
approximately 10 and two times faster, respectively, than that of IM naloxone. The 
geometric mean absolute bioavailability of IN100 and IN200 naloxone was 25% and 59% 
lower, respectively, than that of IM naloxone (Table 4.1).  
Opioid reversal effects of intramuscular and intranasal naloxone. Based on 
results from the pharmacokinetic study, IN100 naloxone was selected for comparison to 
IM naloxone in reversing the miotic effects of the test opioid, oral alfentanil, in the 
absence and presence of grapefruit juice. All subjects completed all six phases of the 
study. Naloxone, alfentanil, and grapefruit juice were generally well-tolerated; two 
subjects reported nausea (attributed to alfentanil and/or grapefruit juice) on all study 
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days that resolved within 5-20 min. One of these subjects and a different subject 
reported pharyngeal discomfort with IN naloxone that resolved within 30 min.    
Relative to baseline, alfentanil produced miosis in all subjects during all phases 
(Figure 3). The mean area under the effect curve from 0-6 h (AUEC0-6h) decreased by 
40% after both IM and IN100 naloxone administration (Figure 4.4). Because naloxone 
was administered one hour after alfentanil, AUEC1-6h was evaluated. In the absence of 
grapefruit juice (days 1-3) (Figure 4.1B), IM naloxone decreased mean AUEC1-6h by a 
modestly higher extent compared to IN100 naloxone (68% and 54%, respectively); the 
maximum magnitude of miosis (Rmax) was similar amongst the three phases (Figure 
4.4). In the absence of naloxone (days 1 and 4), both the mean AUEC0-6h and Rmax 
increased by 40% when grapefruit juice was administered 30 min prior to alfentanil. 
Relative to the presence of grapefruit juice but absence of naloxone (day 4), mean 
AUEC0-6h decreased by 33% and 38%, respectively, with IM and IN100 naloxone; mean 
AUEC1-6h showed similar trends (Figure 4.4).  
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DISCUSSION 
Opioids are a mainstay in pain management and common drugs of choice 
encountered in addiction recovery programs. Although effective, these drugs are 
notorious for overdose, both intentional and accidental (Bohnert et al., 2011). Deaths 
due to opioid overdose result from illicit or licit use, either when taken alone or with 
concomitant medications or other xenobiotics. Parenteral naloxone is the definitive 
treatment for opioid overdose, yet in most cases, the first responders typically are the 
lay bystanders, rather than personnel trained to administer naloxone parenterally. 
Consequently, a market exists for novel, easy-to-use naloxone products that can be 
administered by non-medically trained personnel.  
EvzioTM, an automated device for IM or subcutaneous naloxone administration, 
was approved recently for in-field use by non-medically trained personnel. However, the 
invasive nature and high cost of this product may limit widespread use, prompting the 
development of noninvasive formulations. The parenteral formulation has been 
administered IN in the field with mixed success rates (Barton et al., 2002; Kelly and 
Koutsogiannis, 2002; Glaser et al., 2005; Kelly et al., 2005; Merlin et al., 2010; 2014; 
Sabzghabaee et al., 2014; Zuckerman et al., 2014) due in part to a limited bioavailability 
(~4%) (Dowling et al., 2008), requiring further development of alternate IN formulations. 
Given the lack of predictable efficacy relative to plasma exposure, coupled with the lack 
of a robust animal model, a cost-effective human model to assess reversal of opioids 
effects would expedite development of these new formulations. The objective of the 
current work was to develop a noninvasive, inexpensive, and time-efficient human 
model to assess the opioid reversing effects of naloxone. This model consisted of oral 
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alfentanil as a short-acting test opioid; pupil diameter as a sensitive, noninvasive 
measure of opioid central effect; grapefruit juice as a readily available pharmacokinetic 
booster, standardized for the marker constituent DHB, to increase the dynamic range of 
effect; and IN naloxone as a noninvasive and inexpensive test formulation.  
Selection of a test IN naloxone formulation was based on a preliminary 
pharmacokinetic study in which IV, IM, and IN naloxone were administered to six 
healthy subjects. The pharmacokinetics of IV naloxone were consistent with the 
literature (Albeck et al., 1989). The absolute bioavailability of IM naloxone was higher 
(54% versus 35%), whereas tmax and terminal t1/2 were similar, to previously reported 
values (Dowling et al., 2008). Absolute bioavailability of IN100 naloxone was superior to 
previously published IN formulations (40% versus 4%)(Kelly and Koutsogiannis, 2002; 
Dowling et al., 2008), which can be attributed to differing combinations and quantities of 
surfactants. The bioavailability of IN200 naloxone also was superior to previous IN 
formulations and was approximately half that of IN100 naloxone, which likely reflected a 
larger fraction of the dose lost via pharyngeal drainage. Based on these results, IN100 
was selected for testing in the efficacy study.  
Oral alfentanil elicited a pupillary response that was augmented by grapefruit 
juice (by 40%), consistent with a previous report (Kharasch et al., 2004). Whether or not 
grapefruit juice was administered prior to alfentanil, IM and IN naloxone attenuated 
miosis by similar extents, consistent with comparable systemic exposure to naloxone 
between the two routes. However, the time to maximum response appeared to be 
achieved more rapidly in the absence of grapefruit juice, reflective of a potential leftward 
shift in the time to reach Cmax. Inclusion of a grapefruit juice, indicates that this approach 
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may be useful to assess the effect of additional inhibitory ‘perpetrator’ xenobiotics, 
including drugs and other diet-derived/natural products.  
Despite encouraging results from the current work, limitations are recognized, yet 
addressable upon further refinement. First, given the preliminary nature of the studies, 
the small sample sizes precluded formal statistical comparisons between the various 
treatments. However, data from both studies provide fundamental information for future 
powered studies. For example, using AUEC0-6h as the primary endpoint, a post-hoc 
power calculation indicated a cohort of 16 subjects would be needed to detect a 25% 
difference in AUEC0-6h with 80% power, with a Type I error of 0.05. Second, although 
pupillometry is a noninvasive technique, intense sampling was not feasible with more 
than one subject present on a given study day due to the availability of one 
pupillometer. Increased resources would enable more intense sampling following 
naloxone administration, permitting thorough characterization of the rate of reversal of 
alfentanil-induced miosis. Third, as alfentanil is short-acting, rigorous characterization of 
the duration of opioid reversing effects of naloxone was not possible. As such, testing 
the reversing effects against long-acting opioids (e.g., methadone, oxycodone) is of 
interest, warranting further clinical evaluation. With modifications, including increased 
subject enrollment, staffing, and instrumentation, this approach is well-suited for the 
‘learn and confirm’ paradigm used during early clinical development of new drug 
candidates. 
 This novel human model has applications in addition to aiding in the development 
of new naloxone formulations. Such applications include combinatorial naloxone 
medications, xenobiotic-drug interactions, and xenobiotic-combinatorial naloxone 
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medication interactions. Following a call by the FDA, combinatorial medications 
containing naloxone (e.g., Suboxone®, Targiniq™ ER) have been developed to reduce 
opioid abuse potential or gastrointestinal side effects. These formulations exploit the 
extremely low oral bioavailability of naloxone (1-2%)(Smith et al., 2012) and have been 
beneficial at normalizing bowel movements, although the impact on central effects has 
not been examined thoroughly (DePriest and Miller, 2014; Koopmans et al., 2014). 
Evidence that a PEGylated naloxone product (naloxegol) may be susceptible to CYP3A-
mediated interactions requires further investigation to ensure that increased systemic 
exposure to naloxone does not lead to a central effect, leading to withdrawal symptoms 
in patients suffering from chronic pain.  
In summary, new easy-to-use naloxone formulations and products are under 
development, yet no cost-effective human models to evaluate the reversal of opioid 
central effects have been described. A preliminary pharmacokinetic study showed that 
the absolute bioavailability of a test IN naloxone formulation was comparable to IM 
naloxone, prompting a second study to compare the opioid reversing effects of IN to IM 
naloxone using oral alfentanil as the model opioid. Whether or not the pharmacokinetic 
booster, grapefruit juice, was administered prior to alfentanil, the IN formulation 
appeared to be as effective as IM naloxone in reversing pupil miosis. Continued testing 
of this novel experimental human model is needed to substantiate these observations. 
In conclusion, a noninvasive, cost-effective, and time-efficient human model to assess 
the opioid reversing effects of naloxone was evaluated. The encouraging results warrant 
continued development of this promising ‘no sharps container’ approach. 
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METHODS 
 Clinical study protocols. The Washington State University Institutional Review 
Board reviewed and approved the study protocols and consent forms prior to subject 
enrollment. Potential subjects provided written informed consent and Health Insurance 
Portability and Accountability Act authorization before screening, which consisted of a 
medical history, physical examination, liver function tests, complete blood count, and 
urinalysis that included a 14-panel drug test (14 panel T-cup, Confirm Biosciences, San 
Diego, CA). All women underwent a serum pregnancy test. Subjects were eligible to 
participate based on screening results and inclusion/exclusion criteria (Table 4.2). 
Preparation of intranasal naloxone, oral alfentanil, and grapefruit juice. 
Naloxone hydrochloride, polysorbate 20, and sodium lauryl sulfate were purchased from 
PCCA, Inc (Houston, TX). IN mucosal atomization devices (MAD Nasal™) were 
provided by Teleflex, Inc. (Research Triangle Park, NC). Millex® GP 0.22 µm syringe 
filter units (Merck Millipore, Darmstadt, Germany) and 5 micron filter needles (Becton, 
Dickinson and Company, Franklin Lakes, NJ) were purchased from Fisher Scientific, 
Inc. (Waltham, MA). Sterile saline 0.9% (Becton, Dickinson and Company, Franklin 
Lakes, NJ) and alfentanil 1 mg/2 ml ampules (Hospira, Inc., Lake Forest IL) were 
purchased from McKesson Corporation (San Francisco, CA). Grapefruit juice frozen 
concentrate (Great ValueTM) was purchased from a local store (Walmart, Post Falls, ID; 
lot nos. LOC4N and LOC1N). 
 IN naloxone was prepared by suspending naloxone hydrochloride in a vehicle 
containing 5% polysorbate 20 and 1% sodium lauryl sulfate dissolved in sterile saline to 
yield 5 or 10 mg naloxone/ml. The solutions were sterilized by filtration before 
transferring to syringes for administration (0.23 ml per syringe to deliver 0.1 or 0.2 ml (1 
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mg) per nostril, allowing for 0.13 ml dead space in MAD Nasal™). Alfentanil was 
prepared for oral administration by removing 2 ml from each of 4 ampules using a 
syringe with filter needle (total dose, 4 mg in 8 ml) and diluting into 50 ml of water. The 
contents from each can of grapefruit juice were thawed and pooled, and an aliquot was 
saved for quantitation of the marker constituent, 6’,7’-dihydroxybergamottin (DHB), by 
LC/MS/MS (Vandermolen et al., 2013). The juice was diluted with water to achieve a 
final DHB concentration of ~60 µM. The diluted juice was divided into 240-ml aliquots 
and stored in light-protective containers at -20°C until use; the contents of each 
container were thawed at 4°C the evening before each study day.  
Pharmacokinetic study. Healthy volunteers (5 men, 1 non-pregnant woman), 
aged 23-29 years, were enrolled in a three-phase, sequential, open-label study; none 
were taking concomitant medications. Naloxone (2 mg) was administered IV or IM (2 
mg/2 ml pre-filled syringe, International Medication Systems, LTD., El Monte, CA) or IN 
(10 mg/ml, 100 µl/nostril or 5 mg/ml, 200 µl/nostril). Weight and blood pressure were 
obtained at the beginning of each study day. Plasma (15 ml) was collected serially via 
an indwelling IV catheter at 5, 10, 15, 30, 45, 60, 90, 120, and 240 min after naloxone 
administration (Figure 4.1A). Plasma was quantified for naloxone by LC/MS/MS as 
described previously (Fang et al., 2009). 
Opioid effect reversal study. Healthy volunteers (3 men, 3 non-pregnant 
women), aged 20-32 years, were enrolled in this six-phase, sequential, open-label 
study; none were taking concomitant medications or dietary/herbal supplements except 
for one woman who was taking bupropion chronically for >2 months prior to initiation of 
the study. Subjects were administered 240 ml water (study days 1-3) or grapefruit juice 
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(study days 4-6) 30 min prior to a single oral dose of alfentanil (4 mg) (Figure 4.1B). 
Naloxone (2 mg) was administered IM (study days 2 and 5) or IN (10 mg/ml, 100 
µl/nostril) (study days 3 and 6) one hour after alfentanil (tmax)(Kharasch et al., 2011) 
administration. Pupil diameter of the right eye was measured, at least in triplicate 
(coefficient of variation ≤3.3%), at 5, 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 
and 360 min after alfentanil administration using a NeurOptics VIP-200® pupillometer 
with a resolution of 0.1 mm (San Clemente, CA). The light intensity of the room, 
measured using a Sper Scientific 840021 light meter (Scottsdale, AZ), was always <1 
lux. Vital signs (oxygen saturation, pulse, blood pressure) were obtained concurrent with 
pupil diameter. In the event of an adverse reaction to alfentanil, an extra dose of 
parenteral naloxone and supplemental oxygen were available. Promethazine (Actavis 
Inc., Parsippany, New Jersey) and epinephrine (Mylan Inc, Basking Ridge, NJ) were 
available as anti-nausea and anti-anaphylaxis medications, respectively.  
Pharmacokinetic and effect analysis. Pharmacokinetic and effect outcomes 
were determined via non-compartmental methods using Phoenix® WinNonlin® (v6.3, 
Pharsight, Mountain View, CA). Plasma concentrations outside the dynamic range of 
the LC/MS/MS assay were excluded from pharmacokinetic analysis. The terminal 
elimination rate constant (λz) was determined by linear regression of the terminal portion 
of the log-transformed concentration-time profile using at least three data points. The 
terminal half-life (t1/2) was calculated as ln(2)/λz. The maximum concentration (Cmax), 
time to reach Cmax (tmax), and last measured concentration (Clast) were obtained directly 
from the concentration-time profile. Area under the curve from time zero to the time at 
Clast (AUClast) was determined using the trapezoidal rule, with linear interpolation for 
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intravenous administration and linear up/log down interpolation for extravascular 
administration. AUCinf was calculated as the sum of AUClast and the ratio of Clast to λz. 
Absolute bioavailability (F) was calculated as the ratio of the AUCinf after extravascular 
to that after intravenous administration. Mean residence time (MRT) following 
intravenous (MRTIV) or extravascular (MRTEV) administration was calculated as the ratio 
of AUMCinf to AUCinf, where AUMCinf denotes the area under the moment curve from 
time 0 to infinite time. Mean absorption time (MAT) was calculated as the difference 
between MRTEV and MRTIV. 
Pupil diameter measurements were converted to miosis as a function of the 
percent change from a baseline (pre-dose) measurement. The maximum miotic 
response (Rmax) was obtained directly from the miosis-time profile. The area under the 
effect-time curve from 0-6 h (AUEC0-6h) and from 1-6 h (AUEC1-6h) was determined 
using the trapezoidal rule with linear-up/log-down interpolation.  
Statistical Analysis 
Statistical analyses were conducted using SAS (v9.1.3; SAS Institute, Cary, NC). 
Differences in AUECall, AUEC1-6 h, and Rmax between treatment groups were analyzed 
by standard two way ANOVA and a Bonferroni adjustment (α = 0.05). 
 129 
 
Table 4.1. Pharmacokinetics of naloxone after intravenous, intramuscular, and 
intranasal naloxone 
 
AUClast, area under the plasma concentration-time curve from 0 to 240 minutes; AUCinf, 
AUC from 0 to infinite time; t1/2, terminal half-life; Cmax, maximum plasma concentration; 
tmax, time to reach Cmax; MAT, mean absorption time. Values are geometric means [90% 
confidence intervals] unless indicated otherwise.  
Outcome 
Administration Route 
IV IM 
IN  
(100 μl/nostril) 
IN  
(200 μl/nostril) 
AUClast (min*ng/mL) 650 [535-789] 347 [310-390] 266 [190-373] 147 [112-194] 
AUCinf (min*ng/mL) 748 [586-954] 434 [386-487] 282 [200-399] 168 [117-240] 
t1/2 (min) 91 [64-130] 100 [89-111] 61 [53-72] 80 [56-113] 
Cmax (ng/mL) - 3.1 [2.3-4.2] 5.7 [3.3-10.0] 3.0 [1.7-5.3] 
tmax (min), median (range) - 22.5 (10-60) 12.5 (5-15) 5 (5-15) 
MAT (min), mean ± SE - 74 ± 8.8 6.7 ± 4.9 31 ± 22 
Absolute bioavailability (%) - 55 [43-70] 41 [27-62] 24 [15-33] 
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Table 4.2. Clinical study inclusion and exclusion criteria. 
 Pharmacokinetic Study Opioid effect reversal study 
Inclusion   
 • Men and women aged from 18 to 40 years 
 • Ability to understand the informed consent form 
 • Ability to participate in the study (time, transportation, etc.) 
  • Willing to abstain from grapefruit 
products for one week prior to 
and during the study 
  • Willing to abstain from alcohol 
and caffeinated beverages the 
evening prior to each study day 
Exclusion   
 • Any current major illness or chronic illness such as (but not 
limited to) kidney disease, hepatic disease, diabetes mellitus, 
hypertension, coronary artery disease, chronic obstructive 
pulmonary disease, cancer, or HIV 
 • History of anemia or any other significant hematologic disorder 
 • History of drug or alcohol addiction or major psychiatric illness 
 • A need for chronic opioid analgesics 
 • Use of opioid analgesics 3 weeks prior to initiation of the study 
 • An imminent likely need for opioid analgesics (e.g., planned 
dental or surgical procedure) 
 • History of allergy to naloxone or other opioid antagonists, 
alfentanil or other opiate-like agents, promethazine or other 
phenothiazines 
 
 
• History of intolerance to 
grapefruit-containing products 
 • History of significant nasal allergy or other nasal pathology (e.g., 
polyps, nasal septal deviation) 
 • Women who are pregnant or nursing 
 • Taking concomitant medications, both prescription and non-
prescription (including herbal products) known to alter the 
pharmacokinetics or pharmacodynamics of naloxone or alfentanil 
   
  
gure 4.1. Study design and procedures 
 
Figure 4.1. Study design and procedures. (A) Healthy volunteers (n = 6) were screened and underwent four study days, 
consisting of intravenous (IV), intramuscular (IM), or intranasal (IN, 100 or 200 µl/nostril) naloxone (2 mg) administration. 
Blood (15 ml) was collected at 5, 10, 15, 30, 45, 60, 90, 120, and 240 minutes after naloxone administration. (B and C) 
Healthy volunteers (n = 6) were screened and underwent six study days, each consisting of oral alfentanil (4 mg). Water 
(days 1-3) or grapefruit juice (days 4-6) was administered 30 min before alfentanil. Naloxone (2 mg) was administered IM 
(days 2, 5) or IN (days 3, 6) one hour after alfentanil. Pupil diameter and vital signs were measured at 0, 5, 10, 20, 30, 45, 
60, 75, 90, 120, 150, 180, 240, 300, and 360 min after alfentanil.  
1
3
1
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Figure 4.2. Concentration-time profiles for naloxone following intravenous, i
ntramuscular, or intranasal administration. 
Figure 4.2. Concentration-time profiles for naloxone (2 mg) following intravenous, 
intramuscular, or intranasal (100/nostril or 200 µl/nostril) administration to six healthy 
volunteers. Diamonds denote individual concentrations, and closed circles denote 
geometric mean concentrations. Error bars denote 90% confidence intervals. 
  
Figure 4.3. Mean pupil miosis-time profiles after administration of oral alfentanil. 
 
Figure 4.3. (A-C) Mean pupil miosis-time profiles after administration of oral alfentanil (4 mg) to six healthy volunteers 
pre-treated with water (open symbols) or grapefruit juice (closed symbols). Naloxone (2 mg) was administered 
intramuscularly (B) or intranasally (C) one hour after alfentanil. Error bars denote standard errors.  
1
3
3
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Figure 4.4. Area under the effect-time curve and Rmax following oral administration of 
alfentanil. 
 
Figure 4.4. Area under the effect-time curve from 0-6 h (A) and from 1-6 h (B) and 
maximal pupillary response (C) following oral administration of alfentanil (4 mg) to six 
healthy volunteers pre-treated with water or grapefruit juice. Lines inside the boxes 
denote medians, the ends of the boxes denote one quartile from the median, and 
diamonds denote means. Error bars denote minimum and maximum values. 
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CHAPTER 5 : CONCLUSIONS AND SIGNIFICANCE 
 
Consuming certain foods, supplements, or exotic beverages concurrently with 
prescribed or over-the-counter medications is seemingly benign. However, some of 
these diet-derived substances are capable of modulating the exposure to conventional 
drugs. While a common misconception exists that ‘natural’ equates to ‘safe’, regulatory 
agencies are acknowledging the necessity to understand the potential for dietary 
substances to perpetrate drug interactions (Health Canada, 2011; European Medicines 
Agency: Committee for Human Medical Products, 2012; National Center for 
Complementary and Alternative Medicine, 2013). However, no guidelines to assess 
dietary substance-drug interaction liability have been formalized, and current proposed 
methods require improvement to keep pace with beverage, nutraceutical and 
pharmaceutical development. One considerable challenge in dietary substance-drug 
interaction risk assessment is that dietary substances typically are mixtures of varying 
biochemical composition. This characteristic has been exemplified with respect to the 
fermentation of wine, of which the characteristics of a wine are influenced by varieties of 
grapes, fermentation processes and seasonal changes (Paine and Oberlies, 2007). 
Complete characterization of all constituents in a mixture would be time consuming and 
costly. As such, it has been proposed that a single or few ‘marker constituents’ 
predictive of the whole mixture can be identified, measured and isolated for in vitro and 
in vivo testing. Furthermore, a marker constituent could be measured in the mixture as a 
means to assess its interaction liability using IVIVE methods. To test this approach, the
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 exemplar dietary substance GFJ was selected. GFJ perpetrates myriad drug 
interactions via irreversible inhibition of CYP3A. Consumed at normal volumes, the GFJ 
interaction is limited to inhibition of enteric and not hepatic CYP3A. Victim drugs include 
anti-cancer drugs, statins, immunosuppressants and analgesics (Won et al., 2012; 
Bailey et al., 2013). The interactions with analgesics are concerning given that the 
recent restrictions on prescription opioids may lead to alternate mean of abuse (Bohnert 
et al., 2011). Anecdotal accounts imply that GFJ is being used as a pharmacokinetic 
‘boosting agent’ to increase the euphoric effects of opioids (Daniulaityte et al., 2013; 
Bluelight, 2014). One of these opioids, loperamide, is a peripherally acting opioid 
subject to a high CYP3A4/P-gp mediated first pass effect (Shen et al., 2012). 
Loperamide permeates the BBB, but a CNS effect at clinically tested doses (2-60 mg) is 
precluded by rapid P-gp mediated efflux at the BBB (Jaffe et al., 1980; Tayrouz et al., 
2001; Skarke et al., 2003; Yu et al., 2004; Mukwaya et al., 2005; Streel et al., 2005; 
Niemi et al., 2006). The supratherapeutic doses of loperamide, reported anecdotally 
(70-200 mg), are sizeable compared to those tested in healthy volunteers (≤24 mg). 
Clinical evaluation of these claims would be unethical; therefore, alternative approaches 
must be sought to evaluate the abuse potential of loperamide, and other opioids, in the 
absence and presence of pharmacokinetic boosting agents, including GFJ.  
 The overall goal of this dissertation project was to develop and refine a structured 
approach to conduct dietary substance-drug interaction risk assessment. The global 
hypothesis was that the risk of a grapefruit juice-loperamide interaction can be 
assessed via an integrated translational approach. The short-term goal of this project 
was to assess the abuse potential of the µ-opioid receptor agonist, loperamide, when 
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taken concurrently with GFJ, using a marker constituent as a representative of the 
whole juice. The long-term objective was to develop a methodology to (1) identify 
marker constituents present in dietary substances reflective of the effect of a mixture on 
xenobiotic metabolizing enzyme-mediated interactions, (2) predict pharmacokinetic and 
pharmacodynamic outcomes of dietary substance-drug interactions, and (3) increase 
the knowledge of clinical pharmacokinetic behavior of constituents found in dietary 
substances. Key findings, limitations, innovations and future steps are discussed.  
Aim 1. Develop robust in vitro methods to recover key kinetic parameters 
associated with DHB-mediated inhibition of loperamide metabolism.  
 Despite other candidate inhibitors present in GFJ, DHB was postulated to be a 
major mediator of the CYP3A-mediated GFJ effect and was tested as a marker 
constituent in this dissertation. Considerable work identifying DHB as a potent MBI of 
CYP3A has preceded that described in this dissertation; however, DHB 
pharmacokinetics remain understudied. To begin to address the lack of DHB clinical 
pharmacokinetic knowledge, a highly sensitive LC-MS/MS assay was developed 
(LLOQ, 250 pM), validated (Appendix A) and applied to analyze plasma samples from a 
GFJ-loperamide clinical interaction study where 16 subjects were administered GFJ 
(240 mL) containing 60 µM DHB (6.2 mg, Chapter 3, Appendix B). Additionally, 
quantification methods were developed and partially validated, to quantify further GFJ 
constituents (BG, naringin and naringenin, Appendix B) in human plasma. The 
pharmacokinetic analysis of DHB in human plasma was complicated by the suboptimal 
sampling times chosen which were selected based on loperamide pharmacokinetics. 
The sparse plasma sampling from time 0 to 4 h precluded recovery of robust 
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pharmacokinetic outcomes, but was sufficient to described AUC0-last and Cmax in 11 out 
of 16 subjects. Plasma concentration-time profiles build on the limited qualitative DHB 
and BG exposure data presented by Goosen et al. (2004). With an improved 
understanding of DHB plasma exposure, a well-informed DHB pharmacokinetic study 
design can be devised or DHB predictive models (e.g., PBPK) can be authenticated. 
 To advance a DHB-loperamide PBPK model, the recovery of additional in vitro 
kinetic parameters was essential. Kim et al. (2004) characterized metabolic kinetic 
parameters describing loperamide N-desmethylation in HLMs and recombinant CYPs, 
yet the role of intestinal metabolism of loperamide had not been determined. To 
estimate the contribution of the intestine to loperamide first-pass extraction, saturable 
metabolism parameters (Km and Vmax) were obtained using single donor HIMs 
(Appendix C,) or pooled HIMs (n=12, Appendix D). The Km for individual donors of high, 
medium and low CYP3A4 expression varied from that obtained from a 12-donor pool 
(Appendix D). The observed difference in affinity may be due to the age or preparation 
method of the individual donor HIMs. The Vmax recovered from the pooled donor lot (191 
± 11.7 pmol min-1 mg protein-1) was consistent with the average of the low (60 pmol min-
1 mg protein-1), medium (250 pmol min-1 mg protein-1) and high (290 pmol min-1 mg 
protein-1) CYP3A4 expressing donors. Since N-desmethylloperamide metabolic kinetic 
parameters were unknown, a substrate disappearance assay was conducted in HIMs 
and HLMs to recover the intrinsic clearance (Appendix C).  
To confirm the purported DHB-loperamide interaction in vitro, MBI kinetic 
parameters (KI, kinact) for DHB were recovered using HIMs (Chapter 2) and the index 
reaction, loperamide N-desmethylation. The recovered parameters (Chapter 2) were in 
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accordance with those recovered from midazolam and testosterone hydroxylation in 
single HIM donors (Paine et al., 2004).  
Succeeding this in vitro assessment of the DHB-loperamide interaction in human 
cell fractions, a similar effort was made to assess the interaction potential in rat. The 
subsequent findings using rat liver microsomes (RLMs) and rat intestinal microsomes 
(RIMs) identified DHB as a potent reversible inhibitor of rat Cyp3a (Appendix D). 
However, the organ/tissue distribution in human versus that of rat cytochrome P450s 
varies (Cao et al., 2006). While CYP3A4 is the driver of intestinal oxidative drug 
metabolism in human, the rat expresses the CYP2c and Cyp2d subfamily of enzymes in 
addition to Cyp3a isoforms to a substantial extent (Paine et al., 2005; Cao et al., 2006; 
Paine et al., 2006). The measurement of MBI kinetic parameters in RLMs and RIMs 
using loperamide as the substrate indicated that DHB is a slower-acting MBI in rat 
(Appendix D). In vitro data reflect a species difference that precludes the use of rat 
models for human GFJ-drug interaction assessment.      
A mechanistic static model was applied (Chapter 2) and successfully predicted a 
loperamide-GFJ interaction. To ensure that this successful IVIVE was not serendipitous, 
15 previously reported GFJ-drug interaction studies were selected in accordance to a 
predefined criterion (within 25% of the observed AUCGFJ/AUC). Twelve of these 
interactions were successfully predicted using DHB as a marker constituent. A 
sensitivity analysis indicated that the maximum predicted AUCGFJ/AUC is achieved at 
relatively low DHB concentrations (<1.2 µM). The DHB concentrations used for 
interaction predictions incorporated an estimated enterocyte concentration, determined 
from the PBPK model described in Chapter 3. 
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The most noteworthy misprediction coming from this work was with atorvastatin. 
The atorvastatin AUC in the presence of GFJ was over predicted (300% versus 20%), 
which is likely due to atorvastatin being a substrate for the apically located uptake 
transporter, OATP2B1 (Km, 0.2 µM). An accurate prediction of atorvastatin would 
require thorough characterization to identify a marker constituent and dynamic modeling 
to incorporate inhibition of OATP-mediated uptake transport.  
These findings identified that DHB and a mechanistic static model could be used 
to prioritize new and existing drugs for more advanced GFJ-drug interaction modeling or 
for clinical evaluation. Importantly, DHB was justified for predicting the GFJ-loperamide 
interaction, permitting its application in dynamic, PBPK and PBPK/PD models. The 
following future experiments are recommended based on findings in this specific aim: 
DETERMINE DHB KINETIC PARAMETERS (KM, VMAX) IN HUMAN ENZYME SOURCES USING 
METABOLITES IDENTIFIED IN URINE. The DHB PBPK model described in Chapter 3, 
accounts for only CYP3A4-mediated metabolism, as the recovery of DHB clearance is 
not straightforward by means of parent disappearance methods. Determination of 
saturable kinetic parameters for individual pathways of DHB metabolism is limited by 
the lack of authentic standards of DHB metabolites. Recently, several DHB metabolites 
have been identified in human urine samples (Regueiro et al., 2014). These metabolites 
could be synthetically or chemo-enzymatically synthesized for use as analytical 
standards and recovery of key kinetic parameters of DHB metabolism.  Relevant 
parameters could be obtained in human microsomes (HIMs and HLMs) supplemented 
with NADPH, UDGPA, human S9 fractions and 3'-phosphoadenosine-5'-phosphosulfate 
or in human cell lines (e.g., primary hepatocytes, human primary proximal tubule cells). 
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Data from these studies will improve DHB PBPK models and more accurately predict 
high (saturable) DHB doses or chronic exposure. 
IDENTIFY URIDINE 5'-DIPHOSPHO-GLUCURONOSYLTRANSFERASE (UGT) ENZYMES 
RESPONSIBLE FOR DHB CONJUGATION. Following the recovery of metabolic kinetic 
parameters, recombinant, purified or overexpressed UGT enzyme sources could be 
used to identify the pathways relevant to DHB metabolism. In the absence of authentic 
standards, qualitative analysis could be conducted following incubations of DHB with 
UGTs and substrate disappearance methods. Increased knowledge of DHB metabolism 
will aid in refining the PBPK model (Chapter 3) and explain the lack of quantifiable DHB 
in 2 of the 16 subjects examined in Appendix B. 
CONDUCT A CLINICAL STUDY TO MEASURE DHB ENTEROCYTE CONCENTRATIONS IN 
PATIENTS UNDERGOING GUT BIOPSIES.  Although a sensitivity analysis of a mechanistic 
static model indicated that predicted enteric DHB concentration is only relevant at very 
low concentrations (<1 µM; Chapter 2), predictive models would benefit from accurate 
estimates of enteric DHB concentrations following a known dose of DHB in GFJ. 
Conducting a clinical study in patients undergoing routine intestinal biopsies would add 
little additional risk to patients but valuable information pertaining to DHB enteric 
exposure. Subjects would consume a GFJ product quantified for key constituents (e.g., 
DHB, bergamottin, naringin, naringenin) prior to the procedure. Biopsy samples will be 
quantified using the highly sensitive HPLC-MS/MS assay (described in Chapter 3, 
Appendix A and Appendix B). Assay optimization and validation for the intestinal 
samples/matrices will be required. The quantification of GFJ constituents, and their 
metabolites, in human intestinal biopsies, following the administration of a characterized 
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juice, will provide clinical observations for model comparisons (PBPK or mechanistic 
static). Furthermore, development of a constituent juice concentration-to- constituent 
enterocyte concentration relationship may allow for a more direct assessment of the 
relative dietary substance-drug interaction risk of a given GFJ product. 
TEST ADDITIONAL FURANOCOUMARINS AS A MARKER CONSTITUENT USING A 
MECHANISTIC STATIC MODEL. Despite the promising results supporting the use of DHB as 
a marker constituent of GFJ, BG and furanocoumarin conjugates should be evaluated in 
a likewise manner as the content varies from batch to batch. Also, certain juices (e.g., 
other citrus juices and soft drinks) may differ considerably from the normal rage of 
concentrations of constituents measured in GFJ. This simple mechanistic static 
modeling technique (described in Chapter 2) could be applied to determine the 
contribution of test furanocoumarins to the GFJ effect or with other substances 
containing furanocoumarins. This technique would require an accurate estimate of 
enteric furanocoumarin concentrations; therefore, knowledge obtained from gut biopsies 
would be particularly informative.  
IDENTIFY MARKER CONSTITUENTS IN GFJ PREDICTIVE OF OATP-MEDIATED 
INTERACTIONS. For victims of the GFJ effect that are not mediated by CYP3A, but are 
substrates for OATPs, key marker constituents need further identification. Some work 
has been reported to determine that the furanocoumarins do not mediate this 
interaction, with naringin, naringenin and hesperidin as probable candidates (Won, 
2012). PBPK models for these perpetrator constituents should be developed, along with 
the recovery of the appropriate metabolic (Clint and/or Km and Vmax) and inhibitory kinetic 
parameters (Ki). Identification of candidate marker constituents predictive of OATP-
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mediated GFJ interactions and the recovery of their respective enzyme kinetic 
parameters will allow for PBPK models to be developed. The combination of a DHB 
PBPK interaction model with that of other marker constituents may result in a ‘virtual 
grapefruit juice’ for GFJ-drug interaction risk assessment. 
CONDUCT IN VITRO-TO-IN VIVO EXTRAPOLATIONS IN RAT.  The use of rats as a 
preclinical model to predict drug-drug interactions has been met with minimal success, 
due to frequent species differences in metabolism and distribution of xenobiotic 
metabolizing enzymes. The residue of human CYP3A4 modified by BG and DHB has 
been identified as Gln273 (Lin et al., 2012), but the modification in rat Cyp3a1 is 
unknown and may differ from that of human. In vitro data assessing DHB as an MBI and 
loperamide as a substrate toward rat enzyme sources (Appendix D) revealed that DHB 
inactivates rat Cyp3a1 less rapidly than human CYP3A4 using loperamide N-
desmethylation as the index reaction. The species disconnect is not yet elucidated, and 
developing an understanding may improve the use of rat as a screening tool. A more 
complete understanding of DHB-mediated inactivation in rat is needed. The DHB-
mediated MBI kinetic parameters should be recovered with a rat Cyp3a1 specific probe 
(e.g., 3-[(3,4-difluorobenzyl)oxy]-5,5-dimethyl-4-[4-methylsulfonyl)phenyl] furan-2(5H)-
one, or DFB) (Michaud et al., 2007). DFB is a promising candidate as it is a fluorophore 
and is amendable to a plate reader assay.  
EMPLOY HIGH THROUGHPUT SCREENING METHODS TO RECOVER KINETIC PARAMETERS 
FOR PERPETRATOR CONSTITUENTS. Parallel to the ToxCast initiative and to drug discovery, 
more high throughput methods of screening CYP3A inhibitors should be implemented. 
In light of the costs of HPLC-MS/MS based assays, plate reader-based assays would 
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be exceedingly more cost- and time- efficient for prioritizing marker constituents in 
various dietary substances. Libraries of isolated dietary substance constituents or 
extracts can be tested in human enzyme systems using validated CYP3A4 probes (e.g., 
DFB). High throughput screening tools would accelerate the identification and prediction 
of dietary substance-drug interactions.  
Aim 2. Predict the interaction risk of a GFJ with loperamide, using a single marker 
constituent. 
A PBPK modeling and simulation approach was applied to predict the magnitude 
of a GFJ-loperamide interaction. As discussed in Chapter 3, the loperamide PBPK 
model described loperamide AUC and Cmax to within 30% of observed outcomes. DHB 
plasma concentration-time profiles appeared to be predicted by a DHB PBPK model, 
although the sparse plasma data precluded statistical comparisons of DHB 
pharmacokinetic outcomes. The magnitude (AUCGFJ/AUC) of the GFJ-loperamide 
interaction was predicted to within 20% of that observed. Following this success, DHB-
loperamide interaction simulations were conducted with DHB doses reflective of the 
range labeled on certain dietary supplements (50-300 mg) (Appendix G). The outcomes 
under these conditions showed that hepatic CYP3A4 would be inhibited. Concurrent 
work showed that the quantities of DHB and BG in six dietary supplements tested to be 
far lower than labeled (<70 µg/capsule) (VanderMolen et al., 2014) (Appendix E). BG 
was also measured and unexpectedly detected in one product, albeit at low levels. 
Regardless of the unexpectedly low amount of DHB in the supplements, the in vitro 
reversible inhibitory potency (assessed by midazolam 1’-hydroxylation) of the mixture 
was greater than that of the individual DHB and BG contribution (Appendix E). 
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Additional evaluation of these products will be required to identify marker constituents in 
the products. 
Proceeding with the assessment of the loperamide abuse potential, a PBPK/PD 
model was developed to simulate a clinically relevant pharmacodynamic endpoint (pupil 
miosis) in the presence and absence of DHB. A simulated loperamide dose escalation 
study was conducted to determine the loperamide dose required to elicit an equal 
pupillary response to oral alfentanil (1.7 mg). The estimated dose of ~72 mg was in line 
with anecdotal reports and provides some evidence to support these claims 
(Daniulaityte et al., 2013).  
 The risk of a GFJ-loperamide interaction resulting in centrally-acting effects 
remains low at therapeutic loperamide doses (2-16 mg), even in the presence of GFJ 
(Chapter 2 and Chapter 3). The proposed PBPK/PD modeling and simulation approach 
in Chapter 3 should be used to assess other GFJ-opioid interactions or to design clinical 
studies where pupillary response is an outcome. The following future experiments are 
recommended based on findings in this chapter: 
APPLY A LOPERAMIDE PBPK/PD MODEL TO SPECIAL POPULATIONS. The loperamide 
PBPK/PD model developed and applied in Chapter 3 involved simulations conducted in 
virtual healthy volunteers. Construction of this model in the population based simulator, 
Simcyp®, levies the straightforward application of the model to special populations 
available in the software. These populations include special age groups (e.g., pediatric, 
geriatric), patients with various conditions (e.g., diabetes, obesity, hepatitis) and genetic 
polymorphisms. The model will be applied to these or ‘customizable’ populations (e.g., a 
population enriched for poor metabolizers of CYP2D6) to identify susceptible 
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populations. Modeling and simulation of dietary substance-drug interaction in special 
populations will identify the most susceptible individuals without the added risk of clinical 
evaluation in these subjects.        
ASSESS THE ABUSE POTENTIAL OF A GFJ-OPIOID (I.E. OXYCODONE) INTERACTION 
USING A DHB PBPK MODEL AND THE PROPOSED PBPK/PD MODELING APPROACH.  A 
significant increase in oxycodone AUC has been reported in the presence of GFJ 
(Nieminen et al., 2010). Furthermore, a PBPK model of oxycodone has been published; 
however, converting this existing PBPK model within Simcyp® and incorporating a DHB 
interaction at the level of the intestine requires recombinant CYP enzyme kinetic data 
(Km, Vmax). These essential parameters should be obtained using the methods 
described in Appendix D. An oxycodone PBPK/PD model, developed using the 
methodology described in Chapter 3 will be applied similarly to that of loperamide.  
ASSESS IRREVERSIBLE INHIBITION OF EXTRACTS OF DIETARY SUBSTANCES LABELED TO 
CONTAIN DHB. The labeled DHB and BG content did not agree with the reversible 
CYP3A4 inhibition of several supplement extractions (Appendix E). Accordingly, the 
irreversible potency should be determined using HIMs, midazolam 1’-hydroxylation and 
an IC50 shift approach. This approach will determine if unknown constituents promote 
MBI in HIMs. If the MBI by supplements is potent, further investigation is necessitated to 
identify these constituents. Since these supplements are being mislabeled for their 
content and sold, this information is pertinent to evaluating the safety of such products.  
APPLY A DHB INTERACTION MODEL TO SUSPECTED VICTIM DRUGS. To support the 
long term goals of developing a model framework to assess dietary substance-drug 
interactions, additional perpetrator substances should be examined. Simulations could 
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be conducted with DHB measured in dietary supplements as described in Appendix E, 
or other known CYP3A inhibitors, such as the black pepper constituent piperine (Ki, 36-
77 µM), that too are added to dietary supplements (Bhardwaj et al., 2002). Continued 
application of this approach will promote our understanding of dietary substance-drug 
interaction risk and help mitigate this public health concern.   
 
Aim 3: Evaluate the performance of a human model to assess the reversal of 
opioid effect. 
 Two independent proof-of-concept clinical studies conducted in six healthy 
volunteers each demonstrated that (1) a novel intranasal naloxone formulation could 
achieve similar plasma exposures (F, 41%; AUC0-6 h, 266 ng/ml*min) to intramuscular 
naloxone (F, 55%; AUC0-6 h, 347 ng/ml*min) and (2) attenuation of alfentanil-induced 
miosis by intranasal naloxone was comparable to that of intramuscular naloxone. These 
studies can be used to inform robust human models to assess opioid reversal.   
 In the preliminary human model used to assess orally administered opioid 
reversal agents (Chapter 4), pupillary response was measured in six different subjects 
following alfentanil (4 mg) in the absence and presence of GFJ. The GFJ was quantified 
for DHB (60 µM) and the resulting fold AUCGFJ/AUC was equal to previously published 
findings (Kharasch et al., 2004b). Both intramuscular and intranasal naloxone rapidly 
attenuated the pupillary effects induced by alfentanil; however, pupil miosis data were 
not rich enough to determine a difference in opioid reversal by intramuscular and 
intranasal naloxone formulations. This study was designed to administer naloxone at 
the tmax of alfentanil (~1 h); however, subjects reached tmax earlier than expected in this 
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cohort. Inter- and intra- individual variability in tmax may have complicated the 
interpretation of study outcomes. An alfentanil PBPK model prediction using an aged 
and gender matched virtual population predicted an alfentanil tmax (0.48 h) and time to 
Rmax (0.6 h), accurately predicted the study outcomes (within 30%) (Appendix H). This 
same alfentanil model-prediction in the presence of DHB underpredicted the observed 
increase in AUEC0-6 h in the presence of GFJ by >30%. The under prediction in the 
presence of DHB was due to a limitation of the construction of the alfentanil PBPK 
model. To predict an interaction at the level of the gut using in Simcyp®, the Absorption, 
Dissolution and Metabolism (ADAM) gut transit model must be used. The alfentanil 
model PBPK model was not developed using the ADAM model, because the PK was 
best described using a fixed first-order rate constant obtained from human clinical data. 
Therefore this under prediction was expected given the inappropriateness of the gut 
transit model for alfentanil. As such the alfentanil model should not be used for 
interaction predictions at the level of the gut.   
 Completion of this study resulted in several recommended improvements for 
subsequent studies using this human model for assessing opioid reversal. Due to the 
preliminary nature of this study, it was not powered with a sufficient number of subjects 
to properly evaluate intramuscular and intranasal naloxone formulations. However, 
findings from this work indicated 16 subjects are required to detect a 25% difference 
with 80% power and a Type I error of 0.05. Despite the limited number of subjects, the 
ability to observe the rapid return to baseline following alfentanil induce miosis was 
striking. The rate of which subjects return to baseline may have been better 
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characterized with more intense pupil diameter measurement sampling following 
naloxone administration.  
 Despite these caveats, alfentanil and pupil diameter measurements have an 
application beyond that of assessing opioid reversal. Alfentanil has been used as a 
probe for CYP3A phenotyping (Kharasch et al., 2004a) and may also be useful in 
evaluating dietary substances as CYP3A inhibitors, because the endpoint of pupil 
miosis is noninvasive and cost effective compared to pharmacokinetic analysis of FDA 
recommended probes (US Food and Drug Administration, 2012). Despite the greater 
variability and lessened sensitivity of alfentanil-induced pupil miosis compared to that of 
pharmacokinetic outcomes this approach would offer a means to increase study 
throughput at a lower monetary cost to sponsoring agencies (Kharasch et al., 2004a; 
Kharasch et al., 2007). The following future experiments are recommended based on 
findings in this chapter: 
CONDUCT A POWERED CLINICAL STUDY USING AN IMPROVED HUMAN MODEL TO ASSESS 
THE REVERSAL OF OPIOIDS. Following two independent clinical studies evaluating 
naloxone pharmacokinetics and opioid reversal (Chapter 4), a powered clinical 
evaluation should take place. A randomized, three-phase clinical study in 16 healthy 
subjects will evaluate three naloxone formulations (intravenous, intramuscular, 
intranasal). Oral alfentanil (4 or 6 mg) will be administered, followed by naloxone (2 mg, 
45 minutes after alfentanil). Blood will be collected at 5, 10, 15, 30, 45, 60, 90, 120, 240, 
300 and 360 minutes after alfentanil administration and quantified for both alfentanil and 
naloxone. Pupil diameter and vital signs (blood pressure, O2 saturation, respiratory rate 
and pulse rate) will be measured at 0, 5, 10, 20, 30, 35, 40, 45, 50, 60, 75, 90, 120, 150, 
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180, 240, 300, and 360 min after alfentanil. Effect outcomes of this study (pupil miosis-
time, AUEC) are expected to allow for statistical comparisons between the reversal 
rates of alfentanil-induced miosis by naloxone. The intense sampling of both blood and 
pupil diameter (and other vital signs) will provide a richer data set for more advanced 
PK/PD modeling (discussed below). An alternative approach would involve the use of a 
longer acting opioid (e.g., methadone, oxycodone) and an amended sampling scheme. 
The use of a longer acting opioid (t1/2 > 1h, naloxone t1/2) (Albeck et al., 1989) could 
provide a better measure of naloxone antagonism versus agonist depletion.       
RECOVER PARAMETERS OF NALOXONE EFFECT USING DECONVOLUTION METHODS. 
Experimental designs to measure the in vivo potency of naloxone are not simple. Using 
alfentanil and naloxone plasma concentration-time data and pupil diameter-time 
measurements, deconvolution methods and Phoenix® WinNonlin® (Mountain View, CA) 
software, may aid in comparing outcomes of naloxone clinical effect through the 
recovery of relative parameters constructed in the model.   
ASSESS COMPLEX DDI OR DIETARY SUBSTANCE-OPIOID INTERACTIONS. Orally 
administered combinatorial medications containing naloxone require that naloxone is 
extracted sufficiently via first-pass metabolism (DePriest and Miller, 2014; Koopmans et 
al., 2014). Naloxone is primarily metabolized by UGT2B7 enzymes that are expressed 
in the liver, kidney and intestine (Gill et al., 2012). A complex pharmacokinetic 
interaction perpetrated by an inhibitor of naloxone glucuronidation may elevate systemic 
naloxone concentrations such that the intended effects of the active opioid are 
attenuated. Recently, dietary substances (e.g., kaempherol, silibinin) have been 
identified as potent UGT inhibitors (Gufford et al., 2014). Clinical evaluation of these 
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perpetrator constituents should be conducted in a healthy volunteer study. Naloxone 
plasma concentrations and pupil diameter should be measured following administration 
of a combinatorial product (e.g., Suboxone®, Targiniq™ ER) in the absence and 
presence of a test perpetrator substance.    
Summary and Significance 
 Pharmaceuticals undergo rigorous evaluation prior to market appearance in 
accordance to U.S. FDA regulations and well-defined guidelines to assess the DDI 
potential of a new chemical entity. However the FDA has limited jurisdiction in regards 
to the regulation of dietary substances. Although regulatory agencies are 
acknowledging the importance of dietary substance-drug interaction risk, the burden of 
proof is not on the manufacturer of the product; instead, interaction studies are 
frequently conducted by public sector, academic and pharmaceutical laboratories. A 
framework to alleviate the cost and increase the throughput of dietary substance-drug 
interaction risk assessment is essential.  
 This dissertation project expanded on translational methods to quantitatively 
predict a dietary substance-drug interaction. Using In vitro systems, IVIVE, PBPK/PD 
modeling and simulation, and clinical evaluations a GFJ-loperamide interaction was 
rigorously evaluated. These tools were employed to test a revised framework to study 
dietary substance-drug interactions mediated by CYP enzymes. The application of a 
loperamide PBPK/PD model concluded the likelihood of loperamide-induced central 
opiate-like effects is low at therapeutic doses (2-16 mg) even with GFJ. However, this 
model supported some of the anecdotal claims, which suggest an abuse potential at 
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extreme loperamide doses (70-200 mg). These findings may prove useful for agencies 
to make informed regulatory decisions.  
The emphasis of this dissertation was to improve on currently proposed 
methodologies to predict dietary substance-drug interaction risk, by predicting 
pharmacodynamic endpoints and increasing the throughput of clinical evaluation of 
dietary substance-opioid interactions. The overall outcomes of this dissertation will 
provide investigators and regulatory agencies with a framework to evaluate dietary 
substance-drug interaction risk in a less invasive, time- and cost-efficient manner than 
presently achieved. Ideally, the in vitro and PBPK modeling and simulation approach 
will allow for prospective dietary substance-drug interaction risk assessment. These 
translational approaches will facilitate safer cohesion between conventional 
pharmacotherapy and alternative medicine practices.  
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APPENDICES  
 
APPENDIX A: METHOD DEVELOPMENT AND VALIDATION OF AN HPLC-MS/MS 
METHOD TO QUANTIFY 6’,7’-DIHYDROXYBERGAMOTTIN AND OTHER 
GRAPEFRUIT JUICE CONSTITUENTS IN HUMAN PLASMA. 
 
METHODS 
Materials and chemicals. DHB and psoralen were purchased Caymen Chemical 
(Ann Arbor, MI). LC/MS/MS grade acetonitrile, methanol, dimethyllsulfoxide, ethyl 
acetate, and formic acid were purchased from Thermo Fisher (Waltham, MA). Pooled 
human plasma was purchased from Bioreclamation (Baltimore, MD).  
Calibration standard preparation and sample extraction. Calibration standards 
and quality controls were prepared using blank human plasma at concentrations 
ranging from 0.25-1000 and 0.8-1000 nM for DHB and BG, respectively; and from 1-
2000 and 10-1500 nM for naringin and naringenin, respectively. Thawed plasma 
samples (100 µL) were added to microcentrifuge tubes and extracted by adding ethyl 
acetate (500 μL) containing 400 nM internal standard (psoralen). Samples were 
vortexed for 3 minutes at room temperature then centrifuged (2000 x g, 10 minutes, 
4°C) to separate the aqueous and organic phases. Supernatant (400 µl) was transferred 
to 0.6 mL cluster tubes and dried under heated nitrogen gas (50°C). Samples were 
reconstituted with 100 µL of 95% water:5% acetonitrile:0.1% formic acid (v/v/v) to 
replicate initial chromatographic conditions. 
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Chromatographic conditions for the quantification of grapefruit juice 
constituents in human plasma via HPLC-MS/MS. Plasma samples, standards and 
QCs (10 µl) were separated on a Thermo Aquasil C18 column (3 µm, 2.1 x 50 mm). 
Analytes were eluted using a gradient initially held at 95% mobile phase A (Nanopure 
water with 0.1% formic acid) water and 5% mobile phase B (LC/MS/MS grade 
acetonitrile with 0.1% formic acid) for 0.4 minutes. Mobile phase B was increased 
linearly for 1.1 minutes to 95%, maintained for 0.2 minutes, then returned to initial 
conditions over 0.1 minutes. The column was equilibrated for 2 minutes. Eluent was 
directed to waste for the first 0.4 minutes then to a mass detector. 
Detection of DHB using a Sciex API 5600 TripleTOF mass spectrometer. The 
API TripleTOF mass spectrometer (Framingham, MA) was operated in positive ion 
mode, with a source temperature of 350°C, an ion spray voltage of 3500 V, a 
decoupling potential (DP) of 25 V and a collision energy (CE) of 20 mV. The mass 
range of 203.15-203.18 m/z was selected for quantification. 
Optimized detection of DHB using Sciex API 6500 hybrid triple quadrupole 
mass spectrometer. The Sciex API 6500 hybrid triple quadrupole mass spectrometer 
(Framingham, MA) was operated in multiple reaction monitoring (MRM) mode, with a 
source temperature of 250°C, an ion spray voltage of 2500 V, a DP of 25 V and MRM 
transitions for DHB and psoralen of 273.2→203.1 (CE, 25 mV) and 187.1→131.2 (CE, 
32 mV), respectively. 
Optimized detection of BG on a Sciex API 6500 hybrid triple quadrupole mass 
spectrometer. The Sciex API 6500 hybrid triple quadrupole mass spectrometer 
(Framingham, MA) was operated in multiple reaction monitoring (MRM) mode, with a 
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source temperature of 550°C, an ion spray voltage of 5500 V, DP of 25 V and MRM 
transitions for BG of 339.6→147.1 (CE, 47 mV).  
Detection of naringin and naringenin on a Sciex API 6500 hybrid triple 
quadrupole mass spectrometer. The mass spectrometer was operated in MRM 
mode, with a source temperature of 350°C, an ion spray voltage of 5500 V, DP of 25 V, 
and MRM transitions for naringin and naringenin of 579→271 (CE, -32 mV) and 
273→153 (CE, 47 mV), respectively.  
Stability of DHB in human plasma stored at -80˚C. Plasma (10 mL) was spiked 
with DHB (10 mM in DMSO) to a final concentration of 100 nM DHB. Aliquots (20 x 500 
µl) were then stored at -80°C on February 2, 2013 (first aliquot was never frozen, but 
was extracted for DHB quantification). On selected dates, an aliquot was removed from 
storage and extracted along with freshly prepared calibration standards as described 
above. Extracted samples (n=3) were injected for HPLC-MS/MS analysis in triplicate. 
Freeze-thaw stability of DHB in human plasma. Spiked human plasma was 
prepared as described above (100 nM DHB). Unlike before, aliquots underwent refreeze 
(>24 h) and thaw (<2 h) cycles over the course of two weeks total. Each extraction was 
quantified using calibration standards as described earlier and analyzed by HPLC-
MS/MS in triplicate. The lower limit of quantification was 250 pM based on FDA 
guidelines (US Food and Drug Administration, 2013).  
Data analysis. All quantification was conducted using peak area ratios (psoralen as 
the internal standard) and calibration standards. Data is presented as the mean and 
standard deviation. Accuracy is determined by the calculated concentration relative to 
the nominal concentration and precision is reported as CV% and relative error (RE).  
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RESULTS 
DHB was readily quantifiable at the lowest tested calibration standard (250 pM) 
with a covariate of variance (%CV) <15% and a signal to noise ratio >10 (Table A.1; 
Figure A.1). BG, naringin and naringenin were quantifiable at their lowest prepared 
standard concentrations (0.5, 1 and 1 nM, respectively) with acceptable accuracy and 
precision. The signal to noise ratio for BG varied from 5-7 at 250 pM, but was consistent 
>10 at 500 pM, confirming its LLOQ to be 500 pM based on the predefined criteria. The 
internal standard, psoralen, was chromatographically resolved from DHB (Figure A.1) 
and from BG (RT, 2.8 min), naringin (RT, 1.32) and naringenin (RT, 1.44).  
The stability of DHB spiked into plasma and stored at -80°C was assessed to 
determine the validity of quantifying archived clinical plasma samples for DHB. The 
calculated DHB concentration decreased by less than 10% over an 18-month span of 
storage (Figure A.2). Assessment of freeze thaw cycles indicated a 20% decrease in 
DHB after 3 freeze-thaw cycles and only ~65% remained after a 5th freeze-thaw cycle.  
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DISCUSSION 
 Following thorough optimization a highly sensitive assay to detect DHB was 
developed. Methods were also devised to quantify BG, naringin and naringenin, 
although the latter were not fully validated methods, and include mass spectrometer 
conditions incompatible with DHB precluding optimal simultaneous quantification of all 
four analytes. Sub nanomolar concentrations could be reliably measured for DHB (250 
pM) and BG (500 pM), achieving the sensitivity necessary to obtain plasma 
pharmacokinetics of these analytes in human due to their low plasma exposures 
(Goosen et al., 2004). The high micromolar to millimolar concentrations of naringin and 
naringenin measured in GFJ (Vandermolen et al., 2013) taken together with preliminary 
analysis of human plasma samples indicated these analytes could be more readily 
detected in human plasma following GFJ consumption than DHB and BG. Therefore 
lower calibration standards were not tested.  
 All optimized methods were achieved using a Sciex 6500 hybrid triple quadrupole 
mass spectrometer and the reported conditions, however early development began 
using a high-resolution time-of-flight mass detector. This instrument was used early on 
in the DHB plasma stability experiments presented (Figure A.2) on the dates of 
February 2, 2013 and April 2nd 2013. This difference in platform may explain the 
apparent higher concentrations measured on those dates compared to the later dates. 
Despite this instrumentation difference, DHB appeared to be stable in human plasma 
stored at -80°C for at least 18-months. However, repeated freeze thawing was 
detrimental to DHB stability after 2-3 cycles.  
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(DHB) and the internal standard (IS)  
 
 
 
 
 
 
 
 
 
 
 
Figure A.1. HPLC-MS/MS separation and detection of 6’,7’-Dihydroxybergamottin 
(DHB) and the internal standard (IS) psoralen at the lower limit of DHB quantification 
(250 pM). Signals are normalized to the maximal measured response per MRM trace.  
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Figure 5.1. HPLC-MS/MS separation and 
detection of 6',7'-dihydroxybergamottin. 
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Figure 5.2. DHB stability following storage at -80C. 
 
Figure A.2. DHB stability following storage at -80°C. The date shown corresponds to 
the date of extraction and analysis and the measured DHB concentration was 
determined from interpolation of 8 calibration standards (10-1000 nM). Extractions 
performed on 2/2/2013 and 4/2/2013 were quantified on an AB Sciex TripleTOF and the 
remained on an AB Sciex 6500 mass spectrometer. Bars denote the mean ± SD of 
triplicate extractions. 
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Figure 5.3. DHB freeze-thaw stability in human plasma. 
 
Figure A. 3. DHB quantification of human plasma samples spiked with 100 nM DHB 
and having undergone freeze-thaw cycles (as denoted). Bars denote the mean ± SD of 
triplicate extractions.   
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Table A.1. Precision (%CV) and accuracy (RE) Inter- and intra-day variability of DHB in 
human plasma (n=3). Table 5.1 
 Intraday Interday 
 %CV RE %CV RE 
6’,7’-Dihydroxybergamottin     
1.6 nM 0.72 2.3 2.12 10 
16 nM 1.2 -1.9 13.52 -13 
80 nM 0.91 -2.0 3.95 -10 
800 nM 0.99 2.7 2.92 12 
Bergamottin     
1.6 nM 1.2 -3.1 5.12 -12 
16 nM 1.1 3.0 3.61 10 
80 nM 0.82 4.5 3.92 8.7 
800 nM 0.99 2.9 2.94 13 
Naringen     
1.6 nM 4.2 7 11.2 14 
16 nM 2.2 -4.8 6.5 -11 
80 nM 1.9 -5.2 5.6 -13 
800 nM 1.1 3.2 7.2 8.2 
Naringenin     
1.6 nM 2.1 -4.4 12.3 -14 
16 nM 1.21 5.7 2.25 12 
80 nM 0.99 3.1 3.45 9.1 
800 nM 1.02 7.3 5.61 10 
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APPENDIX B: CHARACTERIZATION OF FURANOCOUMARIN METABOLITES IN 
HUMAN PLASMA FOLLOWING GRAPEFRUIT JUICE CONSUMPTION. 
 
METHODS 
Materials and chemicals. See chapter 3.  
Human Sample procurement. See chapter 3. 
Human plasma. Plasma samples from a grapefruit juice-loperamide interaction 
study (Ainslie et al., 2014) were quantified for DHB and BG. Subjects (n=16) consumed 
240 mL of grapefruit juice quantified for DHB (70 µM). Blood was collected prior to and 
0.5, 1, 2, 3, 4, and 6 h after GFJ consumption. Plasma was stored at -80°C and thawed 
at room temperature under low light conditions. 
Quantification of furanocoumarins and their metabolites by HPLC-MS/MS. 
Plasma samples were quantified for DHB and BG as described in appendix A.  
Data analysis. Pharmacokinetic outcomes were obtained via standard non-
compartmental methods using Phoenix WinNonlin (v6.3). The maximum concentration 
(Cmax), time to reach Cmax (tmax), and last measurable concentration (Clast) were obtained 
directly from the plasma concentration-time profiles. The terminal elimination rate 
constant (λz) was determined by linear regression of the terminal portion of the log-
transformed concentration-time profile using at least three data points. Area under the 
plasma concentration-time curve (AUC) from time zero to 4 h (AUC0-4h) was determined
using the trapezoidal method with linear up/log down interpolation. The AUC from time 
zero to infinity (AUC0-inf) was calculated as the sum of AUC0-4h and C4h/λz.  
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RESULTS 
In human plasma samples, BG was below the limit of quantification in all tested 
samples although DHB was detected in 14 out of 16 subjects and 11 subjects had a 
sufficient quantifiable data to determine pharmacokinetic outcomes (Table B.1). A 
secondary observation during the quantification of DHB in human plasma was an 
unexpected peak using the MRM transitions corresponding to DHB, in certain subjects 
(n=5, Figure B.1). This extraneous peak is hypothesized to correspond to a DHB 
conjugate, undergoing in source fragmentation. Recently, DHB glucuronide conjugates 
had been identified and measured in human urine (Regueiro et al., 2014). 
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Figure 5.1. Representative chromatograms following HPLC-MS/MS analysis of plasma from two subjects. 
  
 
Figure B.1. Representative chromatograms following HPLC-MS/MS analysis of plasma 
from two subjects 4 h after consuming grapefruit juice. Subject 13 (top) with only DHB 
detected and subject 15 (bottom) with DHB and a suspected metabolite.  
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Table B.1. Individual DHB pharmacokinetic outcomes. Table 1.1 
Subject λZ (h-1) Tmax (h) Cmax (nM) AUC0-4h (h*nM) AUC0-inf (h*nM) 
1 0.337 1 12.9 18.8 23.7 
2 0.744 0.5 18.3 33.6 36.2 
3 0.578 0.5 36.1 69.3 79.3 
4 
6 1.699 0.5 3.7 6.6 6.6 
7 0.855 1 13.4 24.0 25.3 
8 0.530 0.5 54.7 115.5 141.1 
9 
10 1.064 1 11.2 15.1 15.5 
11 1 15.8 10.0 
12 0.447 1 31.1 63.3 77.7 
13 3 62.6 98.9 
14 0.246 0.5 32.5 88.5 
15 0.554 0.5 45.6 48.7 54.6 
16 4 17.2 25.7 
18 0.401 1 22.8 51.3 
λZ, terminal elimination slope; Tmax, time to maximal concentration (Cmax); AUC0-4 h, area 
under the plasma concentration-time curve from 0-4 h; AUCinf, AUC from 0 h 
extrapolated to infinite time. aThe percent of area extrapolated from 4 h to infinite time.  
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APPENDIX C: RECOVERY OF IN VITRO KINETIC PARAMETERS OF LOPERAMIDE 
AND N-DESMETHYLLOPERAMIDE METABOLISM IN HUMAN INTESTINAL 
MICROSOMES FROM INDIVIDUAL DONORS. 
  
METHODS 
Materials. See chapter 2.  
Microsomes. Human intestinal microsomes were obtained from individual 
donors selected as high (HI5-J7), medium (HI7-J7) and low (HI8-J7/J8) CYP3A4 protein 
content (Paine et al., 2006).  
Recovery of saturable kinetic parameters for loperamide N-desmethylation. 
Loperamide N-desmethylation was assessed under linear conditions for microsomal 
protein concentration and time (0.1 mg/mL; 20 min) at 37°C and a total incubation 
volume of 200 µL. The substrate, loperamide, was incubated from 0.2-50 µM and 
initiated by the addition of NADPH (1 mM). Incubations were terminated and the primary 
loperamide metabolite, N-desmethylloperamide was quantified using methods 
described in chapter 2.   
Recovery of N-desmethylloperamide intrinsic clearance in human liver and 
intestinal microsomes. N-Desmethylloperamide (1 µM) was incubated in HIMs (0.1 
mg/ml) collected from a single donor (HI7J7) or HLMs (0.1 mg/ml) from pooled donors 
(n=50) for 30 minutes at 37˚C.  Time points (0.25-30 minutes) were collected with the 
removal of 25 µL of incubation mixture, precipitated with 400 µL of acetonitrile 
containing 0.1% formic acid (v/v) and internal standard (D3- N-desmethylloperamide,
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500 nM) in 96-well plates. Plates were centrifuged at 2000 x g for 5 minutes, and 300 µL 
of supernatant were transferred to the final analysis plate. The final plate was dried 
down under heated nitrogen gas (50˚C) then reconstituted in 300 µL of 95% water:5% 
Methanol : 0.1% formic acid (v/v/v) and analyzed by HPLC-MS/MS. The intrinsic 
clearance (CLint) was determined by equation C.1 (Di et al., 2012). 
HPLC-MS/MS quantification of N-desmethylloperamide. Samples (7 μL) were 
separated on an Atlantis C18 column (2.1 X 50 cm, 3µm). The mobile phase gradient 
was carried out on a Shimazdu LC-20AD solvent delivery system and analytes were 
detected with a Sciex TripleTOF 5600 mass spectrometer. The HPLC method is 
described in detail in chapter 2. Analyte detection was achieved with a decoupling 
potential of 25 V and a collision energy of 35 mV, with a mass range for quantification of 
252.1000-252.8000 for N-desmethyl loperamide and 255.1000-255.8000 m/z.  Analyte 
peak integration and sample quantitation was conducted using Analyst software (v1.6; 
Applied Biosystems, Framingham, MA). The lower limit of quantification (LLOQ) was 0.9 
nM and the upper limit of quantification (ULOQ) was 1000 nM.  
Data analysis. A linear regression model was fit to the data in Pheonix® 
WinNonlin®. The intrinsic clearance was determined using equation C.1 assuming a free 
fraction of 1.  
     Equation C.1 
 Where k is the slope, V is the volume of the incubation, M is the amount of 
microsomal protein in the incubation and fub, inc is the unbound fraction in the incubation. 
  
Clint,inc =
−k
V
M






fu,inc
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RESULTS 
 Saturable kinetic parameters for loperamide were recovered by HIMs of three 
individual donors. The recovered Km in high, medium and low CYP3A4 expressing 
individual donors was 12.4, 15.2, and 21.8 µM, respectively, and Vmax was 61, 250, 290 
pmol/min/ mg protein, respectively (Figure C.1).  
 The intrinsic clearance of loperamide (taken as the ratio of Vmax to Km) for high, 
medium and low donors was 23.1, 16.4 and 2.8 µL/min/mg protein, respectively.  
 The intrinsic clearance for N-desmethylloperamide determined by the parent 
disappearance method was 18.41 and 39.08 µL/min/mg protein by HIMs and HLMs, 
respectively (Figure C.2).  
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Figure 5.1. Michaelis-Menten plot for N-desmethylation of loperamide by HIM. 
 
Figure C.1.  Michaelis-Menten plot for N-desmethylation of loperamide by HIMs in a 
high (green), medium (blue) and low (red) CYP3A4 expressing donor. Symbols and 
error bars denote means and S.D.’s, respectively. 
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Figure 1.2. Parent disappearance of N-desmethylloperamide by HIMs and HLMs. 
  
Figure C.2. Parent disappearance of N-desmethylloperamide by HIMs (left) and HLMs 
(right).Symbols denote the mean and S.D.’s of triplicate incubations and the solid line 
denotes the model fit.  
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APPENDIX D: RECOVERY OF IN VITRO KINETIC PARAMETERS OF LOPERAMIDE 
METABOLISM AND INHIBITORY KINETIC PARAMETERS OF DHB IN RAT. 
  
METHODS 
Materials and Chemicals. See chapter 2. 
Rat enzyme sources. Recombinant rat enzymes were a purchased from BD 
Biosciences (San Jose, CA). Pooled (n=400) rat liver microsomes (RLMs) and pooled 
(n=200) rat intestinal microsomes (RIMs) were purchased from XenoTech (Lenexa, KS).   
N-Desmethylloperamide formation in recombinant rat P450 enzymes. 
Loperamide (1 µM) was incubated (37°C) for 20 minutes in recombinant rat P450 
enzymes (Cyp1a1, Cyp2a1, Cyp2a2, Cyp2b1, Cyp2c11, Cyp2c13, Cyp2c13, Cyp2c6, 
Cyp2d1, Cyp2d2, Cyp2e1 and Cyp3a1) at an enzyme concentration of 50 pmol 
P450/mL and a total incubation volume of 200 µL. Incubations were initiated with 
NADPH (2 mM) and terminated at the end of each incubation by the transfer of 100 µl of 
incubation mixture to a 96-well plate containing 300 µl of acetonitrile/0.1% (v/v) formic 
acid and internal standard (500 nM D3-N-desmethylloperamide). Plates were 
centrifuged at 2000 x g for 10 min, and 200 µl of supernatant were transferred to clean 
plates. The contents were dried under heated nitrogen (50°C), reconstituted in 200 µl of 
95% water:5% acetonitrile:0.1% formic acid (v/v/v) (initial chromatographic conditions), 
and analyzed for N-desmethylloperamide by LC/MS/MS (see below).  
Determination of loperamide kinetic parameters (Km and Vmax) in human 
and rat microsomes. Loperamide N-desmethylation was assessed under linear
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conditions for microsomal protein concentration and time in HLMs (0.1 mg/mL; 10 min), 
HIMs (0.1 mg/mL; 20 min), RLMs (0.075 mg/mL; 10 min) and RIMs (0.075 mg/mL; 20 
min) at 37°C and a total incubation volume of 200 µL. The substrate, loperamide, was 
incubated from 0.2-50 µM.  
Reversible inhibition of loperamide metabolism by DHB in human and rat 
microsomes. Loperamide was incubated at its Km as determined above for each 
enzyme source in the presence of DHB (ranging from 0-50 µM). Incubations were 
initiated with NADPH and terminated as described above. IC50 values were recovered 
using equation D.1. after evaluating alternative models. Goodness-of-fit was assessed 
by visual comparison of observed with predicted concentration-time profiles, residual 
analysis, Akaike’s Information Criteria, and precision of parameter estimates (CV%). 
     Equation D.1 
v denotes the observed reaction velocity; vo is the control velocity, in the absence 
of DHB; [DHB] denotes the concentration of DHB in units of µM; IC50 is the 
concentration of DHB required inhibit loperamide N-desmethylation by 50%.  
Determination of mechanism-based inhibition parameters (KI and kinact) in 
human and rat microsomes. Time- and concentration-dependent inhibition of CYP3A4 
activity by DHB in HLMs, HIMs, RLMs and RIMs was assessed as described in chapter 
2. Briefly, primary incubation mixtures consisted of HLMs, HIMs (5 mg/mL) RLMs or 
RIMs (4 mg/mL), DHB (0, 2.5, 5, 10, 30 or 60 µM), and potassium phosphate buffer (0.1 
M, pH 7.4). The mixtures were equilibrated at 37°C for 5 min before initiating reactions 
with NADPH (1 mM final concentration), yielding a final volume of 80 µl; the final 
v =
v0
1+
[DHB]
IC50
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concentration of DMSO was ~1% (v/v). At designated times from 0-5 min, an aliquot (10 
µl) was removed and diluted 20-fold into secondary incubation mixtures containing 
loperamide and NADPH (1 mM), yielding a final loperamide concentration of 60 μM. 
Secondary reactions were terminated after 20 min (HIMs, RIMs) or 10 min (HLMs, 
RLMs) as described above. N-desmethylloperamide formation was measured by HPLC-
MS/MS. Parameters were recovered as described in chapter 2.  
HPLC-MS/MS determination of N-desmethylloperamide and 
didesmethylloperamide in rCYP P450 and microsomes. N-Desmethylloperamide 
was quantified as described in chapter 2. Didesmethlloperamide was qualified 
simultaneous to N-desmethylloperamide with the MRM transitions of 449.1→238.0 and 
a CE of 33 mV.  
Data analysis. N-Desmethllyopmide formation in recombinant enzyme systems 
is presented as the mean of duplicate incubations. Reversible inhibition assays were 
conducted in triplicate and kinetic parameter estimates are presented as the estimate ± 
S.E.’s. MBI kinetic data are presented as the mean of duplicate incubations and their 
kinetic parameters are presented as estimates ± S.E.’s.  
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RESULTS 
  The primary human metabolite of loperamide, N-desmethylloperamide, was 
formed by 5 of the 11 tested rat Cyp P450 enzymes, namely, Cyp2c13, Cyp2d1, 
Cyp2d2, Cyp2e1, Cyp3a1 (Figure D.1). The formation velocity by Cyp3a1 was the 
greatest yet comparable to that of Cyp2c11 and Cyp2d1. Cyp2d1 catalyzed N-
desmethylloperamide formation approximately two fold faster than Cyp2d2. 
Didesmethylloperamide was below the limit of quantification in all incubations, but was 
detectable (above 0.1 nM) in those conducted in Cyp3a1.     
Saturable loperamide concentrations were achieved in all tested microsomal 
systems (Figure D.2). The apparent Km of loperamide N-desmethylation was 
approximately half that in human by both liver and intestinal microsomes compared to 
rat. Vmax determined by RIMs was 18% greater than that by HIMs. Vmax in RLMs was 
twofold greater than in HLMs. Didesmethylloperamide was below the limit of 
quantification in all incubations (1 nM).    
DHB showed potent reversible inhibition (IC50) in all tested microsomal systems. 
Mechanism-based inhibition of loperamide N-desmethlyation by DHB was measured in 
four microsomal systems (HLMs, HIMs, RLMs, RIMs). DHB showed MBI activity in 
HLMs, HIMs and RLMs with similar KI’s. The maximal inactivation rate (kinact) measured 
in these enzyme sources varied. DHB was a most effective MBI in HIMs followed by 
HLMs then RLMs. DHB showed weak MBI in RIMs precluding accurate parameters 
estimate recovery.  
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Figure 5.1 
 
Figure D. 1. Rat P450 enzymes catalyzing the formation of N-desmethylloperamide 
from loperamide (1 µM). Reactions were initiated with NADPH (2 mM). Bars denote 
means of duplicate incubations. N-Desmethylloperamide was below the limit of 
quantification (0.9 nM) in incubations conducted in Cyp1a1, Cyp2a1, Cyp2a2, Cyp2b1, 
Cyp2c11 and Cyp2c6.  
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Figure 1.2. N-Desmethylloperamide formation at increasing loperamide concentrations 
in HLMs, RLMs, HIMs and RIMs. 
 
 
Figure D.2. N-Desmethylloperamide formation at increasing loperamide concentrations 
in HLMs (top left), RLMs (top right), HIMs (bottom left) and RIMs (bottom right). 
Observed data (circles) are presented as the mean of triplicate incubations. Covariate of 
variation was <10% for all points. Lines denote the model fit. The velocity of formation 
with 50 µM loperamide by RLMs exceeded the upper limit of quantification.  
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Table D.1. In vitro kinetic parameters for loperamide (Km and Vmax) and DHB (IC50, kinact 
and KI) in human and rat microsomes. Table 1.1 
 
DHB, 6’,7’-Dihydroxybergamottin; HLMs, human liver microsomes; HIMs, human 
intestinal microsomes; RLMs, rat liver microsomes; RIMs, rat intestinal microsomes; 
Vmax, maximal N-desmethylloperamide formation rate; Km, loperamide concentration 
required to reach half Vmax; IC50, the DHB concentration required to inhibited N-
desmethylloperamide formation by 50% with loperamide incubated at its Km; kinact, the 
maximal enzyme inactivation rate; KI, the DHB concentration required to reach half 
kinact; N.D., experimental value was not determined or conducted; N.R., parameter 
estimate could not be recovered.   
Parameter HLMs RLMs HIMs RIMs 
Vmax (pmol/min/mg 
protein) 
191.4 ± 11.7 384.9 ± 20.2 44.4 ± 2.7 52.8 ± 2.2 
Km (µM) 6.14 ± 1.2 3.1 ± 0.4 6.13 ± 1.1 4.1 ± 0.6 
IC50 (µM) N.D. 2.2 ± 0.2 2.1 ± 0.2 3.2 ± 0.3 
kinact (min-1) 0.24 ± 0.02 0.19 ± 0.02 0.38 ± 0.02 N.R. 
KI (µM) 3.4 ± 1.0 5.0 ± 2.7 5.1 ± 0.9 N.R. 
 185 
APPENDIX E: INHIBITORY POTENCY OF SUPPLEMENTS LABELED TO CONTAIN 
DHB AND/OR BG TOWARD CYP3A ACTIVITY.4 
 
METHODS 
Materials and chemicals. 6′,7′-Dihydroxybegamottin was purchased from Cayman 
Chemical (Ann Arbor, MI; purity ≥ 98.0%); bergamottin was purchased from Sigma-
Aldrich (purity ≥ 98.0). Midazolam (purity ≥ 99.9%), 1’-hydroxymidazolam (purity ≥ 
98.0%), ketoconazole (purity ≥ 98.0%), alprazolam (purity ≥ 99.0%), and NADPH were 
purchased from Sigma-Aldrich. Simply Grapefruit brand GFJ was purchased from 
SimplyOrange Juice Co. (Apopka FL; lot AMC3 E 01:13). Methanol (MeOH) was 
purchased from Fischer Scientific (Waltham, MA). UPLC-grade water and acetonitrile 
were purchased from Fisher Scientific. Pooled HIMs (n = 18 donors) were purchased 
from Xenotech (Lenexa, KS). Six supplements labeled to contain DHB and/or 
bergamottin were purchased from the following sources: SciFit DHB 300 (SciFit, 
Oakmont, PA; lot 57454), Trisorbagen (Anabolic Xtreme, Tempe AZ; lot 202609), 
Xceler8 DHB (VitaSport, Chino Hills, CA; lot US 37700), AttentionLink (Hi-Tech 
Pharmaceuticals, Inc., Norcross, GA; lot 08132039), Finaflex 1-Alpha (Redefine 
Nutrition, Alpharetta, GA; lot 824912013), and Finaflex 1-Andro (Redefine Nutrition, 
Alpharetta, GA; lot 0500313).
                                            
4 This appendix previously appeared as an article in the Journal of Pharmaceutical and 
Biomedical Analysis and is printed with permission from Elsevier. The original citation is 
as follows: VanderMolen KW, Ainslie GR, Paine MF and Oberlies NH. Labeled content 
of two furanocoumarins in dietary supplements correlates with neither actual content nor 
CYP3A inhibitory activity. J Pharm Biomed Anal. 2014 Sep;98:260-5. 
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Extraction of supplements labeled to contain DHB. See previously described 
methods (Vandermolen et al., 2013). 
CYP3A inhibition assay. A dilution scheme was devised using the product with the 
highest measured amount of DHB (SciFit DHB 300). The corresponding extract was 
reconstituted with methanol (130 μL), which was diluted 1:10 in methanol. Each of these 
methanolic solutions was dilu
ted further into incubation mixtures (see below) to yield final DHB concentrations of 1 
and 0.1 μM; the higher concentration approximates the Ki of DHB towards CYP3A using 
HIMs as an enzyme source and midazolam as the probe substrate. (Paine et al., 2004) 
All other supplements were reconstituted and diluted in the same manner as SciFit DHB 
300. A grapefruit juice extract was reconstituted with methanol (50 μL), an aliquot was 
further diluted 1:10 in methanol. These methanolic solutions were diluted further into 
incubation mixtures to yield final DHB concentrations of 1 and 0.1 µM.  
Incubation mixtures, prepared in 96-well plates, consisted of midazolam (4 µM), 
HIMs (0.05 mg/mL protein), inhibitor (diluted extract, DHB, bergamottin, ketoconazole) 
or vehicle control, and potassium phosphate buffer (100 mM, pH 7.4). The final 
concentrations of DHB, bergamottin, and ketoconazole were 1 and 0.1 μM; the final 
concentration of methanol (v/v) was 1.0%. After equilibrating the mixtures for 5 min at 
37°C, reactions were initiated with NADPH (1 mM final concentration), yielding a final 
volume of 200 μL. Reactions were terminated after 4 min by removing a 100-µL aliquot 
and adding to 300 µL of ice-cold CH3CN containing internal standard (300 µg/mL 
alprazolam). Samples were vortexed (~30 s) and centrifuged (3000 g × 10 min at 4 °C), 
after which 100 µL of supernatant were removed and analyzed for 1′-hydroxymidazolam 
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by LC-MS-MS on an API 6500 QTrap operated in MRM mode and equipped with an 
electrospray ionization source. Calibration standards were matrix-matched and were 
linear from 3.9 to 2000 nM. The QTrap was coupled to a Shimadzu Nextera UHPLC 
system (Kyoto, Japan). Chromatographic separation of midazolam, 1′-
hydroxymidazolam, and alprazolam was achieved with a Thermo Scientific Aquasil C18 
(2.1 × 50 mm, 3 µm) HPLC column (Waltham, MA) using a gradient method following a 
7-µL injection of each supernatant. The gradient system consisted of A, 0.1% formic 
acid in water and B, 0.1% formic acid in acetonitrile, at a flow rate of 0.75 mL/min: 0-0.4 
min, 5% B; 0.4-1.5 min, 5-95% B; 1.5-2.1 min, 95% B; 2.1-2.11, 95-5% B; 2.11-3.0, 5% 
B. Sample and column temperatures were 4°C and 40°C, respectively. Quality controls 
(QCs) of 10, 100, and 1500 nM were used to assess accuracy. All standards and QCs 
were accurate to within 20% of the nominal value; QC precision was <15% relative 
error.    
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RESULTS 
The mean ± SD vehicle control reaction velocities of 1-hydroxymidazolam formation 
was 416 ± 29 pmol/min/mg protein. The CYP3A inhibitor, ketoconazole, abolished 1’-
hydroxymidazolam formation at 1 µM and inhibited activity by ~75% at 0.1 µM (Figure 
D.1). Bergamottin showed no inhibition at the concentrations tested. DHB at 0.1 and 1 
µM inhibited activity by 5 and 42%, respectively. Except for bergamottin, concentration 
dependency was observed for each treatment (p<0.05; 2-way ANOVA with Bonferroni 
adjustment). The CYP3A inhibitory activity of SciFit was similar to that of the grapefruit 
juice extract, which, like SciFit, was diluted such that the final concentrations of DHB 
were 0.1 and 1 µM. If the grapefruit juice extract were normalized to SciFit based on the 
initial volume of methanol added to the extract (50 μL and 130 μL for grapefruit juice 
and SciFit, respectively), SciFit would be approximately 2.5x more potent than a glass 
of grapefruit juice. In addition to SciFit, two supplements (Trisorbagen and 
AttentionLink) demonstrated potent inhibition of CYP3A activity despite very low 
measured amounts of DHB and bergamottin. Finaflex 1-Alpha appeared to stimulate 
CYP3A activity at the lower concentration, which has been observed with low 
concentrations of bergamottin (< 2.5 μM) in incubations with HIMS and midazolam. 
(Paine et al., 2005)  
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Figure 1.3. Comparison of the effects of supplements labeled to contain 6',7'-dihydroxybergamottin (DHB) 
 
Figure E.1. Comparison of the effects of supplements labeled to contain 6',7'-
dihydroxybergamottin (DHB) with known CYP3A inhibitors on CYP3A activity in human 
intestinal microsomes. Pure DHB and bergamottin, as well as the known CYP3A 
inhibitor ketoconazole, were tested at 0.1 µM (open bars) or 1 µM (solid bars). The 
methanolic extract of SciFit was tested such that the final concentration of DHB was 0.1 
or 1 μM. All other supplement extracts were tested at the same dilutions as SciFit (10x 
and 1x; open bars and closed bars, respectively). The grapefruit juice extract (GFJ) was 
tested such that the final concentration of DHB was 0.1 or 1 μM. The concentrations of 
DHB in the incubations containing SciFit, GFJ, and purified DHB were the same (0.1 
and 1 µM; open and filled blue bars, respectively). Bars and error bars denote the 
means and SDs, respectively, of triplicate incubations. Inhibition by ketoconazole at 1 
µM was below the limit of quantification. *p < 0.05 versus the 10x dilution; #p < 0.05 
versus pure DHB at 0.1 µM; Ŧp < 0.05 versus pure DHB at 1 µM. Statistical comparisons 
were made via two-way ANOVA with a Bonferroni adjustment.   
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APPENDIX F: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF 
LOPERAMIDE. 
  
METHODS 
Physiologically-based pharmacokinetic model development. A model 
structure was devised to incorporate intestinal and hepatic metabolism of loperamide 
(Figure F.1). Partition coefficients (kp’s) were calculated using GasroPlus (v8.0; 
Simulation Plus Inc., Lancaster, CA). Physiological parameters for blood flow (Q) and 
tissue weights were obtained from the International Commission on Radiological 
Protection. Loperamide ka was recovered from the clinical data (Ainslie et al., 2014). 
Metabolism kinetic parameters for loperamide (Km and Vmax) and N-
desmethylloperamide (CLint) were obtained in appendix C. PBPK models for loperamide 
and N-desmethylloperamide using Berkley Madonna (v8.3.18; University of California at 
Berkeley, Berkeley, CA ) using the code provided below. 
Data analysis. Model-predicted pharmacokinetic outcomes were compared to 
the clinical study described in chapter 2. Non-compartmental methods were used as 
described in appendix B.  
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RESULTS 
The model predicted loperamide AUC0-72 h (94 nM*h) and Cmax (4.5 nM) was 
within 15 and 30 % of the observed geometric mean [90% CI] values (110 [90-130] and 
6.5 [5.3-8.1], respectively. 
The model under predicted N-desmethylloperamide AUC0-72 (225 nM*h) and Cmax 
(4.8 nM) by 20 and 40 %, respectively, compared to observed geometric mean {90% CI] 
AUC0-72 h (280 [260-300] nM*h) and Cmax (7.9 [6.7-9.2] nM).
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Figure 5.1. Loperamide PBPK model structure. 
 
Figure F.1. Loperamide PBPK model structure.
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Figure 1.2. Model simulated plasma concentration-time profiles of loperamide and N-
desmethylloperamide. 
 
Figure F.2. Model simulated plasma concentration-time profiles of loperamide (left, blue 
line) and N-desmethylloperamide (right, red line) on log-axis and with linear axis (inset). 
Observed clinical data for loperamide (closed circles) and N-desmethylloperamide 
(open circles). Observed values are presented as geometric mean and the upped 90% 
confidence interval.    
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Berkeley Madonna code for Loperamide: 
; Berkeley Madonna script 
; *** Loperamide *** 
;  
; Garrett Ainslie (University of North Carolinia)  
; Compiled on: 2012-10-05 
;  
; ========= 
; 
CV = ( (CVfa * Qfa) + (CVbr * Qbr) + (CVgu * Qgu) + (CVki * Qki) + (CVrpd * Qrpd) + 
(CVspd * Qspd) + (CVli * Qli)) / QC    ; venous concentration (nmol/L) 
CA = (QC * CV) / (QC + (1))    ; arterial concentration (nmol/L) 
dCV = ( (dCVfa * Qfa) + (dCVbr * Qbr) + (dCVgu * Qgu) + (dCVki * Qki) + (dCVrpd * 
Qrpd) + (dCVspd * Qspd) + (dCVli * Qli)) / QC    ; venous concentration (nmol/L) 
dCA = (QC * dCV) / (QC + (1))    ; arterial concentration (nmol/L) 
 
;CONCENTRATIONS 
Cfa = Afa / Vfa    ; cellular concentration (nmol/L) 
Cbr = Abr / Vbr    ; cellular concentration (nmol/L) 
Cgu = Agu / Vgu    ; cellular concentration (nmol/L) 
Cki = Aki / Vki    ; cellular concentration (nmol/L) 
Cspd = Aspd / Vspd    ; cellular concentration (nmol/L) 
Cli = Ali / Vli    ; cellular concentration (nmol/L) 
CVfa = Cfa / Pfab    ; venous organ concentration (nmol/L) 
CVbr = Cbr / Pbrb    ; venous organ concentration (nmol/L) 
CVgu = Cgu / Pgub    ; venous organ concentration (nmol/L) 
CVki = Cki / Pkib    ; venous organ concentration (nmol/L) 
CVspd = Cspd / Pspdb    ; venous organ concentration (nmol/L) 
CVli = Cli / Plib    ; venous organ concentration (nmol/L) 
Crpd = Arpd / Vrpd    ; cellular concentration (nmol/L) 
CVrpd = Crpd / Prpdb    ; venous organ concentration (nmol/L) 
CX = CA / 1    ; exhaled concentration (nmol/L) 
 
dCfa = dAfa / Vfa    ; cellular concentration (nmol/L) 
dCbr = dAbr / Vbr    ; cellular concentration (nmol/L) 
dCgu = dAgu / Vgu    ; cellular concentration (nmol/L) 
dCki = dAki / Vki    ; cellular concentration (nmol/L) 
dCspd = dAspd / Vspd    ; cellular concentration (nmol/L) 
dCli = dAli / Vli    ; cellular concentration (nmol/L) 
dCVfa =dCfa / dPfab    ; venous organ concentration (nmol/L) 
dCVbr = dCbr / dPbrb    ; venous organ concentration (nmol/L) 
dCVgu = dCgu / dPgub    ; venous organ concentration (nmol/L) 
dCVki = dCki / dPkib    ; venous organ concentration (nmol/L) 
dCVspd = dCspd / dPspdb    ; venous organ concentration (nmol/L) 
dCVli = dCli / dPlib    ; venous organ concentration (nmol/L) 
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dCrpd = dArpd / Vrpd    ; cellular concentration (nmol/L) 
dCVrpd = dCrpd / dPrpdb    ; venous organ concentration (nmol/L) 
dCX = dCA / 1    ; exhaled concentration (nmol/L) 
; Parameters 
; ========== 
; 
;FLOWS 
QC = QCC * BWc    ; cardiac output (L/h) 
QbrC = 0.12    ; fractional blood flow 
QCC = 11.22    ; cardiac allometric constant (L/h/kg^CAE) 
QfaC = 0.05    ; fractional blood flow 
QkiC = 0.171922    ; fractional blood flow 
QliC = 0.25    ; fractional blood flow 
QPC = 15    ; respiratory allometric constant (L/h/kg^RAE) 
QguC = 0.141127 
QspdAC = 0.27    ; overall fractional blood flow 
QspdC = QspdAC - QfaC    ; fractional blood flow 
 
Qfa = QfaC * QC    ; scaled fractional blood flow 
Qbr = QbrC * QC    ; scaled fractional blood flow 
Qgu = QguC * QC    ; scaled fractional blood flow 
Qki = QkiC * QC    ; scaled fractional blood flow 
QrpdAC = 1 - QspdAC    ; overall fractional blood flow 
QrpdC = QrpdAC - (QbrC + QguC + QkiC + QliC)    ; fractional blood flow 
Qrpd = QrpdC * QC    ; scaled fractional blood flow 
Qli = QliC * QC    ; scaled fractional blood flow 
Qspd = QspdC * QC    ; scaled fractional blood flow 
 
;VOLUMES 
BW = 70    ; body mass (kg) 
VT = 0.857    ; proportion of vascularised tissue 
VfaC = 0.214    ; fractional volume 
VbrC = 0.02    ; fractional volume 
VspdAC = 0.43    ; overall fractional volume 
VliC = 0.0257    ; fractional volume 
VguC = 0.02    ; fractional volume, estimated 
Vgu = VguC * BW    ; scaled fractional volume 
VkiC = 0.03405    ; fractional volume 
VspdC = VspdAC - VfaC    ; fractional volume 
Vki = VkiC * BW    ; scaled fractional volume 
Vspd = VspdC * BW    ; scaled fractional volume 
Vfa = VfaC * BW    ; scaled fractional volume 
Vbr = VbrC * BW ; scaled fractional volume 
Vli = VliC * BW    ; scaled fractional volume 
VrpdAC = VT - VspdAC    ; overall fractional volume 
VrpdC = VrpdAC - (VbrC + VguC + VkiC + VliC)    ; fractional volume 
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Vrpd = VrpdC * BW    ; scaled fractional volume 
 
;PARTITIONING 
 
;===LOP==== 
Pfab = 2.46    ; tissue:blood partition coefficient 
Pbrb = 1.93    ; tissue:blood partition coefficient 
Pkib = 2.99    ; tissue:blood partition coefficient 
Prpdb = 1    ; tissue:blood partition coefficient 
Pspdb = 0.8    ; tissue:blood partition coefficient 
Plib = 3.2    ; tissue:blood partition coefficient 
Pgub = 1    ; tissue:blood partition coefficient 
 
;====dLOP==== 
 
dPfab = 16.88    ; tissue:blood partition coefficient 
dPbrb = 9.19    ; tissue:blood partition coefficient 
dPkib = 3.46    ; tissue:blood partition coefficient 
dPrpdb = 1    ; tissue:blood partition coefficient 
dPspdb = 3.53    ; tissue:blood partition coefficient 
dPlib = 5.74    ; tissue:blood partition coefficient 
dPgub = 1    ; tissue:blood partition coefficient 
 
;DOSING 
Ka = .437012    ; oral uptake rate (/h) 
PDOSE = 16    ; oral dose (mg) 
 
MW = 447 ;LOP molecular weight 
PPDOSE = PDOSE * 1000 *1000/ MW    ; scaled oral dose (nmol) 
 
;METABOLISM 
VmaxCivMME01li = 3718    ; maximum rate of metabolism (molar; in vitro; microsomal) 
(mol/h/kg) 
KmME01li = Kmli   ; Michaelis constant (nmol/L) 
Kmli = 16.9 * 1000 ;Michaelis constant (umol / L converted to nmol / L) 
 
VmaxCivMME01gu = 1423    ; maximum rate of metabolism (molar; in vitro; 
microsomal) (mol/h/kg) 
KmME01gu = Kmgu    
Kmgu = 12.42 *1000 ; Michaelis constant (umol/L converted to nmol/L) 
VmaxME01li = VmaxCivMME01li * BWc     ; maximum rate of metabolism (entire 
organism) (umol/h) 
VmaxME01gu = VmaxCivMME01gu * BWc    ; maximum rate of metabolism (entire 
organism) (umol/h) 
 
;ALLOMETRY 
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CAE = 0.75    ; cardiac allometric exponent 
DS = 0.33    ; proportion of dead space (not involved in gas exchange) 
RAE = 0.75    ; respiratory allometric exponent 
P = 1 - DS    ; proportion of inhaled gas involved in gas exchange 
BWc = BW ^ CAE    ; cardiac scaling output factor (kg) 
 
; Run settings 
; ============ 
; 
METHOD STIFF 
DTMIN = 1e-11 
DTMAX = 0.010 
DTOUT = 0 
TOLERANCE = 1e-11 
STARTTIME = 0 
STOPTIME =72 
 
; Dynamics 
; ======== 
; 
 
MRS = PPDOSE * exp((-Ka * TIME))    ; amount remaining in stomach (kg) 
TIS = Ka * MRS    ; total input from stomach (kg) 
 
;MRgu = (VmaxME01gu * CVgu) / (KmME01gu + CVgu)    ; rate of change of 
metabolism (mg/h/kg) 
MRgu = (VmaxME01gu * Cgu) / (KmME01gu + Cgu)    ; rate of change of metabolism 
(mg/h/kg) 
 
FA = 0.02 
d/dt (uptake) =  (TIS )    ; uptake derivative (kg) 
INIT uptake = 0 
 
d/dt (AMgu) =  MRgu    ; amount metabolised derivative (kg) 
INIT AMgu = 0 
 
MRli = (VmaxME01li * CVli) / (KmME01li + CVli)    ; rate of change of metabolism 
(nmol/h/kg) 
;MRli = (VmaxME01li * Cli) / (KmME01li + Cli)    ; rate of change of metabolism 
(nmol/h/kg) 
 
;====LOP==== 
d/dt (AMli) = MRli    ; amount metabolised derivative (kg) 
INIT AMli = 0 
 
d/dt (Ali) = (Qli * (CA - CVli) ) - MRli   
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INIT Ali = 0 
 
d/dt (Afa) = Qfa * (CA - CVfa)     
INIT Afa = 0 
 
d/dt (Abr) = Qbr * (CA - CVbr)    
INIT Abr = 0 
 
d/dt (Agu) = (Qgu * (CA - CVgu) + TIS*FA) - MRgu    
INIT Agu = 0 
 
d/dt (Aki) = Qki * (CA - CVki)   
INIT Aki = 0 
 
d/dt (Arpd) = Qrpd * (CA - CVrpd)     
INIT Arpd = 0 
 
d/dt (Aspd) = Qspd * (CA - CVspd)     
INIT Aspd = 0 
 
;===dLOP==== 
Fm=0.9 
 
d/dt (dAMli) = MRli*Fm    ; amount metabolised derivative (kg) 
INIT dAMli = 0 
 
d/dt (dAli) = (Qli * (dCA - dCVli) ) + MRli - dMRli   
INIT dAli = 0 
 
dMRli = (dVmaxME01li * dCVli) / (dKmME01li + dCVli)    ; rate of change of metabolism 
(nmol/h/kg) 
dVmaxME01li = 10000 
dKmME01li = 8000 
 
d/dt (dAfa) = Qfa * (dCA - dCVfa)     
INIT dAfa = 0 
 
d/dt (dAbr) = Qbr * (dCA - dCVbr)    
INIT dAbr = 0 
 
d/dt (dAgu) = (Qgu * (dCA - dCVgu) )+ MRgu    
INIT dAgu = 0 
 
d/dt (dAki) = Qki * (dCA - dCVki)   
INIT dAki = 0 
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d/dt (dArpd) = Qrpd * (dCA - dCVrpd)     
INIT dArpd = 0 
 
d/dt (dAspd) = Qspd * (dCA - dCVspd)     
INIT dAspd = 0 
 
 
DISPLAY KA, VmaxCivMME01gu, VmaxCivMME01li, Kmli, Kmgu, 
dVmaxME01li,dKmME01li, dPfab,Pfab, Pgub, Fa  
 
DISPLAY CV, dCV 
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APPENDIX G: PHYSIOLOGICALLY-BASED PHARMACOKINETIC DHB-
LOPERAMIDE INTERACTION MODEL SIMULATIONS. 
  
METHODS 
Model simulations. Simulations were conducted using the PBPK models described for 
loperamide and DHB in chapter 3 using Simcyp®. Loperamide (16 mg) was simulated 
and the absence and presence of DHB (50 & 300 mg) to represent the labeled DHB 
content in certain dietary substances. Virtual trials were conducted in 100 virtual healthy 
subjects.
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RESULTS 
Pharmacokinetic outcomes of loperamide and DHB. The PBPK interaction 
model predicted an increase in loperamide exposure by DHB in a dose-dependent 
manner. A 50 mg dose of DHB was predicted to increase loperamide Cmax and AUC0-72 h 
by 260% and 140 %, respectively, with no change to t1/2. A 300 mg dose of DHB was 
predicted to increase loperamide Cmax and AUC0-72 h by 320 and 190 %, respectively 
(Table G.1). The increase in loperamide plasma exposure was accompanied by an 
increase in t1/2, indicating DHB-mediated inhibition of hepatic CYP3A4. To further 
interrogate the model, the simulated loperamide fraction metabolized by individual CYP 
isoforms was examined. At this dose of DHB (300 mg) the fraction metabolized (fm) by 
CYP3A4 was decreased by three fold, prompting compensation (increased fm) by 
CYP2C8 and CYP2D6 in the liver (Figure G.1). The fraction excreted in the urine 
remained constant.  
 DHB AUC0-72 h and Cmax was not dose linear from 50 -300 mg. The terminal half-
life of the 300 mg dose was 20-fold greater than at 50 mg, reflective of the model only 
accounting of CYP3A4-mediated metabolism and of extensive suicide inhibition by 
DHB.   
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. 
 
Figure5G.1. Simulated loperamide hepatic fraction metabolized (fm) by hepatic CYP2B6 
(green), CYP2C8 (blue), CYP2D6 (white) and CYP3A4 (red) and the fraction excreted 
(fe, cyan) in urine of loperamide (16 mg) in the absence (A) and presence (B) of a 300-
mg dose of DHB. Results represent a trial conducted in 100 virtual healthy subjects.  
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Table1G.1. Pharmacokinetic outcomes following oral loperamide and DHB 
 DHB dose (mg) 
 0 50 300 
Loperamide    
Cmax (nM) 9.6 [8.9-10.4] 35.1 [33.3-36.9] 40 [38-42] 
AUC0-72 h (nM*h) 164 [152-178] 388 [363-415] 473 [440-507] 
t1/2 (h) 40 [36-43] 41 [37-44] 42 [39-46] 
Cmax ratio - 3.6 [3.4-3.9] 4.2 [3.9-4.4] 
AUC0-72 h ratio - 2.4 [2.3-2.5] 2.9 [2.7-3.1] 
DHB    
Cmax (µM) - 0.14 [0.11-0.19] 6.4 [5.0-8.1]  
AUC0-72 h (µM*h) - 0.61 [0.40-0.94] 15.6 [10.7-22.1] 
t1/2 (h) - 6.6 [5.3-8.3] 122 [88-171] 
 DHB, 6’,7’-Dihdyroxybergamottin; Cmax, maximal plasma concentration; AUC0-72, area 
under the model predicted plasma-concentration curve from time 0 h to 72 h; Cmax ratio, 
the ratio of loperamide Cmax in the presence to that in the absence of DHB; AUC0-72 h 
ratio, the ratio of loperamide AUC0-72 in the presence to that in the absence of DHB; t1/2, 
terminal half-life. All data are presented as the geometric mean [90% confidence 
intervals]. 
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APPENDIX H: PHYSIOLOGICALLY-BASED 
PHARMACOKINETIC/PHARMACODYNAMIC MODEL SIMULATIONS OF 
ALFENTANIL IN HEALTHY SUBJECTS. 
  
METHODS 
Model simulations. Simulations were conducted using an alfentanil PBPK/PD 
model constructed in Simcyp® and reported in detail in chapter 3, with the modification 
that Emax was set to 100%. Alfentanil induced miosis and plasma concentration time 
profiles were simulated in 6 virtual healthy volunteers aged 21-32 years following a 4 
mg dose of alfentanil in the absence and presence of 6.2 mg DHB (as a marker 
constituent of whole GFJ).    
Data analysis. Non compartmental analysis was reported from Simcyp®. 
Pharmacokinetic and pharmacodynamic outcomes were reported as either mean, 
median or as geometric mean values with 95% confidence intervals.  
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RESULTS AND DISCUSSION 
Alfentanil plasma concentrations and pupil miosis were simulated for 6 hours 
following a 4 mg oral dose and certain pharmacokinetic outcomes were determined 
(Table H.1) in the presence and absence of DHB. The model predicted less than a 10% 
increase in alfentanil plasma AUC and Cmax. This under prediction is likely due to the 
alfentanil model being constructed using a first order absorption rate instead of the 
ADAM model. Accordingly, the predicted increase in AUEC was less than 5% in the 
presence of GFJ/DHB. The model-predicted maximal response (Rmax) was over 
predictive of the observed value presented in chapter 4 by ~20%. Model-predicted time 
to reach Rmax was approximately equal to the observed values. These results reveal 
that (1) timelier development of this model may have aided in the clinical study design 
(chapter 4), and (2) model refinement would be required to accurately apply this 
alfentanil model to a GFJ/DHB-mediated interaction.   
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Table H.1. Model-predicted pharmacokinetic and pharmacodynamic outcomes following 
oral alfentanil administration in healthy volunteers. 
Pharmacokinetic 
Outcomes 
Mean Median Geometric 
mean 
95% Confidence 
Interval 
H2O      
Cmax (ng/mL) 60.5 60.8 56.2 50.7 62.2 
Tmax (h) 0.49 0.45 0.45 0.41 0.51 
AUC0-6 h (ng/mL.h) 166 137 135 114 160 
GFJ 
     
Cmax (ng/mL) 63.5 63.9 58.9 53.2 65.3 
Tmax (h) 0.54 0.5 0.49 0.44 0.55 
AUC0-6 h (ng/mL.h) 182 148 147 124 174 
Ratios 
     
Cmax ratio 1.05 1.04 1.05 1.04 1.06 
AUC0-6 h ratio 1.09 1.08 1.09 1.08 1.10 
Pharmacodynamic 
Outcomes 
    
H2O 
     
Rmax (%) 65.0 67.1 62.3 57.5 67.5 
t(Rmax) (h) 0.67 0.63 0.64 0.6 0.69 
AUEC0-6 h (%*h) 191 160 153 128 184 
DHB 
     
Rmax (%) 66.8 68.7 64.4 59.7 69.4 
t(Rmax)  (h) 0.71 0.65 0.68 0.63 0.73 
AUEC0-6 h (%*h) 206 172 166 139 199 
H2O, pretreatment with 240 mL water; DHB, pretreatment with 6.2 mg 6’,7’-
dihydroxybergamottin; Cmax, maximal observed concentration, Tmax, time to reach Cmax; 
AUC0-6, the area under the plasma concentration-time curve from 0-6 hours; Cmax ratio, 
the ratio of Cmax in the presence to that in the absence of DHB; AUC0-6 h ratio, the ratio 
of AUC0-6 h in the presence to that in the absence of DHB; Rmax, the maximal simulated 
pupillary response;  
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